CN1195851C - 用于前列腺癌免疫疗法的化合物及其用途 - Google Patents
用于前列腺癌免疫疗法的化合物及其用途 Download PDFInfo
- Publication number
- CN1195851C CN1195851C CNB988041391A CN98804139A CN1195851C CN 1195851 C CN1195851 C CN 1195851C CN B988041391 A CNB988041391 A CN B988041391A CN 98804139 A CN98804139 A CN 98804139A CN 1195851 C CN1195851 C CN 1195851C
- Authority
- CN
- China
- Prior art keywords
- seq
- leu
- cdna
- sequence
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 51
- 206010060862 Prostate cancer Diseases 0.000 title abstract description 41
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract description 41
- 150000001875 compounds Chemical class 0.000 title abstract description 10
- 238000009169 immunotherapy Methods 0.000 title abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 176
- 229920001184 polypeptide Polymers 0.000 claims abstract description 160
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 159
- 229960005486 vaccine Drugs 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 108020004414 DNA Proteins 0.000 claims description 58
- 210000002307 prostate Anatomy 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 230000004927 fusion Effects 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000012745 toughening agent Substances 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 108010018777 Prostatein Proteins 0.000 claims description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims 5
- 230000036039 immunity Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract description 81
- 108090000623 proteins and genes Proteins 0.000 abstract description 51
- 102000004169 proteins and genes Human genes 0.000 abstract description 32
- 239000002299 complementary DNA Substances 0.000 description 290
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 262
- 108020004707 nucleic acids Proteins 0.000 description 219
- 102000039446 nucleic acids Human genes 0.000 description 219
- 150000007523 nucleic acids Chemical class 0.000 description 219
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 164
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 162
- 241000282414 Homo sapiens Species 0.000 description 148
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 100
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 100
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 98
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 90
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 75
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 74
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 71
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 71
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 57
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 42
- 210000001519 tissue Anatomy 0.000 description 40
- 239000000523 sample Substances 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 22
- 239000003814 drug Substances 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000002018 overexpression Effects 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 14
- 210000000496 pancreas Anatomy 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 125000006853 reporter group Chemical group 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 10
- 102100038358 Prostate-specific antigen Human genes 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 102220023257 rs387907546 Human genes 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100039856 Histone H1.1 Human genes 0.000 description 6
- 101001035402 Homo sapiens Histone H1.1 Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229940127121 immunoconjugate Drugs 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 102220369447 c.1352G>A Human genes 0.000 description 5
- 238000002619 cancer immunotherapy Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 208000037841 lung tumor Diseases 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102220023258 rs387907548 Human genes 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- -1 Threonine and L-Ala Chemical class 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 101710103262 Glandular kallikrein Proteins 0.000 description 3
- 102100027369 Histone H1.4 Human genes 0.000 description 3
- 101001009443 Homo sapiens Histone H1.4 Proteins 0.000 description 3
- 101000897979 Homo sapiens Putative spermatid-specific linker histone H1-like protein Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 102100034681 Myeloblastin Human genes 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 102100021861 Putative spermatid-specific linker histone H1-like protein Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 102000057032 Tissue Kallikreins Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229930003756 Vitamin B7 Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102220004457 rs11567847 Human genes 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 239000011735 vitamin B7 Substances 0.000 description 3
- 235000011912 vitamin B7 Nutrition 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical compound [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 102220369446 c.1274G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 229940092456 curosurf Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102100023715 Poly(A)-specific ribonuclease PARN Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000004054 benzoquinones Chemical class 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GPWDPLKISXZVIE-UHFFFAOYSA-N cyclo[18]carbon Chemical compound C1#CC#CC#CC#CC#CC#CC#CC#CC#C1 GPWDPLKISXZVIE-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了治疗前列腺癌的化合物及方法。本发明化合物包括含有前列腺肿瘤蛋白至少一部分的多肽。本发明还提供了用于前列腺癌免疫疗法、包含这类多肽的疫苗和药物组合物,或编码这类多肽的DNA分子,同时也提供了制备本发明多肽的DNA分子。
Description
技术领域
本发明广泛涉及用于治疗前列腺癌的组合物和方法。此发明更特别涉及包含前列腺蛋白至少一部分的多肽,以及编码此类多肽的DNA分子。这类多肽可用于治疗前列腺癌的疫苗和药物组合物中。
发明背景
前列腺癌是男性中最常见的癌症。如50岁以上的男性中估计发病率约为30%。相当多的临床证据显示人前列腺癌有向骨转移的倾向,且此病呈现为不可避免地从雄性激素依赖状态发展为雄性激素不应性状态,导致患者死亡率的提高。这种普遍的疾病当前正成为美国男性中癌症致死的第二高病因。
尽管对此疾病的疗法进行了许多研究,但前列腺癌仍然是难于治疗的。通常情况下,治疗是基于外科手术和/或放射疗法进行的,但在相当大部分的病例中这些方法都是无效的。两种先前鉴定的前列腺特异性蛋白-前列腺特异抗原(PSA)和前列腺酸性磷酸酶(PAP)-具有有限的治疗和诊断潜力。例如,PSA水平并不总是能很好地与前列腺癌的出现相关联,在一部分非前列腺癌病例中也呈阳性,包括良性前列腺增生(BPH)。此外,PSA测量值与前列腺体积大小有关,并不显示转移水平。
因此,本领域中仍需要改善的疫苗和治疗方法以医治前列腺癌。
发明概述
本发明提供了前列腺癌免疫疗法的化合物和方法。一方面,本发明提供了包含前列腺肿瘤蛋白至少一个免疫原性部分的多肽或所说蛋白质的变体,此变体与原蛋白质的区别仅在于有保守性替代和/或修饰,该前列腺肿瘤蛋白包含由具有选自下组核苷酸序列之序列的DNA分子所编码的氨基酸序列:SEQ ID NO:2,3,8-29,41-45,47-52,54-65,70,73-74,79,81,87,90,92,93,97,103,104,107,109-111,115-160,171,173-175,177,181,188,191,193,194,198,203,204,207,209-211,220,222-224,所述核苷酸序列的互补体及其变体。
在相关方面,本发明提供了编码上述多肽的DNA分子。在特殊的实施例中,这类DNA分子包括下组提供的序列:SEQ ID NO:2,3,8-29,41-45,47-52,54-65,70,73-74,79,81,87,90,92,93,97,103,104,107,109-111,115-160,171,173-175,177,181,188,191,193,194,198,203,204,207,209-211,220和222-224。本发明进一步提供了包含上述DNA分子的表达载体,及用此类表达载体转化或转染了的宿主细胞。在优选的实施方案中,宿主细胞选自大肠杆菌、酵母和哺乳类细胞。
另一方面,本发明还提供了含有第一和第二种创造性多肽的融合蛋白,或者含有一种创造性多肽和一种已知前列腺抗原的融合蛋白。本发明还提供了药物组合物,其中含有一种或多种上述多肽,或编码这类多肽的DNA分子,以及生理学上可接受的载体,同时还提供了疫苗,此疫苗含有一种或多种这类多肽或DNA分子与非特异性免疫应答增强剂的联合。
在相关方面,提供了含有一种或多种多肽及生理学上可接受载体的药物组合物以治疗前列腺癌,其中多肽含有前列腺肿瘤蛋白或其变体的一免疫原性部分,所述变体与原蛋白质的区别仅在于保守性替代和/或修饰,该前列腺肿瘤蛋白由具有选自下组核苷酸序列之序列的DNA分子所编码:SEQ ID NO:5-7,30-40,46,53,66-69,71,72,75-78,80,82-86,88,89,91,94-96,98-102,105,106和161-170,179,180,182-187,189,190,192,195-197,199-202,205,206,208,212-219,221,所述核苷酸序列的互补体及其变体。本发明还提供了治疗前列腺癌的疫苗,其中含有与非特异性免疫应答增强剂组合的这类多肽,同时还提供了含有具有下述序列的一种或多种DNA分子的药物组合物及疫苗:SEQ ID NO:5-7,30-40,46,53,66-69,71,72,75-78,80,82-86,88,89,91,94-96,98-102,105,106和16 1-170,179,180,182-187,189,190,192,195-197,199-202,205,206,208,212-219和221。本发明还提供了含有一种或多种上述融合蛋白的药物组合物及疫苗。
另一方面,本发明还提供了用于抑制患者体内前列腺癌发展的方法,包括给予有效量的至少一种上述药物组合物和/或疫苗。
参照以下详述及附图,本发明的这些及其它方面是明显可见的。在此公开的所有文献是作为独立每篇全文收入作为参考文献的。
发明详述
正如上面所提到的,本发明广泛涉及前列腺癌免疫疗法的组合物和方法。此发明组合物通常为至少含有前列腺肿瘤蛋白一部分的多肽。本发明中还包括可与本发明多肽结合的分子(例如抗体或其片段)。这类分子在此称为“结合剂”。
具体地说,本发明公开了含有人前列腺肿瘤蛋白或其变体至少一部分的多肽,所述变体与所说蛋白质的区别仅在于保守性替代和/或修饰,其中的前列腺肿瘤蛋白包含由具有选自下组核苷酸序列之序列的DNA分子所编码的氨基酸序列:SEQ ID NO:2,3,8-29,41-45,47-52,54-65,70,73-74,79,81,87,90,92,93,97,103,104,107,109-111,115-160,181,188,191,193,194,198,203,204和207-224,所述核苷酸序列的互补体及其变体。在此所用的“多肽”一词指任何长度的氨基酸链,包括全长蛋白质,其中的氨基酸残基由共价肽键所连接。因而,含有上述前列腺蛋白之一一部分的多肽可能完全由此部分组成,或者此部分可能存在于含其它序列的一更大多肽中。此额外序列可来源于天然蛋白质或是异源的,且这类序列可具有免疫活性和/或抗原性。
在此所用的人前列腺肿瘤蛋白的“免疫原性部分”是能在前列腺癌患者体内引起免疫应答、并且同样能够与前列腺癌患者血清中的抗体结合的部分。因此,此处所述的蛋白质免疫原性部分可用抗体结合试验鉴定。这些试验通常可用本领域普通技术人员已知的多种方法中的任何一种进行,例如,在Harlow和Lane,《抗体:实验室手册》(冷泉港实验室,冷泉港,纽约,1988)中所述的方法。例如,可将多肽固定于固相支持物(如下所述)上,并与患者血清接触,以使血清中的抗体与被固定的多肽结合。随后可除去未结合的血清,而用如125I标记的蛋白A检测结合了的抗体。或者,可利用多肽来产生单克隆和多克隆抗体,以用于检测前列腺癌患者血液或其它液体中该多肽的存在情况。
本发明的组合物和方法中还含有上述多肽及DNA分子的变体。此处所用的多肽“变体”是与所述多肽区别仅在于保守性替代和/或修饰、而仍保留了多肽的治疗性、抗原性和/或免疫原性等特性的多肽。多肽变体与已鉴定的多肽优选有至少约70%、更优选至少约90%、最优选至少约95%同一性。对于有免疫活性的前列腺肿瘤多肽,其变体或者可通过修饰上述多肽之一的氨基酸序列并评估此修饰多肽的免疫活性而得以鉴定。对于可用于制备诊断性结合剂的前列腺肿瘤多肽来说,变体的鉴定可通过评估修饰多肽产生可用来检测前列腺癌存在与否的抗体的能力进行。这些修饰序列可用如在此所描述的典型步骤进行制备和检测。
此处所用的“保守性替代”是指某一氨基酸被另一具相似特性的氨基酸所替代,肽化学领域内的技术人员可预知此多肽的二级结构和亲水特性并未实质性改变。通常说来,下述氨基酸组代表了保守性改变:(1)丙氨酸、脯氨酸、甘氨酸、谷氨酸、天冬氨酸、谷氨酰胺、天冬酰胺、丝氨酸、苏氨酸;(2)半胱氨酸、丝氨酸、酪氨酸、苏氨酸;(3)缬氨酸、异亮氨酸、亮氨酸、甲硫氨酸、丙氨酸、苯丙氨酸;(4)赖氨酸、精氨酸、组氨酸;和(5)苯丙氨酸、酪氨酸、色氨酸、组氨酸。
变体可同时或只包含其他的修饰,包括删除或添加对该多肽抗原性、二级结构和亲水特性影响微小的氨基酸。例如,可将信号(或前导)序列在蛋白质的氨基末端与多肽缀合,该序列可以与蛋白质一起翻译,并在翻译后指导蛋白质的转移。多肽也可与接头或其它序列缀合,以易于多肽合成、纯化或鉴定(如多聚组氨酸)、或者增强多肽与固相支持物的结合。例如,可以将多肽与免疫球蛋白的Fc区缀合。
核苷酸“变体”是与所述核苷酸序列区别在于有一个或多个核苷酸缺失、取代或添加的序列。这类修饰可用标准的诱变技术方便地引入,诸如Adelman等(DNA,2:183,1983)中所教导的寡核苷酸介导的定点诱变。核苷酸变体可以是天然存在的等位变体,或者是非天然存在的变体。变体核苷酸序列与所述序列优选有至少约70%、更优选至少约80%、最优选至少约90%同一性。这些变体核苷酸序列通常在严格条件下能与所述核苷酸序列杂交。此处所述“严格条件”是指先在6XSSC、0.2%SDS溶液中洗涤;在6XSSC、0.2%SDS中于65℃杂交过夜;然后在1XSSC、0.1%SDS中于65℃洗两次,每次30分钟,再在0.2XSSC、0.1%SDS中于65℃洗两次,每次30分钟。
此处所用的“多肽”还包括组合或融合多肽。“组合多肽”是含有至少一个上述免疫原性部分及一种或多种额外的免疫原性的前列腺肿瘤特异性序列的多肽,它们通过肽键连接成一条氨基酸单链。这些序列可直接连接在一起(即无插入的氨基酸),或可通过不会明显削弱多肽组分免疫原性的连接序列(如Gly-Cys-Gly)连接在一起。
可用本领域熟知的多种方法中的任一种,从前列腺肿瘤组织中分离出本发明的前列腺肿瘤蛋白和编码此类蛋白质的DNA分子。相当于编码本发明前列腺肿瘤蛋白之一的基因(或其一部分)的DNA序列可用如下详述的提取技术从前列腺肿瘤cDNA文库中分离出来。这类DNA序列的例子可见于SEQ ID NO:1-107,109-111,115-171,173-175,177和179-224。这样得到的部分DNA序列可用于设计寡核苷酸引物,以在一聚合酶链式反应(PCR)中扩增全长DNA序列,所用技术在本领域是众所周知的(可见如Mullis等人,Cold Spring HarberSymp.Quant.Biol.,51:263,1987;Erlich编,PCR技术,StocktonPress,纽约,1989)。一旦获得了编码多肽的DNA序列,即可用标准的诱变技术,如Adelman等(DNA,2:183,1983)中所教的寡核苷酸介导的定点诱变,轻易地引入上述任何一种修饰。
还可用合成或重组方式产生本文公开的前列腺肿瘤蛋白。少于约100个氨基酸及通常少于约50个氨基酸的合成多肽可用本领域普通技术人员熟知的技术制备。例如,这类多肽可用任何可购买的固相技术合成,如Merrifield固相合成方法,其中氨基酸被依次加到正在延长的氨基酸链上(可见于如,Merrifield,美国化学学会杂志(J.Am.Chem.Soc.85:2149-2146,1963)。多肽自动合成仪可购自如Perkin Elmer/应用生物系统分部(Foster城,CA)等厂家,并可按制造商的指示进行操作。
任何上述多肽均可重组产生,即将编码多肽的DNA序列插入表达载体中,并在适当的宿主中表达蛋白质。本领域普通技术人员所知的种种表达载体中的任一种均可用来表达本发明的重组多肽。在转化或转染了含有重组多肽编码DNA分子之表达载体的任何适当宿主细胞中均可进行表达。合适的宿主细胞包括原核细胞、酵母和高等真核细胞。优选所用的宿主细胞是大肠杆菌、酵母或哺乳类细胞系,如CHO细胞。以此方式表达的DNA序列可编码天然存在的多肽、天然存在多肽的部分,或它们的其它变体。
一般说来,不考虑制备方法,此处所公开的多肽被制成基本纯的形式(即经氨基酸组成和一级结构分析测定显示此多肽是均一的)。优选该多肽至少约90%纯,更优选至少约95%纯,最优选至少约99%纯。在以下详述的某些优选实施方案中,这些基本纯的多肽被掺入药物组合物或疫苗中以用于本文公开的一种或多种方法内。
在相关方面,本发明提供了含有第一和第二种本发明多肽的融合蛋白,或者含本发明多肽之一及一已知前列腺抗原的融合蛋白,还提供了这类融合蛋白的变体。本发明的融合蛋白还可包括位于第一和第二种多肽之间的连接肽。
编码本发明融合蛋白的DNA序列可用已知的重组DNA技术,将编码第一和第二多肽的独立DNA序列装配进合适的表达载体中而构建成。编码第一多肽的DNA序列其3’端通过或不通过肽接头而与编码第二多肽的DNA序列之5’端连接,以使序列的阅读框架一致,能允许将两DNA序列经mRNA翻译成能保持第一和第二多肽生物活性的单一融合蛋白。
可用一肽接头序列来隔开第一和第二多肽一段距离,以保证每一多肽折叠成其二级和三级结构。用本领域熟知的标准技术将这样的肽接头序列插入融合蛋白中。可基于以下因素选择合适的肽接头序列:(1)形成柔性伸展构象的能力;(2)不会形成可与第一和第二多肽上的功能性表位相互作用的二级结构;(3)缺少会与多肽的功能性表位反应的疏水性或带电荷残基。优选的肽接头序列包括甘氨酸、天冬酰胺和丝氨酸残基。其它的近中性氨基酸,诸如苏氨酸和丙氨酸,也可用于接头序列中。可有效用作接头的氨基酸序列包括在Maratea等,基因40:39-46,1985;Murphy等,美国国家科学院院报83:8258-8262,1986;美国专利号4,935,233和美国专利号4,751,180中所公开的那些序列。接头序列长度可为约1-50个氨基酸。当第一和第二多肽具有可用来隔开它们的功能性结构域和阻止空间干扰的非必需N-末端氨基酸区域时,就不需要这样的肽序列。
将该连接的DNA序列可操作性地连接到合适的转录或翻译调节元件上。负责DNA表达的调节元件只位于编码第一多肽的DNA序列的5’端。相似地,用于结束翻译的终止密码子和转录终止信号只存在于编码第二多肽的DNA序列的3’端。
含前列腺肿瘤蛋白之免疫原性部分的本发明多肽常可用于前列腺癌的免疫疗法中,其中多肽可刺激患者自身对前列腺肿瘤细胞的免疫应答。另一方面,本发明提供了将一种或多种免疫活性多肽用于患者前列腺癌免疫治疗的方法,所述免疫活性多肽由具SEQ ID NO:1-107、109-111、115-171、173-175,177和179-224中所提供的序列的DNA分子所编码(或含有一种或多种这类多肽的融合蛋白和/或编码这类多肽的DNA)。此处所述“患者”是指任何温血动物,优选是人,患者可以是患病的,或不患有可察觉的疾病。因而,上述免疫活性多肽(或融合蛋白或编码这类多肽的DNA分子)可用于治疗前列腺癌或抑制前列腺癌的发展。可在对主要肿瘤进行外科手术切除和/或给予放射治疗和常规化学治疗药物进行治疗之前或之后给予多肽。
在这些方面,多肽或融合蛋白常存在于药物组合物及/或疫苗中。药物组合物中可包含一个或多个多肽,其中每一种可包含一种或多种上述序列(或其变体),组合物中还可包含一种生理学上可接受的载体。疫苗中可包含一种或多种此类多肽及一非特异性的免疫应答增强剂,诸如佐剂、可生物降解的微球体(如:polylactic galactide)或脂质体(其中掺入了多肽)。药物组合物和疫苗中还可包含前列腺肿瘤抗原的其他表位,它们或者掺入到组合多肽(即含多个表位的单一多肽)内或者存在于一独立多肽中。
或者,药物组合物或疫苗中可包含编码一个或多个上述多肽的DNA,以便原位产生该多肽。在这类药物组合物和疫苗中,该DNA可存在于本领域普通技术人员已知的种种送递系统中的任一种中,包括核酸表达系统、细菌和病毒表达系统。恰当的核酸表达系统含有在患者体内进行表达所必需的DNA序列(诸如适合的启动子)。细菌送递系统包括施用在其细胞表面上表达前列腺细胞抗原表位的细菌(如Bacillus-Calmette-Guerrin)。在优选的实施方案中,可用病毒表达系统(如牛痘或其它痘病毒、逆转录病毒或腺病毒)引入DNA,其中可包括非致病性(缺陷型)、能够复制的病毒的应用。合适的系统公开于例如Fisher-Hoch等人,PNAS 86:317-321,1989;Flexner等人,Ann.N.Y.Acad.Sci.569:86-103,1989;Flexner等人,疫苗8:17-21,1990;美国专利号4,603,112、4,769,330和5,017,487;WO89/01973;美国专利号4,777,127;GB2,200,651;EP0,345,242;WO91/02805;Berkner,生物技术6:616-627,1988;Rosenfeld等人,科学252:431-434,1991;Kolls等人,PNAS91:215-219,1994;Kass-Eisler等人,PNAS90:11498-11502,1993;Guzman等人,循环88:2838-2848,1993;和Guzman等人,Cir.Res.73:1202-1207,1993。对于本领域的普通技术人员来说,将DNA引入这类表达系统的技术是众所周知的。此DNA也可是如所述般为“裸露”的,例如,在PCT申请公开WO90/11092,和Ulmer等人,科学259:1745-1749,1993,由Cohen在科学259:1691-1692,1993中进行了综述。通过将DNA包裹到可生物降解的小珠上,将其高效运送到细胞中,可增加裸露DNA的摄入。
给药方式、频率以及剂量将随个体的不同而变化,与其它疾病免疫疗法中所用的相当。一般说来,药物组合物和疫苗可通过注射(如皮内注射、肌肉内注射、静脉内注射或皮下注射)、鼻内(如通过吸入)或口服的方式给与。可在3-24周的期间内给药1-10剂,优选间隔3个月给予4剂,此后可定期给与增强剂。不同的患者可能有其它适当方案。合适的剂量是指能有效地在被治疗患者内产生针对前列腺肿瘤细胞的免疫应答(细胞的和/或体液的)的多肽或DNA量。合适的免疫应答是指比基础水平(即未治疗水平)高至少10-50%。一般说来,一个剂量中的多肽量(或一个剂量中的DNA所原位产生的多肽量)是大约1pg-100mg/kg宿主,通常是大约10pg-1mg/kg宿主,优选是大约100pg-1μg/kg宿主。合适的剂量大小将随患者的个头而变化,但通常是大约0.01ml-5ml。
虽然本领域技术人员已知的任何合适载体均可用于本发明的药物组合物中,但载体类型将依赖于给药方式而变化。对非肠道给药,诸如皮下注射之类,载体优选地包括水、盐水、酒精、脂质、蜡和/或缓冲液。对口服给药来说,可应用任何上述载体或固相载体,诸如甘露糖醇、乳糖、淀粉、硬脂酸镁、糖精钠(Sodium saccharine)、滑石、纤维素、葡萄糖、蔗糖和/或碳酸镁。可生物降解的微球体(如polylactic glycolide)也可用作本发明药物组合物中的载体。合适的可生物降解的微球体公开于例如美国专利号4,897,268和5,075,109中。
任何非特异性免疫应答增强剂均可用于本发明的疫苗中。例如,佐剂即为其中一种。多数佐剂含有设计用来保护抗原免受快速分解代谢的物质,例如氢氧化铝或矿物油,还有免疫应答的非特异性刺激物,如脂质A、百日咳杆菌(Bordella pertussis)或结核杆菌(Mycobacterium tuberculosis)。这样的佐剂可以购买得到,例如,弗氏不完全佐剂和完全佐剂(Difco实验室,底特律,MI)和MerckAdjuVant 65(Merck and Company,Inc.,Rahway,NJ)。
此处公开的多肽也可用于前列腺癌的离体治疗中。例如,可用市售细胞分离系统,诸如CellPro Incorporated’s(Bothell,WA)CEAPRATETM系统(可见美国专利号5,240,856;美国专利号5,215,926;WO89/06280;WO91/16116和WO92/07243)之类,从患者的外周血中分离得到免疫系统的细胞,如T细胞。用包含在送递载体(如微球体)中的一种或多种免疫活性多肽刺激分离细胞,以得到抗原特异性T细胞。随后用标准技术扩增肿瘤抗原特异性T细胞群体,并将此细胞返回施用于患者。
本发明的多肽也可(或其中之一)被用于产生结合剂,如抗体或其片段,它们能检测转移性人前列腺肿瘤。本发明的结合剂常可用本领域普通技术人员所知的方法制备,包括此文中所述的代表性方法。用本文所述的代表性试验,结合剂能够区分患者患有前列腺肿瘤与否。换而言之,抗前列腺肿瘤蛋白或其合适部分的抗体或其他结合剂,将在至少约20%的原发性或转移性前列腺癌患者中产生显示患有该病的信号,并在至少约90%的未患原发性或转移性前列腺癌的个体中产生显示不患此病的阴性信号。这类前列腺肿瘤蛋白的合适部分是能够用来产生结合剂的部分,所述结合剂能够在基本上所有的(即至少约80%,优选至少约90%)由全长蛋白质指示为前列腺癌患者内指示存在原发性或转移性前列腺癌,并且能够在基本上所有的由全长蛋白质检测为阴性的样品中显示不存在前列腺癌。下述代表性试验(如二抗夹心试验)通常可用于评估结合剂检测转移性人前列腺肿瘤的能力。
如本文所述制备的多肽,其产生能用来检测原发性或转移性前列腺肿瘤的抗体的能力通常可通过产生针对该多肽的一种或多种抗体(例如,用本文所述的代表性方法)并测定这类抗体检测患者体内这类肿瘤的能力来评估。可通过分析有和无原发性或转移性前列腺癌的患者的生物样品中可与所产生抗体结合的多肽的存在情况来进行这一测定。这类检测分析可用例如下述代表性步骤完成。可产生能通过这类操作检测出至少20%原发性或转移性前列腺肿瘤之抗体的多肽被认为可用于检测原发性或转移性人前列腺肿瘤的测定中。多肽特异性抗体可单独使用或联合使用以提高灵敏度。
能检测原发性或转移性人前列腺肿瘤的多肽可被用作标志,以诊断前列腺癌或监测患者体内的病情发展。在一实施方案中,患者内的前列腺癌可通过评估患者的生物学样品中一种或多种上述多肽的水平相对于预先确定的临界值(cut-off value)进行诊断。此处所用的合适“生物学样品”包括血液、血清、尿和/或前列腺分泌物。
一种或多种以上多肽的水平可用特异于此多肽的任何结合剂来评估。本发明上下文中的“结合剂”是任何可与上述多肽结合的物质(诸如化合物或细胞)。此处所述“结合”是指两独立分子间的非共价结合[其中每种分子都可是游离的(即在溶液中)或存在于细胞或固体支持物的表面],从而形成了“复合体”。这样一种复合体可以是游离的,或若固定(共价或非共价)在一支持材料上。一般可通过测定复合体形成的结合常数来评估结合能力。结合常数是复合体浓度除以各组分浓度的乘积而得到的值。一般说来,在本发明的上下文中,当复合体形成的结合常数超过约103升/摩尔时,两种化合物即是“结合”的。结合常数的测定方法是本领域普通技术人员所熟知的。
任何满足上述要求的试剂均可作为结合剂。例如,结合剂可以是有或无肽成分的核糖体、RNA分子或肽。在一优选实施方案中,结合伴侣是抗体或其片段。这类抗体可以是多克隆的或单克隆的。此外,这些抗体可以是单链的、嵌合的、移植CDR的或人源化的。可用本文所述方法或本领域技术人员熟知的其他方法制备抗体。
本领域常规技术人员已知多种使用结合伴侣检测样品中的多肽标记的测定方式。见例,Harlow和Lane,《抗体:实验室手册》,冷泉港实验室,1988。在一优选实施方案中,测定包括使用固定在固相支持物上的结合伴侣来结合多肽并将其从样品其余部分中取出。结合的多肽随后可用含报告基团的第二结合伴侣检测。合适的第二结合伴侣包括可与结合伴侣/多肽复合体结合的抗体。或者,可利用竞争性分析,其中多肽被报告基团所标记,并在样品与结合伴侣共同保温后使其结合到固定化的结合伴侣上。样品中组分抑制标记多肽与结合伴侣结合的程度预示了样品与固定化的结合伴侣的反应活性。
固相支持物可以是本领域普通技术人员所已知的、抗原可附着于其上的物质。例如,固相支持物可以是微量滴定板上的检验孔或硝酸纤维素膜或其它合适的膜。或者,支持物可以是珠子或盘,诸如玻璃、纤维玻璃、乳胶或塑料材料,如聚苯乙烯或聚氯乙烯。支持物也可以是磁性颗粒或纤维光学传感器,例如公开于美国专利号5,359,681中的那些材料。结合剂可用本领域技术人员已知的多种技术固定在固相支持物上,这些技术在专利和科学文献中有充分的描述。在本发明的上下文中,“固定化”一词指非共价结合(如吸附),及共价结合(可为抗原与支持物上官能团间的直接连接,或通过交联试剂的连接)。通过吸附到微量滴定板的孔上或膜上而固定化的方法是优选的。在这类情形中,可通过在适合的缓冲液中,使结合剂与固相支持物接触一段合适的时间而完成吸附。接触时间随温度而变化,但通常是在约1小时到1天之间。一般说来,将塑料微量滴定板(如聚苯乙烯或聚氯乙烯)小孔与约10ng-10μg、优选约100ng-1μg的结合剂接触,足以固定适当量的结合剂。
一般可通过将双功能试剂与支持物首先反应来完成结合剂与固相支持物的共价附着,所述双功能剂可与支持物及结合剂上的官能团(如羟基或氨基)二者反应。例如,利用苯醌,或通过在固相支持物上的醛基与结合伴侣上的胺基和活性氢之间发生缩合,可以将结合剂与具有适当聚合物包被的支持物共价连接起来。[参阅,皮尔斯免疫工程学目录和手册(Pierce Immunotechndogy Catalog and Handbook),1991,于A12-A13]。
在某些实施方案中,进行的分析是双抗体夹心分析。首先将固定在固相支持物(常为微量滴定板的孔)上的抗体与样品接触,以使样品中的多肽结合到固定化的抗体上,从而完成这一分析。随后将未结合的样品从固定化多肽-抗体复合体中去除,并加入能结合多肽上另一位点的二抗(含一报道基团)。然后用适于特定报告基团的方法测定依然结合于固相支持物上的二抗量。
更具体地说,一旦抗体如上所述被固定于支持物上,通常封闭支持物上残余的蛋白质结合位点。许多适合的封闭剂对本领域普通技术人员是已知的,如小牛血清白蛋白或吐温20TM(Sigma化学公司,圣路易斯,MO)。然后将固定化抗体与样品共同保温,使多肽与抗体结合。温育前可用合适的稀释液稀释样品,如磷酸盐缓冲液(PBS)。一般说来,合适的接触时间(即保温时间)是足以检测前列腺癌患者样品中多肽存在情况的时间。优选的接触时间是足以使结合水平达到结合和未结合多肽平衡时结合水平的至少95%的时间。本领域普通技术人员会认识到,通过一段时间内的结合水平,可以很方便地测定达到平衡所必需的时间。室温时,大约30分钟的保温时间通常就足够了。
然后,可用适合的缓冲液(如含0.1%吐温20TM的PBS)清洗固相支持物而去除未结合样品。含报告基团的二抗可随后加到固相支持物上。优选的报告基团包括酶(如辣根过氧化物酶)、底物、辅助因子、抑制剂、染料、放射性核素、发光基团、荧光基团和生物素。抗体与报告基团的缀合可用本领域普通技术人员所知的标准方法完成。
然后将二抗与固定化的抗体-多肽复合体温育足够长时间,以检测相关多肽。通常根据试验一段时间后的结合水平来确定适当的温育时间。接着除去未结合的二抗,并通过报告基团检测结合的二抗。检测报告基团的方法取决于报告基团的性质。对于放射性基团,闪烁计数法或放射自显影方法通常是可行的。光谱法可用来检测染料、发光基团和荧光基团。生物素可用偶联了其它报告基团(通常是放射性或荧光基团或酶)的抗生物素蛋白来检测。通常通过加入底物(一般持续特定时间)、再用光谱法或其它方法分析反应产物而对酶报告基团进行检测。
为了确定前列腺癌的存在与否,通常将检测自仍结合于固相支持物的报告基团的信号与相当于预定临界值的信号进行比较。在一个优选的实例中,临界值是将固定化的抗体与来自未患前列腺癌患者的样品一起温育而得到的平均信号。通常,产生的信号高于预定临界值3倍标准误差的样品被认为是前列腺癌阳性的。在另一个优选的实例中,临界值是用Receiver Operator曲线,根据Sackett等人(临床流行病学:临床医学的基础科学,Little Brown and Co.,1985年,第106-7页)的方法测定的。简单的说,在这个实例中,将对应于诊断检测结果每一个可能临界值的正阳性比率(也就是灵敏性)和假阳性比率(100%特异性)配对作图,可确定临界值。图上离左上角最近的临界值(也就是围住最大面积的值)是最精确的临界值,产生信号高于用这种方法确定的临界值的样品可认为是阳性的。或者,沿着图将临界值向左移动以减小假阳性比率,或者向右以减小假阴性比率。通常,产生的信号高于由此法确定的临界值的样品被认为是前列腺癌阳性。
在一个相关实例中,是以流通或色条试验形式进行该分析的,其中抗体被固定在膜上,如硝酸纤维素。在流通试验中,当样品流经膜时,样品中的多肽即与固定化的抗体相结合。然后,当含有二抗的溶液流经膜时,标记的二抗即与抗体-多肽复合体相结合。结合的二抗的检测可依上述方法进行。在色条试验形式中,将结合了抗体的膜的一端浸入含样品的溶液中。样品沿着膜迁移,经过含二抗的区域,至固定化的抗体的区域。二抗在固定化抗体的区域的集中说明前列腺癌的存在。通常,二抗在该位点的集中产生了可见的样式,如一条线。没有这种样式说明是阴性结果。通常,固定在膜上的抗体的选用量是,当生物样品中含有足以能在双抗夹心试验中产生阳性信号的多肽水平时,在上述检测方式中也能产生可肉眼察觉的样式。优选地,固定在膜上的抗体量为约25ng-1μg,更优选为约50ng-500ng。这类检测可对很小量的生物样品进行。
当然,存在大量适合于与本发明抗原或抗体一起使用的试验方法。上述描述只是举例说明。
在另一个实例中,上述多肽可作为前列腺癌发展的标记使用。在这个实例中,上述就前列腺癌诊断所述的测定可随时间进行,并评估反应性多肽水平的改变情况。举例而言,可在6个月至1年期间每24-72小时进行一次测定,以后按需要进行。通常,经结合剂检测,多肽水平持续增加,说明患者体内前列腺癌一直在发展。相反,当反应多肽的水平维持稳定或随时间降低时,前列腺癌不在发展。
用在上述方法中的抗体可由本领域技术人员已知的众多技术制备。参阅,如Harlow和Lane,《抗体:实验室手册》,冷泉港实验室,1988。在一种此类技术中,首先将含抗原性多肽的免疫原注射入多种哺乳动物(如小鼠、大鼠、兔、绵羊和山羊等)中的任一种中。在这一步中,本发明的多肽不需修饰即可作为免疫原。或者,特别是对于相对短的多肽而言,可将多肽与载体蛋白(如牛血清白蛋白或匙孔血蓝蛋白)连接在一起,以激发更强的免疫应答。将免疫原注射入动物宿主,优选根据预定的时间表,再注射一次或多次加强免疫,并定时对动物取血。对多肽特异的多克隆抗体可以从抗血清中,通过例如利用了偶联至合适固相支持物上的多肽的亲和层析法纯化得到。
特异于目的抗原性多肽的单克隆抗体,举例而言,可以用Kohler和Milstein,欧洲免疫学杂志,6:511-519,1976的技术和改进方法制备。简单的说,这些方法涉及制备能产生具有所需特异性(也就是与目的多肽的反应性)的抗体的永久细胞系。这种细胞系,可以由例如上述免疫动物的脾脏细胞获取。接着将脾脏细胞永生化,例如通过与骨髓瘤细胞融合伙伴、最好是与免疫动物同系的骨髓瘤细胞融合伙伴融合。可以采用多种融合技术。例如,将脾脏细胞和骨髓瘤细胞与非离子型表面活性剂混合几分钟,然后以低密度平铺在能够支持杂合细胞生长而不能支持骨髓瘤细胞生长的选择性培养基上。优选的选择技术中利用了HAT(次黄嘌呤、氨基喋呤、胸苷)筛选。经过足够时间,通常大约1到2周后,就可观察到杂合体集落。挑取单个集落,检测其与多肽的结合活性。优选具有高反应活性和特异性的杂交瘤。
单克隆抗体可以从正在生长的杂交瘤集落上清液中分离得到。此外,可采用多种技术提高产量,例如将杂交瘤细胞系注射到合适的脊椎动物宿主如小鼠的腹腔中,然后可从腹水或血液中收获单克隆抗体。抗体中的污染物可以用常规技术除去,如层析法、凝胶过滤、沉淀和抽提。本发明的多肽可在纯化过程中用于例如亲和层析步骤。
本发明的单克隆抗体可用作治疗剂,以减小或消除前列腺肿瘤。抗体可单独使用(例如用来抑制转移),或与一种或多种治疗药剂偶联。在这方面合适的试剂包括放射性核素、分化诱导剂、药物、毒素和它们的衍生物。常用的放射性核素包括90Y、123I、125I、131I、186Re、188Re、211At和212Bi。优选的药物包括氨甲喋呤,和嘧啶与嘌呤类似物。优选的分化诱导剂包括phorbol esters和丁酸。优选的毒素包括蓖麻毒蛋白,相思豆毒蛋白,白喉毒素、霍乱毒素,gelonin,假单胞菌外毒素,志贺菌毒素和美洲商陆抗病毒蛋白。
治疗药剂可直接或间接(如通过连接基团)与合适的单克隆抗体偶联(如共价键合)当药剂与抗体两者各拥有一个能与对方反应的取代基时,它们之间可发生直接反应。例如,一方上含有的亲核基团(如氨基或巯基)可与另一方上含有的含羰基基团(如酸酐或酸性卤化物)或含良好离去基团(如卤化物)的烷基反应。
或者,将治疗药剂与抗体通过一个连接基团偶联起来可能比较理想。连接基团可发挥间隔子的作用,隔开抗体和药剂,以避免干扰它们的结合能力。连接基团还可以用来提高药剂或抗体上取代基的化学反应活性,从而提高偶联效率。化学反应活性的提高还可以促进原本不可能的药剂或药剂上的官能团的使用。
对本领域技术人员来说,显然有许多双功能或多功能试剂(相同或不同功能)(如描述于Pierce化学品公司产品目录,Rockfold,ZL),可作为连接基团使用。偶联可通过例如氨基、羧基、巯基或氧化的糖类残基实现。有许多参考文献描述了此类方法,如授予Rodwell等人的美国专利4,671,958。
如若治疗药剂中不含本发明免疫缀合物的抗体部分时更有效力,则可能会希望使用在进入细胞过程中或此后可以被切割的连接基团。已经描述了许多不同的可切割连接基团。药剂在细胞内与连接基团脱离的机制包括下列原因引起的切割:还原二硫键(如美国专利号4,489,710,授予Spitler),照射光不稳定性键(如美国专利号4,625,014,授予Senter等),水解衍生的氨基酸侧链(如美国专利号4,638,045,授予Kohn等),血清补体介导的水解(如美国专利号4,671,958,授予Rodwell等),和酸催化的水解(如美国专利号4,569,789,授予Blattler等)。
也可能会希望将多药剂偶联至抗体上。在一个实例中,将一种药剂的多个分子偶联至一个抗体分子上。在另一个实例中,可将多种药剂偶联至一种抗体上。不管具体是哪种方案,带有多药剂的免疫缀合物可由多种方法制备。例如,多药剂可直接偶联至一个抗体分子上,或者用可提供多个连接位点的接头。或者,可使用载体。
载体可以多种方式携带药剂,包括直接地或经由连接基团的共价键合。合适的载体包括蛋白质如白蛋白(如美国专利号4,507,234,授予Kato等),肽和多糖如氨基葡聚糖(如美国专利号4,699,784,授予Shih等)。载体也可由非共价键合或包裹方式携带,如脂质体内(如美国专利号4,429,008和4,873,088)。放射性核素药剂专用的载体包括光卤化小分子和螯合物。例如,美国专利号4,735,792中公开了一些具有代表性的光卤化小分子及其合成方法。放射性核素螯合物可由那些含氮和硫原子作为供体原子而结合金属或金属氧化物放射性核素的螯合化合物制得。例如,授予Davison等人的美国专利第4,673,562号中公开了具有代表性的螯合化合物及其合成。
抗体和免疫缀合物的施予有许多种方式可以采用。典型的施予方式有静脉注射、肌内注射、皮下注射或施与到切除肿瘤的病灶。显然,抗体/免疫缀合物的精确剂量会因为所用抗体、肿瘤上的抗原密度和抗体的清除速率而改变。
本发明的诊断试剂中还可包括编码一或多种上述多肽或其一或多个部分的DNA序列。例如,可在基于聚合酶链式反应的试验中使用至少两个寡核苷酸引物,以扩增来源于生物样品的前列腺肿瘤特异性cDNA,其中至少一个寡核苷酸引物对编码本发明前列腺肿瘤蛋白的DNA分子是特异的。然后用本领域熟知的技术,如凝胶电泳,检测扩增cDNA的存在。类似地,可在杂交试验中使用对编码本发明前列腺肿瘤蛋白的DNA分子特异的寡核苷酸探针以检测生物样品中本发明多肽的存在。
正如此处使用的,术语“对DNA分子特异的寡核苷酸引物/探针”指与所述DNA分子有至少约80%、优选至少约90%、更优选至少约95%同一性的寡核苷酸序列。可有效应用于本发明诊断方法的寡核苷酸引物和/或探针最好含至少约10-40个核苷酸。在一个较好的实例中,寡核苷酸引物含有具有选自SEQ ID NO:1-107、109-111、115-171、173-175、177和179-224的序列的DNA分子上至少约10个连续核苷酸。优选地,用于本发明诊断方法的寡核苷酸探针含有具有选自SEQ ID NO:1-107、109-111、115-171、173-175、177和179-224之序列的DNA分子上至少约15个连续核苷酸。基于PCR的试验和杂交试验的技术在本领域中是熟知的(参阅,如Mullis等,同上;Ehrlich,同上)。因此,引物或探针可用于检测生物样品(包括血液、精液、前列腺组织和/或前列腺肿瘤组织)中的前列腺肿瘤特异性序列。
提供下列实施例作为说明而非限制。
实施例
实施例1
前列腺肿瘤多肽的分离和鉴定
此例描述从前列腺肿瘤cDNA文库中分离前列腺肿瘤多肽。
以用于cDNA合成和质粒克隆试剂盒(BRL Life Technologies公司,Gaithersburg,MD 20897)的Superscript质粒系统,依照生产商推荐的方法,从前列腺肿瘤polyA+ RNA构建人前列腺肿瘤cDNA表达文库。具体地说,用polytron(Kinematica公司,瑞士)匀浆前列腺肿瘤组织,依照生产商的指示,用Trizol试剂(BRL LifeTechnologies公司)提取总RNA。然后,用Qiagen oligotex旋转柱mRNA纯化试剂盒(Qiagen公司,Santa Clarita,CA 91355),依照生产商推荐的方法纯化多聚腺苷酸RNA。第一链cDNA用NotI/Oligo-dTl8引物合成。合成双链cDNA,与EcoRI/BaXI衔接头(Invitrogen公司,San Diego,CA)连接并用Not I消化。将cDNA用Chroma Spin-1000柱(Clontech公司,Palo Alto,CA94303)大小分离后,连接进入pCDNA3.1(Invitrogen公司)的EcoRI/Not I位点,并用电穿孔法转化到Electro Max大肠杆菌DH10B细胞(BRLLife Technologies)内。
用同样步骤,由一组六组织标本(Clontech公司)建立正常人胰腺cDNA表达文库。通过测定独立克隆数、带有插入片段的克隆所占百分比、平均插入片段大小以及序列分析来表征cDNA文库。前列腺肿瘤cDNA文库中有1.64×107个独立克隆,其中70%的克隆带有插入片段,平均插入片段大小为1745个碱基对。正常人胰腺cDNA文库有3.3×106个独立克隆,其中69%的克隆带有插入片段,平均插入片段大小为1120个碱基对。对于两个文库,序列分析表明大多数克隆带有全长cDNA序列,是合成自mRNA的,而混有最低限度的rRNA和线粒体DNA污染。
利用上述前列腺肿瘤和正常人胰腺cDNA文库,参照Hara等人所述(Blood,84:189-199,1994)略有改动,进行cDNA文库扣除。具体地说,按如下所述构建前列腺肿瘤特异性扣除cDNA文库。取70μg正常人胰腺cDNA文库用EcoRI、Not I和Sfu I消化,随后用DNA聚合酶Klenow片段补平。经酚-氯仿抽提、乙醇沉淀后,将DNA溶于100μl水中,热变性,并加入100μl(100μg)光学探针生物素(Vector Laboratories公司,Burlingame,CA)混匀,依照生产商推荐的方法,将所得混合物置于冰上用270瓦日光灯照射20分钟。再加入50μl光学探针生物素,重复生物素化反应。用丁醇抽提五次后,经乙醇沉淀DNA,再溶于23μl水中作为驱动DNA(driver DNA)。
为制备示踪DNA(tracer DNA),取10μg前列腺肿瘤cDNA文库,用BamHI和XhoI消化,酚-氯仿抽提,走Chroma spin-400柱(Clontech公司)。乙醇沉淀后,将示踪DNA溶于5μl水中。将示踪DNA与15μl驱动DNA和20μl 2X杂交缓冲液(1.5M NaCl/10mMEDTA/50mM HEPES pH7.5/0.2%SDS)混匀,用矿物油覆盖,充分热变性。将样品立即转移至68℃水浴保温20小时(长时间杂交[LH])。然后将反应混合物进行链霉抗生物素蛋白处理,接着酚-氯仿抽提。此步骤再重复三次。将扣除后的DNA沉淀,溶解于12μl水中,加入8μl驱动DNA和20μl 2X杂交缓冲液混匀,68℃杂交2小时(短时间杂交[SH])。除去生物素化双链DNA后,将扣除后的DNA插入氯霉素抗性质粒pBCSK+(Stratagene公司,La Jolla,CA 92037)的BamHI/XhoI位点,并用电穿孔法转化到Electro Max大肠杆菌DH10B细胞内,建立前列腺肿瘤特异性扣除cDNA文库(前列腺扣除1)。
为了分析扣除cDNA文库,从扣除前列腺肿瘤特异性文库中随机挑取100个独立克隆制备质粒DNA,并根据插入片段大小进行分组。通过用Perkin Elmer公司的应用生物系统自动测序仪373A型(FosterCity,CA)进行测序,对具有代表性的cDNA克隆进行进一步鉴定。6个cDNA克隆,即下文中的F1-13、F1-12、F1-16、H1-1、H1-9和H1-4,显示在扣除前列腺特异性cDNA文库中含量丰富。经测定F1-12的3’和5’cDNA序列分别提供于SEQ ID NO:2和3中;F1-13、F1-16、H1-1、H1-9和H1-4的3’cDNA序列分别提供于SEQ ID NO:1和4-7。
将分离克隆的cDNA序列与EMBL和GeneBank数据库(发布至96年)中的已知序列进行比较。4个前列腺肿瘤cDNA克隆:F1-13、F1-16、H1-1和H1-4,确定为编码以下已经确认的蛋白质:前列腺特异性抗原(PSA),人腺体激肽释放酶,人肿瘤表达增强基因和线粒体细胞色素C氧化酶亚基II。H1-9与已经确认的人自主复制序列相同。没有发现F1-12 cDNA序列的同源序列。
经过随后的研究,分离出了F1-12的全长cDNA序列。此序列提供于SEQ ID NO:107,相应推测的氨基酸序列提供于SEQ ID NO:108。
为了克隆含量较少的前列腺肿瘤特异性基因,通过用正常人胰腺cDNA文库以及上述扣除前列腺肿瘤特异性cDNA文库中的3种含量最丰富的基因:人腺体激肽释放酶、前列腺特异性抗原(PSA)和线粒体细胞素C氧化酶亚基II对上述前列腺肿瘤cDNA文库进行扣除,进行cDNA文库的扣除。具体地说,向驱动DNA中加入于pcDNA3.1中的人腺体激肽释放酶、前列腺特异性抗原和线粒体细胞色素C氧化酶亚基II cDNA各1μg,按照上述进行扣除,以提供再次扣除的cDNA文库,此后将其称为增效的前列腺肿瘤特异性扣除cDNA文库。
从增效的前列腺肿瘤特异性扣除cDNA文库中分离得到22个cDNA克隆。经测定,克隆J1-17,L1-12,N1-1862,J1-13,J1-19,J1-25,J1-24,K1-58,K1-63,L1-4和L1-14的3’和5’cDNA序列依次提供于SEQ ID NO:8-9,10-11,12-13,14-15,16-17,18-19,20-21,22-23,24-25,26-27和28-29。克隆J1-12,J1-16,J1-21,K1-48,K1-55,L1-2,L1-6,N1-1858,N1-1860,N1-1861和N1-1864经测定的3’cDNA序列依次提供于SEQ ID NO:30-40。将这些序列与上述基因库中的序列进行比较,显示出与5个含量最丰富的DNA种类中的3个(J1-17,L1-12和N1-1862;SEQ ID NO:8-9,10-11,12-13)没有明显同源性。剩下的两个含量最丰富的种类,一个(J1-12;SEQ ID NO:30)与已经确认的人肺表面活性剂相关蛋白相同,另一个(K1-48;SEQ ID NO:33)与R.norvegicus的2-芳基丙酰辅酶A差向异构酶mRNA有一定同源性。从增效的前列腺肿瘤特异性扣除cDNA文库中分离的17个含量较少的cDNA克隆中,4个(J1-16,K1-55,L1-6和N1-1864;分别为SEQ ID NO:31,34,36和40)与已经确认的序列相同,2个(J1-21和N1-1860;分别为SEQ ID NO:32和38)显示与非人序列有一定同源性,2个(L1-2和N1-1861;分别为SEQ ID NO:35和39)显示与已知的人序列有一定同源性。对多肽J1-13,J1-19,J1-24,J1-25,K1-58,K1-63,L1-4和L1-14(SEQ ID NO:14-15,16-17,20-21,18-19,22-23,24-25,26-27和28-29)没有发现显著同源性。
经随后的研究,分离出了J1-17,L1-12和N1-1862的全长cDNA序列(分别为SEQ ID NO:109-111)。相应推测的氨基酸序列提供于SEQID NO:112-114。
在进一步的实验中,通过用由三种正常前列腺polyA+RNA的汇集物制得的正常前列腺cDNA对前列腺肿瘤cDNA文库进行扣除(前列腺扣除2),鉴定出了另外4个克隆。这些克隆(下面称作U1-3064,U1-3065,V1-3692和1A-3905)经测定的cDNA序列依次提供于SEQ IDNO:69-72。将测定的序列与基因库中的序列进行比较,显示出与U1-3065没有明显同源性。
通过用正常胰腺cDNA文库对增效的前列腺肿瘤特异性cDNA文库进行扣除,完成再次增效扣除(前列腺扣除增效2),并用PSA、J1-17、肺表面活性剂相关蛋白、线粒体DNA、细胞色素C氧化酶亚基II、N1-1862、自主复制序列、L1-12和肿瘤表达增强基因进一步增强效果。分离得到另外4个克隆,此后称为V1-3686,R1-2330,1B-3976和V1-3679。这些克隆经测定的cDNA序列依次提供于SEQ ID NO:73-76。将这些序列与基因库内的序列进行比较,显示出与V1-3686和R1-2330没有明显同源性。
对上述三次前列腺扣除(前列腺扣除2,增效的前列腺肿瘤特异性扣除cDNA文库和前列腺扣除增效2)进一步分析,鉴定得到了另外16个克隆,即1G-4736,1G-4738,1G-4741,1G-4744,1G-4734,1H-4774,1H-4781,1H-4785,1H-4787,1H-4796,1I-4810,1I-4811,1J-4876,1K-4884和1K-4896。这些克隆经测定的cDNA序列依次提供于SEQ ID NO:77-92。将这些序列与上述基因库中的序列进行比较,显示与1G-4741,1G-4734,1I-4807,1J-4876和1K-4896(SEQ ID NO:79,81,87,90和92)没有明显同源性。对分离克隆进一步分析,确定了1G-4736,1G-4738,1G-4741,1G-4744,1H-4774,1H-4781,1H-4785,1H-4787,1H-4796,1I-4807,1J-4876,1K-4884和1K-4896的更大范围cDNA序列,依次提供于SEQ IDNO:179-188和191-193,并确定了1I-4810和1I-4811的另外部分cDNA序列,分别提供于SEQ ID NO:189和190。
将通过用正常胰腺cDNA对正常前列腺cDNA文库进行扣除,又进行了一次扣除(前列腺扣除3)。这样鉴定得到了另外6个克隆,即1G-4761,1G-4762,1H-4766,1H-4770,1H-4771和1H-4772(SEQ IDNO:93-98)。将这些序列与基因库中的序列进行比较,显示出与1G-4761和1H-4771(SEQ ID NO:93和97)没有明显同源性。对分离克隆进一步分析,确定了1G-4761,1G-4762,1H-4766和1H-4772的延续cDNA序列,依次提供于SEQ ID NO:194-196和199,并确定了1H-4770和1H-4771的另外部分cDNA序列,分别提供于SEQ ID NO:197和198。
对由3位前列腺癌患者的polyA+RNA制得的前列腺肿瘤cDNA文库,用正常胰腺cDNA文库进行扣除(前列腺扣除4),鉴定出了8个克隆,即1D-4297,1D-4309,1D.1-4278,1D-4288,1D-4283,1D-4304,1D-4296和1D-4280(SEQ ID NO:99-107)。将这些序列与基因库中的序列进行比较,发现与1D-4283和1D-4304(分别为(SEQ IDNO:103和104)没有显著同源性。对分离克隆进一步分析,确定了1D-4309,1D.1-4278,1D-4288,1D-4283,1D-4304,1D-4296和1D-4280的延续cDNA序列,依次提供于SEQ ID NO:200-206。将由上述前列腺扣除1和前列腺扣除2分离得到的cDNA克隆进行集落PCR扩增,并用微阵技术(Synteni,Palo Alto,CA)确定它们在前列腺肿瘤、正常前列腺和各种其它正常组织中的mRNA表达水平。简单的说,将PCR扩增产物点到载片上成点阵形式,每种产物在点阵中占据唯一位置。从待测组织样品中提取mRNA,逆转录,并制备荧光标记cDNA探针。用标记的cDNA探针探查微阵,扫描载片并测量荧光强度。此强度与杂交强度相关。发现两个新克隆(P509S和P510S)在前列腺肿瘤和正常前列腺中过度表达,而在检测的其它所有正常组织(肝,胰,皮肤,骨髓,脑,乳房,肾上腺,膀胱,睾丸,唾液腺,大肠,肾,卵巢,肺,脊髓,骨骼肌和结肠)中低水平表达。经测定P509S和P510S的cDNA序列分别提供于SEQ ID No:223和224。将这些序列与基因库中的序列进行比较,发现与先前确认的EST有一定同源性。
实施例2
前列腺肿瘤多肽组织特异性的测定
用基因特异引物,采用逆转录PCR检测多种正常和肿瘤组织中具有代表性的前列腺肿瘤多肽F1-16,H1-1,J1-17,L1-12,F1-12和N1-1862的mRNA表达水平。
简单的说,使用Trizol试剂,按上述从多种正常和肿瘤组织中提取总RNA。取1-2μg总RNA,使用SuperScriptII逆转录酶(BRL LifeTechnologies公司)于42℃进行第一链的合成1小时。接着用基因特异引物通过PCR扩增cDNA。为了确保逆转录PCR半定量的本性,使用β肌动蛋白作为各个检测组织的内在对照。首先,制备第一链cDNA的梯度稀释物,利用β肌动蛋白特异引物进行逆转录PCR检测。接着,选择一个能使β肌动蛋白模板线性扩增并且足够灵敏反映初始拷贝数差异的稀释度。使用这些条件,测定各组织各个逆转录反应中的β肌动蛋白水平。通过用DNA酶处理,并且确保使用未加入逆转录酶而制备的第一链cDNA时得到阴性PCR结果,使DNA污染降到最低。
测定四种不同类型的肿瘤组织(来自2位患者的前列腺肿瘤,来自3位患者的乳房肿瘤,结肠肿瘤,肺肿瘤)和16种不同的正常组织(包括前列腺,结肠,肾,肝,肺,卵巢,胰,骨骼肌,皮肤,胃,睾丸,骨髓和脑)中mRNA的表达水平,发现F1-16在前列腺肿瘤组织、结肠肿瘤和正常前列腺中高水平表达,在正常肝、皮肤和睾丸中低水平表达,而在其它检测组织中检测不到表达;H1-1在前列腺肿瘤、肺肿瘤、乳房肿瘤、正常前列腺、正常结肠和正常脑中高水平表达,在正常肺、胰脏、骨骼肌、皮肤、小肠和骨髓中表达低得多,而在其它检测组织中检测不到表达。J1-17和L1-12显得在前列腺中特异性地过度表达,两个基因在前列腺肿瘤和正常前列腺中都高水平表达,而在其它所有检测组织中表达水平很低,甚至检测不到。N1-1862在60%的前列腺肿瘤中过度表达,在正常结肠和肾中能检测到表达。因此,逆转录PCR结果揭示,F1-16、H1-1、J1-17、N1-1862和L1-12要么具有前列腺特异性,要么在前列腺中表达水平显著提高。
进一步的逆转录PCR结果显示,F1-12在60%的前列腺肿瘤中过度表达,在正常肾中能检测到表达。而在其它所有检测组织中不能检测到表达。类似地,R1-2330在40%的前列腺肿瘤中过度表达,在正常肾脏和肝脏中能检测到表达,而在其它所有检测组织中不能检测到表达。U1-3064在60%的前列腺肿瘤中过度表达,在乳房和结肠肿瘤中也表达,但在正常组织中不能检测到表达。
对R1-2330、U1-3064和1D-4279的逆转录PCR鉴定表明,这3种抗原在前列腺和/或前列腺肿瘤中过度表达。
对4个前列腺肿瘤、2个正常前列腺样品、2个BPH前列腺和正常结肠、肾、肝、肺、胰、骨骼肌、脑、胃、睾丸、小肠和骨髓的Northern分析表明,L1-12在前列腺肿瘤和正常前列腺中过度表达,而在检测的其它正常组织中检测不到。J1-17在2个前列腺肿瘤中检测到,而在其它检测组织中没有检测到。N1-1862在3个前列腺肿瘤中过度表达,在正常前列腺、结肠和肾脏中表达,而在其它检测组织中不表达。F1-12在2个前列腺肿瘤中高度表达,而在其它所有检测组织中检测不到。
用上述微阵技术测定此处所述代表性抗原在前列腺肿瘤、乳房肿瘤和下列正常组织:前列腺,肝,胰,皮肤,骨髓,脑,乳房,肾上腺,膀胱,睾丸,唾液腺,大肠,肾,卵巢,肺,脊髓,骨骼肌和结肠中的表达水平。发现L1-12在正常前列腺和前列腺肿瘤中过度表达,在正常骨骼肌中有一些表达。J1-12和F1-12在前列腺肿瘤中都过度表达,在其它所有检测组织中表达较低或检测不到。N1-1862在前列腺肿瘤和正常前列腺中高水平表达,在正常大肠和正常结肠中低水平表达,在其它所有检测组织中检测不到表达。R1-2330在前列腺肿瘤和正常前列腺中过度表达,在其它所有检测组织中较低水平表达。1D-4279在前列腺肿瘤和正常前列腺中过度表达,在正常脊髓中较低水平表达,在其它所有检测组织中检测不到。
实施例3
通过基于PCR的扣除,分离和鉴定前列腺肿瘤多肽
cDNA扣除文库购自Clontech公司,其中含有用10种其它正常组织cDNA(脑,心脏,肾,肝,肺,卵巢,胎盘,骨骼肌,脾和胸腺)进行扣除、接着又进行了第一轮PCR扩增的正常前列腺cDNA。依照生产商推荐的方法,对此文库进行第二轮PCR扩增。将所得cDNA片段亚克隆到载体pT7 Blue T-vector(Novagen,Madison,WI)中,并转化到XL-1 Blue MRF’大肠杆菌(Stratagene公司)内。从独立克隆中分离DNA,并用Perkin Elmer公司的应用生物系统自动测序仪373A型进行测序。
将59个阳性克隆测序。将这些克隆的DNA序列与上述基因库中的序列进行比较,显示与其中25个克隆没有明显同源性,即P5,P8,P9,P18,P20,P30,P34,P36,P38,P39,P42,P49,P50,P53,P55,P60,P64,P65,P73,P75,P76,P79和P84。这些克隆经测定的cDNA序列依次提供于SEQ ID No:41-45,47-52和54-65。发现P29、P47、P68、P80和P82(分别为SEQ ID No:46,53和66-68)与先前确认的DNA序列有一定程度同源性。就发明者所知,这些序列从未发现存在于前列腺中。
以上述基于PCR的方法学进一步研究,分离得到了180多个其它克隆,发现其中23个克隆与已知序列没有明显同源性。这些克隆经测定的cDNA序列提供于SEQ ID No:115-123,127,131,137,145,147-151,153,156-158和160。23个克隆(SEQ ID No:124-126,128-130,132-136,138-144,146,152,154,155和159)与先前确认的EST有一定同源性。另有10个克隆(SEQ ID No:161-170)与已知基因有一定程度同源性。发现另一个克隆P703有5种剪接变体。变体DE1、DE13和DE14经测定的DNA序列依次提供于SEQ ID No:171,175和177,相应推测的氨基酸序列依次提供于SEQ ID No:172,176和178。剪接变体DE2和DE6的DNA序列依次提供于SEQ ID No:173和174。
用上述逆转录PCR方法测定在肿瘤组织[前列腺(n=5),乳房(n=2),结肠和肺]、正常组织[前列腺(n=5),结肠,肾,肝,肺(n=2),卵巢(n=2),骨骼肌,皮肤,胃,小肠和脑),激活和未激活的PBMC中代表性克隆的mRNA表达水平。除另外指明,每种组织均只测定一个样品。
发现P9在正常前列腺和前列腺肿瘤中相比于检测的所有正常组织有高度表达(正常结肠除外,其中有相当水平的表达)。与检测的所有12种正常组织相比,P20在正常前列腺和前列腺肿瘤中有高度表达。与除肺(2个样品中的1个)外的所有正常组织相比,P20在乳房肿瘤(n=2)、结肠肿瘤和肺肿瘤中的表达有适度提高。与除肺、胃外的其它正常组织相比,P18在正常前列腺,前列腺肿瘤和乳房肿瘤中的表达提高。与大多数其它正常组织相比,P5在正常前列腺中的表达有适度提高。然而,在正常肺和PBMC中观察到表达有一定提高。也观察到P5在前列腺肿瘤(5个样品中的2个)、乳房肿瘤和1个肺肿瘤样品中的表达有提高。至于P30,与检测的12个其它正常组织中的6个相比,它在正常前列腺和前列腺肿瘤中有相似表达水平。发现在乳房肿瘤、1个肺肿瘤样品,1个结肠肿瘤样品,还有正常PBMC中表达提高。相比于大多数正常组织,P29在所有5个前列腺肿瘤和所有5个正常前列腺中过度表达。然而,观察到P29在正常结肠和正常肺(2个样品均如此)中有显著的表达。相比于检测的所有其它正常组织,P80在所有5个前列腺肿瘤和所有5个正常前列腺中过度表达,在结肠肿瘤中表达提高。
用上述方法进一步研究,分离得到了下列12个其它克隆:10-d8,10-h10,11-c8,7-g6,8-b5,8-b6,8-d4,8-d9,8-g3,8-h11,g-f12和g-f3。10-d8,10-h10,11-c8,8-d4,8-d9,8-h11,g-f12和g-f3经测定的DNA序列依次提供于SEQ ID No:207、208、209、216、217、220、221和222。7-g6、8-b5和8-g3经测定的正向和反向DAN序列提供于SEQ ID No:210和211,212和213,214和215,218和219。将这些序列与基因库中的序列进行比较,显示与7-g6和g-f3的序列没有明显同源性。发现克隆10-d8、11-c8和8-h11与先前分离的EST有一定同源性,而10-h10、8-b5、8-b6、8-d4、8-d9、8-g3和g-f12与先前确认的基因有一定同源性。
实施例4
多肽合成
在Perkin Elmer公司的应用生物系统430A多肽合成仪上采用FMOC化学,用HPTU(O-苯并三唑-N,N,N’,N’-四甲基脲六氟磷酸酯)活化法合成多肽。可将Gly-Cys-Gly序列额外加在肽的氨基末端,以便于缀合、与固定表面结合或标记肽。可用下述裂解混合物:三氟乙酸∶乙二硫醇∶苯甲硫醚∶水∶苯酚(40∶1∶2∶2∶3),从固相支持物上裂解下肽。裂解2小时后,可在冷甲基-叔丁基醚中沉淀多肽。然后将肽沉淀物溶于含0.1%三氟乙酸(TFA)的水中,冷冻干燥后经碳1 8反相HPLC纯化。可用于水(含0.1%TFA)中的0%-60%乙腈(含0.1%三氟乙酸)梯度洗脱肽。冻干纯级分后,可通过电喷射或其它类型的质谱法以及氨基酸分析鉴定肽。
根据上述内容,可以理解,尽管本发明为了阐述目的而描述了一些特定实施方案,但可作各种改动,而仍不偏离本发明的精神和范围。
序列表
(1)基本信息
(i)申请人:Xu,Jiangchun
Dillin,Davin C.
(ii)发明名称:可用于前列腺癌免疫疗法的化合物及其用途
(iii)序列数:224
(iv)联系地址:
(A)收件人:SEED and BERRY LLP
(B)街道:6300 Columbia Center,701 Fifth Avenue
(C)城市:Seattle
(D)州:WA
(E)国家:美国
(F)邮政编码:98104
(v)计算机可读形式
(A)介质类型:软盘
(B)计算机:IBM PC兼容机
(C)操作系统:PC-DOS/MS-DOS
(D)软件:Patent In Release #1.0,版本#1.30(EPO)
(vi)当前申请信息:
(A)申请号:
(B)申请日:1998年2月23日
(C)分类号:
(viii)代理人/代理机构信息:
(A)姓名:Maki,David J.
(B)代理号:31,392
(C)参考/文档号:210121.427C3
(ix)联系信息
(A)电话:(206)622-4900
(B)传真:(206)682-6031
(2)关于SEQ ID NO:1的信息
(i)序列特征
(A)长度:814个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:1:
TTTTTTTTTT TTTTTCACAG TATAACAGCT CTTTATTTCT GTGAGTTCTA CTAGGAAATC 60
ATCAAATCTG AGGGTTGTCT GGAGGACTTC AATACACCTC CCCCCATAGT GAATCAGCTT 120
CCAGGGGGTC CAGTCCCTCT CCTTACTTCA TCCCCATCCC ATGCCAAAGG AAGACCCTCC 180
CTCCTTGGCT CACAGCCTTC TCTAGGCTTC CCAGTGCCTC CAGGACAGAG TGGGTTATGT 240
TTTCAGCTCC ATCCTTGCTG TGAGTGTCTG GTGCGTTGTG CCTCCAGCTT CTGCTCAGTG 300
CTTCATGGAC AGTGTCCAGC ACATGTCACT CTCCACTCTC TCAGTGTGGA TCCACTAGTT 360
CTAGAGCGGC CGCCACCGCG GTGGAGCTCC AGCTTTTGTT CCCTTTAGTG AGGGTTAATT 420
GCGCGCTTGG CGTAATCATG GTCATAACTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA 480
ATTCCACACA ACATACGAGC CGGAAGCATA AAGTGTAAAG CCTGGGGTGC CTAATGAGTG 540
ANCTAACTCA CATTAATTGC GTTGCGCTCA CTGNCCGCTT TCCAGTCNGG AAAACTGTCG 600
TGCCAGCTGC ATTAATGAAT CGGCCAACGC NCGGGGAAAA GCGGTTTGCG TTTTGGGGGC 660
TCTTCCGCTT CTCGCTCACT NANTCCTGCG CTCGGTCNTT CGGCTGCGGG GAACGGTATC 720
ACTCCTCAAA GGNGGTATTA CGGTTATCCN NAAATCNGGG GATACCCNGG AAAAAANTTT 780
AACAAAAGGG CANCAAAGGG CNGAAACGTA AAAA 814
(2)关于SEQ ID NO:2的信息
(i)序列特征
(A)长度:816个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:2:
ACAGAAATGT TGGATGGTGG AGCACCTTTC TATACGACTT ACAGGACAGC AGATGGGGAA 60
TTCATGGCTG TTGGAGCAAT AGAACCCCAG TTCTACGAGC TGCTGATCAA AGGACTTGGA 120
CTAAAGTCTG ATGAACTTCC CAATCAGATG AGCATGGATG ATTGGCCAGA AATGAAGAAG 180
AAGTTTGCAG ATGTATTTGC AAAGAAGACG AAGGCAGAGT GGTGTCAAAT CTTTGACGGC 240
ACAGATGCCT GTGTGACTCC GGTTCTGACT TTTGAGGAGG TTGTTCATCA TGATCACAAC 300
AAGGAACGGG GCTCGTTTAT CACCAGTGAG GAGCAGGACG TGAGCCCCCG CCCTGCACCT 360
CTGCTGTTAA ACACCCCAGC CATCCCTTCT TTCAAAAGGG ATCCACTAGT TCTAGAAGCG 420
GCCGCCACCG CGGTGGAGCT CCAGCTTTTG TTCCCTTTAG TGAGGGTTAA TTGCGCGCTT 480
GGCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCCCC 540
AACATACGAG CCGGAACATA AAGTGTTAAG CCTGGGGTGC CTAATGANTG AGCTAACTCN 600
CATTAATTGC GTTGCGCTCA CTGCCCGCTT TCCAGTCGGG AAAACTGTCG TGCCACTGCN 660
TTANTGAATC NGCCACCCCC CGGGAAAAGG CGGTTGCNTT TTGGGCCTCT TCCGCTTTCC 720
TCGCTCATTG ATCCTNGCNC CCGGTCTTCG GCTGCGGNGA ACGGTTCACT CCTCAAAGGC 780
GGTNTNCCGG TTATCCCCAA ACNGGGGATA CCCNGA 816
(2)关于SEQ ID NO:3的信息
(i)序列特征
(A)长度:773个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:3:
CTTTTGAAAG AAGGGATGGC TGGGGTGTTT AACAGCAGAG GTGCAGGGCG GGGGCTCACG 60
TCCTGCTCCT CACTGGTGAT AAACGAGCCC CGTTCCTTGT TGTGATCATG ATGAACAACC 120
TCCTCAAAAG TCAGAACCGG AGTCACACAG GCATCTGTGC CGTCAAAGAT TTGACACCAC 180
TCTGCCTTCG TCTTCTTTGC AAATACATCT GCAAACTTCT TCTTCATTTC TGGCCAATCA 240
TCCATGCTCA TCTGATTGGG AAGTTCATCA GACTTTAGTC CANNTCCTTT GATCAGCAGC 300
TCGTAGAACT GGGGTTCTAT TGCTCCAACA GCCATGAATT CCCCATCTGC TGTCCTGTAA 360
GTCGTATAGA AAGGTGCTCC ACCATCCAAC ATGTTCTGTC CTCGAGGGGG GGCCCGGTAC 420
CCAATTCGCC CTATANTGAG TCGTATTACG CGCGCTCACT GGCCGTCGTT TTACAACGTC 480
GTGACTGGGA AAACCCTGGG CGTTACCAAC TTAATCGCCT TGCAGCACAT CCCCCTTTCG 540
CCAGCTGGGC GTAATANCGA AAAGGCCCGC ACCGATCGCC CTTCCAACAG TTGCGCACCT 600
GAATGGGNAA ATGGGACCCC CCTGTTACCG CGCATTNAAC CCCCGCNGGG TTTNGTTGTT 660
ACCCCCACNT NNACCGCTTA CACTTTGCCA GCGCCTTANC GCCCGCTCCC TTTCNCCTTT 720
CTTCCCTTCC TTTCNCNCCN CTTTCCCCCG GGGTTTCCCC CNTCAAACCC CNA 773
(2)关于SEQ ID NO:4的信息
(i)序列特征
(A)长度:828个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:4:
CCTCCTGAGT CCTACTGACC TGTGCTTTCT GGTGTGGAGT CCAGGGCTGC TAGGAAAAGG 60
AATGGGCAGA CACAGGTGTA TGCCAATGTT TCTGAAATGG GTATAATTTC GTCCTCTCCT 120
TCGGAACACT GGCTGTCTCT GAAGACTTCT CGCTCAGTTT CAGTGAGGAC ACACACAAAG 180
ACGTGGGTGA CCATGTTGTT TGTGGGGTGC AGAGATGGGA GGGGTGGGGC CCACCCTGGA 240
AGAGTGGACA GTGACACAAG GTGGACACTC TCTACAGATC ACTGAGGATA AGCTGGAGCC 300
ACAATGCATG AGGCACACAC ACAGCAAGGA TGACNCTGTA AACATAGCCC ACGCTGTCCT 360
GNGGGCACTG GGAAGCCTAN ATNAGGCCGT GAGCANAAAG AAGGGGAGGA TCCACTAGTT 420
CTANAGCGGC CGCCACCGCG GTGGANCTCC ANCTTTTGTT CCCTTTAGTG AGGGTTAATT 480
GCGCGCTTGG CNTAATCATG GTCATANCTN TTTCCTGTGT GAAATTGTTA TCCGCTCACA 540
ATTCCACACA ACATACGANC CGGAAACATA AANTGTAAAC CTGGGGTGCC TAATGANTGA 600
CTAACTCACA TTAATTGCGT TGCGCTCACT GCCCGCTTTC CAATCNGGAA ACCTGTCTTG 660
CCNCTTGCAT TNATGAATCN GCCAACCCCC GGGGAAAAGC GTTTGCGTTT TGGGCGCTCT 720
TCCGCTTCCT CNCTCANTTA NTCCCTNCNC TCGGTCATTC CGGCTGCNGC AAACCGGTTC 780
ACCNCCTCCA AAGGGGGTAT TCCGGTTTCC CCNAATCCGG GGANANCC 828
(2)关于SEQ ID NO:5的信息
(i)序列特征
(A)长度:834个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:5:
TTTTTTTTTT TTTTTACTGA TAGATGGAAT TTATTAAGCT TTTCACATGT GATAGCACAT 60
AGTTTTAATT GCATCCAAAG TACTAACAAA AACTCTAGCA ATCAAGAATG GCAGCATGTT 120
ATTTTATAAC AATCAACACC TGTGGCTTTT AAAATTTGGT TTTCATAAGA TAATTTATAC 180
TGAAGTAAAT CTAGCCATGC TTTTAAAAAA TGCTTTAGGT CACTCCAAGC TTGGCAGTTA 240
ACATTTGGCA TAAACAATAA TAAAACAATC ACAATTTAAT AAATAACAAA TACAACATTG 300
TAGGCCATAA TCATATACAG TATAAGGAAA AGGTGGTAGT GTTGAGTAAG CAGTTATTAG 350
AATAGAATAC CTTGGCCTCT ATGCAAATAT GTCTAGACAC TTTGATTCAC TCAGCCCTGA 420
CATTCAGTTT TCAAAGTAGG AGACAGGTTC TACAGTATCA TTTTACAGTT TCCAACACAT 480
TGAAAACAAG TAGAAAATGA TGAGTTGATT TTTATTAATG CATTACATCC TCAAGAGTTA 540
TCACCAACCC CTCAGTTATA AAAAATTTTC AAGTTATATT AGTCATATAA CTTGGTGTGC 600
TTATTTTAAA TTAGTGCTAA ATGGATTAAG TGAAGACAAC AATGGTCCCC TAATGTGATT 660
GATATTGGTC ATTTTTACCA GCTTCTAAAT CTNAACTTTC AGGCTTTTGA ACTGGAACAT 720
TGNATNACAG TGTTCCANAG TTNCAACCTA CTGGAACATT ACAGTGTGCT TGATTCAAAA 780
TGTTATTTTG TTAAAAATTA AATTTTAACC TGGTGGAAAA ATAATTTGAA ATNA 834
(2)关于SEQ ID NO:6的信息
(i)序列特征
(A)长度:818个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:6:
TTTTTTTTTT TTTTTTTTTT AAGACCCTCA TCAATAGATG GAGACATACA GAAATAGTCA 60
AACCACATCT ACAAAATGCC AGTATCAGGC GGCGGCTTCG AAGCCAAAGT GATGTTTGGA 120
TGTAAAGTGA AATATTAGTT GGCGGATGAA GCAGATAGTG AGGAAAGTTG AGCCAATAAT 180
GACGTGAAGT CCGTGGAAGC CTGTGGCTAC AAAAAATGTT GAGCCGTAGA TGCCGTCGGA 240
AATGGTGAAG GGAGACTCGA AGTACTCTGA GGCTTGTAGG AGGGTAAAAT AGAGACCCAG 300
TAAAATTGTA ATAAGCAGTG CTTGAATTAT TTGGTTTCGG TTGTTTTCTA TTAGACTATG 360
GTGAGCTCAG GTGATTGATA CTCCTGATGC GAGTAATACG GATGTGTTTA GGAGTGGGAC 420
TTCTAGGGGA TTTAGCGGGG TGATGCCTGT TGGGGGCCAG TGCCCTCCTA GTTGGGGGGT 480
AGGGGCTAGG CTGGAGTGGT AAAAGGCTCA GAAAAATCCT GCGAAGAAAA AAACTTCTGA 540
GGTAATAAAT AGGATTATCC CGTATCGAAG GCCTTTTTGG ACAGGTGGTG TGTGGTGGCC 600
TTGGTATGTG CTTTCTCGTG TTACATCGCG CCATCATTGG TATATGGTTA GTGTGTTGGG 660
TTANTANGGC CTANTATGAA GAACTTTTGG ANTGGAATTA AATCAATNGC TTGGCCGGAA 720
GTCATTANGA NGGCTNAAAA GGCCCTGTTA NGGGTCTGGG CTNGGTTTTA CCCNACCCAT 780
GGAATNCNCC CCCCGGACNA NTGNATCCCT ATTCTTAA 818
(2)关于SEQ ID NO:7的信息
(i)序列特征
(A)长度:817个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:7:
TTTTTTTTTT TTTTTTTTTT TGGCTCTAGA GGGGGTAGAG GGGGTGCTAT AGGGTAAATA 60
CGGGCCCTAT TTCAAAGATT TTTAGGGGAA TTAATTCTAG GACGATGGGT ATGAAACTGT 120
GGTTTGCTCC ACAGATTTCA GAGCATTGAC CGTAGTATAC CCCCGGTCGT GTAGCGGTGA 180
AAGTGGTTTG GTTTAGACGT CCGGGAATTG CATCTGTTTT TAAGCCTAAT GTGGGGACAG 240
CTCATGAGTG CAAGACGTCT TGTGATGTAA TTATTATACN AATGGGGGCT TCAATCGGGA 300
GTACTACTCG ATTGTCAACG TCAAGGAGTC GCAGGTCGCC TGGTTCTAGG AATAATGGGG 360
GAAGTATGTA GGAATTGAAG ATTAATCCGC CGTAGTCGGT GTTCTCCTAG GTTCAATACC 420
ATTGGTGGCC AATTGATTTG ATGGTAAGGG GAGGGATCGT TGAACTCGTC TGTTATGTAA 480
AGGATNCCTT NGGGATGGGA AGGCNATNAA GGACTANGGA TNAATGGCGG GCANGATATT 540
TCAAACNGTC TCTANTTCCT GAAACGTCTG AAATGTTAAT AANAATTAAN TTTNGTTATT 600
GAATNTTNNG GAAAAGGGCT TACAGGACTA GAAACCAAAT ANGAAAANTA ATNNTAANGG 660
CNTTATCNTN AAAGGTNATA ACCNCTCCTA TNATCCCACC CAATNGNATT CCCCACNCNN 720
ACNATTGGAT NCCCCANTTC CANAAANGGC CNCCCCCCGG TGNANNCCNC CTTTTGTTCC 780
CTTNANTGAN GGTTATTCNC CCCTNGCNTT ATCANCC 817
(2)关于SEQ ID NO:8的信息
(i)序列特征
(A)长度:799个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:8:
CATTTCCGGG TTTACTTTCT AAGGAAAGCC GAGCGGAAGC TGCTAACGTG GGAATCGGTG 60
CATAAGGAGA ACTTTCTGCT GGCACGCGCT AGGGACAAGC GGGAGAGCGA CTCCGAGCGT 120
CTGAAGCGCA CGTCCCAGAA GGTGGACTTG GCACTGAAAC AGCTGGGACA CATCCGCGAG 180
TACGAACAGC GCCTGAAAGT GCTGGAGCGG GAGGTCCAGC AGTGTAGCCG CGTCCTGGGG 240
TGGGTGGCCG ANGCCTGANC CGCTCTGCCT TGCTGCCCCC ANGTGGGCCG CCACCCCCTG 300
ACCTGCCTGG GTCCAAACAC TGAGCCCTGC TGGCGGACTT CAAGGANAAC CCCCACANGG 360
GGATTTTGCT CCTANANTAA GGCTCATCTG GGCCTCGGCC CCCCCACCTG GTTGGCCTTG 420
TCTTTGANGT GAGCCCCATG TCCATCTGGG CCACTGTCNG GACCACCTTT NGGGAGTGTT 480
CTCCTTACAA CCACANNATG CCCGGCTCCT CCCGGAAACC ANTCCCANCC TGNGAAGGAT 540
CAAGNCCTGN ATCCACTNNT NCTANAACCG GCCNCCNCCG CNGTGGAACC CNCCTTNTGT 600
TCCTTTTCNT TNAGGGTTAA TNNCGCCTTG GCCTTNCCAN NGTCCTNCNC NTTTTCCNNT 660
GTTNAAATTG TTANGCNCCC NCCNNTCCCN CNNCNNCNAN CCCGACCCNN ANNTTNNANN 720
NCCTGGGGGT NCCNNCNGAT TGACCCNNCC NCCCTNTANT TGCNTTNGGG NNCNNTGCCC 780
CTTTCCCTCT NGGGANNCG 799
(2)关于SEQ ID NO:9的信息
(i)序列特征
(A)长度:801个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:9:
ACGCCTTGAT CCTCCCAGGC TGGGACTGGT TCTGGGAGGA GCCGGGCATG CTGTGGTTTG 60
TAANGATGAC ACTCCCAAAG GTGGTCCTGA CAGTGGCCCA GATGGACATG GGGCTCACCT 120
CAAGGACAAG GCCACCAGGT GCGGGGGCCG AAGCCCACAT GATCCTTACT CTATGAGCAA 180
AATCCCCTGT GGGGGCTTCT CCTTGAAGTC CGCCANCAGG GCTCAGTCTT TGGACCCANG 240
CAGGTCATGG GGTTGTNGNC CAACTGGGGG CCNCAACGCA AAANGGCNCA GGGCCTCNGN 300
CACCCATCCC ANGACGCGGC TACACTNCTG GACCTCCCNC TCCACCACTT TCATGCGCTG 360
TTCNTACCCG CGNATNTGTC CCANCTGTTT CNGTGCCNAC TCCANCTTCT NGGACGTGCG 420
CTACATACGC CCGGANTCNC NCTCCCGCTT TGTCCCTATC CACGTNCCAN CAACAAATTT 480
CNCCNTANTG CACCNATTCC CACNTTTNNC AGNTTTCCNC NNCGNGCTTC CTTNTAAAAG 540
GGTTGANCCC CGGAAAATNC CCCAAAGGGG GGGGGCCNGG TACCCAACTN CCCCCTNATA 600
GCTGAANTCC CCATNACCNN GNCTCNATGG ANCCNTCCNT TTTAANNACN TTCTNAACTT 660
GGGAANANCC CTCGNCCNTN CCCCCNTTAA TCCCNCCTTG CNANGNNCNT CCCCCNNTCC 720
NCCCNNNTNG GCNTNTNANN CNAAAAAGGC CCNNNANCAA TCTCCTNNCN CCTCANTTCG 780
CCANCCCTCG AAATCGGCCN C 801
(2)关于SEQ ID NO:10的信息
(i)序列特征
(A)长度:789个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:10:
CAGTCTATNT GGCCAGTGTG GCAGCTTTCC CTGTGGCTGC CGGTGCCACA TGCCTGTCCC 60
ACAGTGTGGC CGTGGTGACA GCTTCAGCCG CCCTCACCGG GTTCACCTTC TCAGCCCTGC 120
AGATCCTGCC CTACACACTG GCCTCCCTCT ACCACCGGGA GAAGCAGGTG TTCCTGCCCA 180
AATACCGAGG GGACACTGGA GGTGCTAGCA GTGAGGACAG CCTGATGACC AGCTTCCTGC 240
CAGGCCCTAA GCCTGGAGCT CCCTTCCCTA ATGGACACGT GGGTGCTGGA GGCAGTGGCC 300
TGCTCCCACC TCCACCCGCG CTCTGCGGGG CCTCTGCCTG TGATGTCTCC GTACGTGTGG 360
TGGTGGGTGA GCCCACCGAN GCCAGGGTGG TTCCGGGCCG GGGCATCTGC CTGGACCTCG 420
CCATCCTGGA TAGTGCTTCC TGCTGTCCCA NGTGGCCCCA TCCCTGTTTA TGGGCTCCAT 480
TGTCCAGCTC AGCCAGTCTG TCACTGCCTA TATGGTGTCT GCCGCAGGCC TGGGTCTGGT 540
CCCATTTACT TTGCTACACA GGTANTATTT GACAAGAACG ANTTGGCCAA ATACTCAGCG 600
TTAAAAAATT CCAGCAACAT TGGGGGTGGA AGGCCTGCCT CACTGGGTCC AACTCCCCGC 660
TCCTGTTAAC CCCATGGGGC TGCCGGCTTG GCCGCCAATT TCTGTTGCTG CCAAANTNAT 720
GTGGCTCTCT GCTGCCACCT GTTGCTGGCT GAAGTGCNTA CNGCNCANCT NGGGGGGTNG 780
GGNGTTCCC 789
(2)关于SEQ ID NO:11的信息
(i)序列特征
(A)长度:772个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:11:
CCCACCCTAC CCAAATATTA GACACCAACA CAGAAAAGCT AGCAATGGAT TCCCTTCTAC 60
TTTGTTAAAT AAATAAGTTA AATATTTAAA TGCCTGTGTC TCTGTGATGG CAACAGAAGG 120
ACCAACAGGC CACATCCTGA TAAAAGGTAA GAGGGGGGTG GATCAGCAAA AAGACAGTGC 180
TGTGGGCTGA GGGGACCTGG TTCTTGTGTG TTGCCCCTCA GGACTCTTCC CCTACAAATA 240
ACTTTCATAT GTTCAAATCC CATGGAGGAG TGTTTCATCC TAGAAACTCC CATGCAAGAG 300
CTACATTAAA CGAAGCTGCA GGTTAAGGGG CTTANAGATG GGAAACCAGG TGACTGAGTT 360
TATTCAGCTC CCAAAAACCC TTCTCTAGGT GTGTCTCAAC TAGGAGGCTA GCTGTTAACC 420
CTGAGCCTGG GTAATCCACC TGCAGAGTCC CCGCATTCCA GTGCATGGAA CCCTTCTGGC 480
CTCCCTGTAT AAGTCCAGAC TGAAACCCCC TTGGAAGGNC TCCAGTCAGG CAGCCCTANA 540
AACTGGGGAA AAAAGAAAAG GACGCCCCAN CCCCCAGCTG TGCANCTACG CACCTCAACA 600
GCACAGGGTG GCAGCAAAAA AACCACTTTA CTTTGGCACA AACAAAAACT NGGGGGGGCA 660
ACCCCGGCAC CCCNANGGGG GTTAACAGGA ANCNGGGNAA CNTGGAACCC AATTNAGGCA 720
GGCCCNCCAC CCCNAATNTT GCTGGGAAAT TTTTCCTCCC CTAAATTNTT TC 772
(2)关于SEQ ID NO:12的信息
(i)序列特征
(A)长度:751个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:12:
GCCCCAATTC CAGCTGCCAC ACCACCCACG GTGACTGCAT TAGTTCGGAT GTCATACAAA 60
AGCTGATTGA AGCAACCCTC TACTTTTTGG TCGTGAGCCT TTTGCTTGGT GCAGGTTTCA 120
TTGGCTGTGT TGGTGACGTT GTCATTGCAA CAGAATGGGG GAAAGGCACT GTTCTCTTTG 180
AAGTANGGTG AGTCCTCAAA ATCCGTATAG TTGGTGAAGC CACAGCACTT GAGCCCTTTC 240
ATGGTGGTGT TCCACACTTG AGTGAAGTCT TCCTGGGAAC CATAATCTTT CTTGATGGCA 300
GGCACTACCA GCAACGTCAG GGAAGTGCTC AGCCATTGTG GTGTACACCA AGGCGACCAC 360
AGCAGCTGCN ACCTCAGCAA TGAAGATGAN GAGGANGATG AAGAAGAACG TCNCGAGGGC 420
ACACTTGCTC TCAGTCTTAN CACCATANCA GCCCNTGAAA ACCAANANCA AAGACCACNA 480
CNCCGGCTGC GATGAAGAAA TNACCCCNCG TTGACAAACT TGCATGGCAC TGGGANCCAC 540
AGTGGCCCNA AAAATCTTCA AAAAGGATGC CCCATCNATT GACCCCCCAA ATGCCCACTG 600
CCAACAGGGG CTGCCCCACN CNCNNAACGA TGANCCNATT GNACAAGATC TNCNTGGTCT 660
TNATNAACNT GAACCCTGCN TNGTGGCTCC TGTTCAGGNC CNNGGCCTGA CTTCTNAANN 720
AANGAACTCN GAAGNCCCCA CNGGANANNC G 751
(2)关于SEQ ID NO:13的信息
(i)序列特征
(A)长度:729个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:13:
GAGCCAGGCG TCCCTCTGCC TGCCCACTCA GTGGCAACAC CCGGGAGCTG TTTTGTCCTT 60
TGTGGANCCT CAGCAGTNCC CTCTTTCAGA ACTCANTGCC AAGANCCCTG AACAGGAGCC 120
ACCATGCAGT GCTTCAGCTT CATTAAGACC ATGATGATCC TCTTCAATTT GCTCATCTTT 180
CTGTGTGGTG CAGCCCTGTT GGCAGTGGGC ATCTGGGTGT CAATCGATGG GGCATCCTTT 240
CTGAAGATCT TCGGGCCACT GTCGTCCAGT GCCATGCAGT TTGTCAACGT GGGCTACTTC 300
CTCATCGCAG CCGGCGTTGT GGTCTTAGCT CTAGGTTTCC TGGGCTGCTA TGGTGCTAAG 360
ACTGAGAGCA AGTGTGCCCT CGTGACGTTC TTCTTCATCC TCCTCCTCAT CTTCATTGCT 420
GAGGTTGCAA TGCTGTGGTC GCCTTGGTGT ACACCACAAT GGCTGAGCAC TTCCTGACGT 480
TGCTGGTAAT GCCTGCCATC AANAAAAGAT TATGGGTTCC CAGGAANACT TCACTCAAGT 540
GTTGGAACAC CACCATGAAA GGGCTCAAGT GCTGTGGCTT CNNCCAACTA TACGGATTTT 600
GAAGANTCAC CTACTTCAAA GAAAANAGTG CCTTTCCCCC ATTTCTGTTG CAATTGACAA 660
ACGTCCCCAA CACAGCCAAT TGAAAACCTG CACCCAACCC AAANGGGTCC CCAACCANAA 720
ATTNAAGGG 729
(2)关于SEQ ID NO:14的信息
(i)序列特征
(A)长度:816个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:14:
TGCTCTTCCT CAAAGTTGTT CTTGTTGCCA TAACAACCAC CATAGGTAAA GCGGGCGCAG 60
TGTTCGCTGA AGGGGTTGTA GTACCAGCGC GGGATGCTCT CCTTGCAGAG TCCTGTGTCT 120
GGCAGGTCCA CGCAGTGCCC TTTGTCACTG GGGAAATGGA TGCGCTGGAG CTCGTCAAAG 180
CCACTCGTGT ATTTTTCACA GGCAGCCTCG TCCGACGCGT CGGGGCAGTT GGGGGTGTCT 240
TCACACTCCA GGAAACTGTC NATGCAGCAG CCATTGCTGC AGCGGAACTG GGTGGGCTGA 300
CANGTGCCAG AGCACACTGG ATGGCGCCTT TCCATGNNAN GGGCCCTGNG GGAAAGTCCC 360
TGANCCCCAN ANCTGCCTCT CAAANGCCCC ACCTTGCACA CCCCGACAGG CTAGAATGGA 420
ATCTTCTTCC CGAAAGGTAG TTNTTCTTGT TGCCCAANCC ANCCCCNTAA ACAAACTCTT 430
GCANATCTGC TCCGNGGGGG TCNTANTACC ANCGTGGGAA AAGAACCCCA GGCNGCGAAC 540
CAANCTTGTT TGGATNCGAA GCNATAATCT NCTNTTCTGC TTGGTGGACA GCACCANTNA 600
CTGTNNANCT TTAGNCCNTG GTCCTCNTGG GTTGNNCTTG AACCTAATCN CCNNTCAACT 660
GGGACAAGGT AANTNGCCNT CCTTTNAATT CCCNANCNTN CCCCCTGGTT TGGGGTTTTN 720
CNCNCTCCTA CCCCAGAAAN NCCGTGTTCC CCCCCAACTA GGGGCCNAAA CCNNTTNTTC 780
CACAACCCTN CCCCACCCAC GGGTTCNGNT GGTTNG 816
(2)关于SEQ ID NO:15的信息
(i)序列特征
(A)长度:783个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:15:
CCAAGGCCTG GGCAGGCATA NACTTGAAGG TACAACCCCA GGAACCCCTG GTGCTGAAGG 60
ATGTGGAAAA CACAGATTGG CGCCTACTGC GGGGTGACAC GGATGTCAGG GTAGAGAGGA 120
AAGACCCAAA CCAGGTGGAA CTGTGGGGAC TCAAGGAANG CACCTACCTG TTCCAGCTGA 180
CAGTGACTAG CTCAGACCAC CCAGAGGACA CGGCCAACGT CACAGTCACT GTGCTGTCCA 240
CCAAGCAGAC AGAAGACTAC TGCCTCGCAT CCAACAANGT GGGTCGCTGC CGGGGCTCTT 300
TCCCACGCTG GTACTATGAC CCCACGGAGC AGATCTGCAA GAGTTTCGTT TATGGAGGCT 360
GCTTGGGCAA CAAGAACAAC TACCTTCGGG AAGAAGAGTG CATTCTANCC TGTCNGGGTG 420
TGCAAGGTGG GCCTTTGANA NGCANCTCTG GGGCTCANGC GACTTTCCCC CAGGGCCCCT 480
CCATGGAAAG GCGCCATCCA NTGTTCTCTG GCACCTGTCA GCCCACCCAG TTCCGCTGCA 540
NCAATGGCTG CTGCATCNAC ANTTTCCTNG AATTGTGACA ACACCCCCCA NTGCCCCCAA 600
CCCTCCCAAC AAAGCTTCCC TGTTNAAAAA TACNCCANTT GGCTTTTNAC AAACNCCCGG 660
CNCCTCCNTT TTCCCCNNTN AACAAAGGGC NCTNGCNTTT GAACTGCCCN AACCCNGGAA 720
TCTNCCNNGG AAAAANTNCC CCCCCTGGTT CCTNNAANCC CCTCCNCNAA ANCTNCCCCC 780
CCC 783
(2)关于SEQ ID NO:16的信息
(i)序列特征
(A)长度:801个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:16:
GCCCCAATTC CAGCTGCCAC ACCACCCACG GTGACTGCAT TAGTTCGGAT GTCATACAAA 60
AGCTGATTGA AGCAACCCTC TACTTTTTGG TCGTGAGCCT TTTGCTTGGT GCAGGTTTCA 120
TTGGCTGTGT TGGTGACGTT GTCATTGCAA CAGAATGGGG GAAAGGCACT GTTCTCTTTG 180
AAGTAGGGTG AGTCCTCAAA ATCCGTATAG TTGGTGAAGC CACAGCACTT GAGCCCTTTC 240
ATGGTGGTGT TCCACACTTG AGTGAAGTCT TCCTGGGAAC CATAATCTTT CTTGATGGCA 300
GGCACTACCA GCAACGTCAG GAAGTGCTCA GCCATTGTGG TGTACACCAA GGCGACCACA 360
GCAGCTGCAA CCTCAGCAAT GAAGATGAGG AGGAGGATGA AGAAGAACGT CNCGAGGGCA 420
CACTTGCTCT CCGTCTTAGC ACCATAGCAG CCCANGAAAC CAAGAGCAAA GACCACAACG 480
CCNGCTGCGA ATGAAAGAAA NTACCCACGT TGACAAACTG CATGGCCACT GGACGACAGT 540
TGGCCCGAAN ATCTTCAGAA AAGGGATGCC CCATCGATTG AACACCCANA TGCCCACTGC 600
CNACAGGGCT GCNCCNCNCN GAAAGAATGA GCCATTGAAG AAGGATCNTC NTGGTCTTAA 660
TGAACTGAAA CCNTGCATGG TGGCCCCTGT TCAGGGCTCT TGGCAGTGAA TTCTGANAAA 720
AAGGAACNGC NTNAGCCCCC CCAAANGANA AAACACCCCC GGGTGTTGCC CTGAATTGGC 780
GGCCAAGGAN CCCTGCCCCN G 801
(2)关于SEQ ID NO:17的信息
(i)序列特征
(A)长度:740个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:17:
GTGAGAGCCA GGCGTCCCTC TGCCTGCCCA CTCAGTGGCA ACACCCGGGA GCTGTTTTGT 60
CCTTTGTGGA GCCTCAGCAG TTCCCTCTTT CAGAACTCAC TGCCAAGAGC CCTGAACAGG 120
AGCCACCATG CAGTGCTTCA GCTTCATTAA GACCATGATG ATCCTCTTCA ATTTGCTCAT 180
CTTTCTGTGT GGTGCAGCCC TGTTGGCAGT GGGCATCTGG GTGTCAATCG ATGGGGCATC 240
CTTTCTGAAG ATCTTCGGGC CACTGTCGTC CAGTGCCATG CAGTTTGTCA ACGTGGGCTA 300
CTTCCTCATC GCAGCCGGCG TTGTGGTCTT TGCTCTTGGT TTCCTGGGCT GCTATGGTGC 360
TAAGACGGAG AGCAAGTGTG CCCTCGTGAC GTTCTTCTTC ATCCTCCTCC TCATCTTCAT 420
TGCTGAAGTT GCAGCTGCTG TGGTCGCCTT GGTGTACACC ACAATGGCTG AACCATTCCT 480
GACGTTGCTG GTANTGCCTG CCATCAANAA AGATTATGGG TTCCCAGGAA AAATTCACTC 540
AANTNTGGAA CACCNCCATG AAAAGGGCTC CAATTTCTGN TGGCTTCCCC AACTATACCG 600
GAATTTTGAA AGANTCNCCC TACTTCCAAA AAAAAANANT TGCCTTTNCC CCCNTTCTGT 660
TGCAATGAAA ACNTCCCAAN ACNGCCAATN AAAACCTGCC CNNNCAAAAA GGNTCNCAAA 720
CAAAAAAANT NNAAGGGTTN 740
(2)关于SEQ ID NO:18的信息
(i)序列特征
(A)长度:802个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:18:
CCGCTGGTTG CGCTGGTCCA GNGNAGCCAC GAAGCACGTC AGCATACACA GCCTCAATCA 60
CAAGGTCTTC CAGCTGCCGC ACATTACGCA GGGCAAGAGC CTCCAGCAAC ACTGCATATG 120
GGATACACTT TACTTTAGCA GCCAGGGTGA CAACTGAGAG GTGTCGAAGC TTATTCTTCT 180
GAGCCTCTGT TAGTGGAGGA AGATTCCGGG CTTCAGCTAA GTAGTCAGCG TATGTCCCAT 240
AAGCAAACAC TGTGAGCAGC CGGAAGGTAG AGGCAAAGTC ACTCTCAGCC AGCTCTCTAA 300
CATTGGGCAT GTCCAGCAGT TCTCCAAACA CGTAGACACC AGNGGCCTCC AGCACCTGAT 360
GGATGAGTGT GGCCAGCGCT GCCCCCTTGG CCGACTTGGC TAGGAGCAGA AATTGCTCCT 420
GGTTCTGCCC TGTCACCTTC ACTTCCGCAC TCATCACTGC ACTGAGTGTG GGGGACTTGG 480
GCTCAGGATG TCCAGAGACG TGGTTCCGCC CCCTCNCTTA ATGACACCGN CCANNCAACC 540
GTCGGCTCCC GCCGANTGNG TTCGTCGTNC CTGGGTCAGG GTCTGCTGGC CNCTACTTGC 600
AANCTTCGTC NGGCCCATGG AATTCACCNC ACCGGAACTN GTANGATCCA CTNNTTCTAT 660
AACCGGNCGC CACCGCNNNT GGAACTCCAC TCTTNTTNCC TTTACTTGAG GGTTAAGGTC 720
ACCCTTNNCG TTACCTTGGT CCAAACCNTN CCNTGTGTCG ANATNGTNAA TCNGGNCCNA 780
TNCCANCCNC ATANGAAGCC NG 802
(2)关于SEQ ID NO:19的信息
(i)序列特征
(A)长度:731个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:19:
CNAAGCTTCC AGGTNACGGG CCGCNAANCC TGACCCNAGG TANCANAANG CAGNCNGCGG 60
GAGCCCACCG TCACGNGGNG GNGTCTTTAT NGGAGGGGGC GGAGCCACAT CNCTGGACNT 120
CNTGACCCCA ACTCCCCNCC NCNCANTGCA GTGATGAGTG CAGAACTGAA GGTNACGTGG 180
CAGGAACCAA GANCAAANNC TGCTCCNNTC CAAGTCGGCN NAGGGGGCGG GGCTGGCCAC 240
GCNCATCCNT CNAGTGCTGN AAAGCCCCNN CCTGTCTACT TGTTTGGAGA ACNGCNNNGA 300
CATGCCCAGN GTTANATAAC NGGCNGAGAG TNANTTTGCC TCTCCCTTCC GGCTGCGCAN 360
CGNGTNTGCT TAGNGGACAT AACCTGACTA CTTAACTGAA CCCNNGAATC TNCCNCCCCT 420
CCACTAAGCT CAGAACAAAA AACTTCGACA CCACTCANTT GTCACCTGNC TGCTCAAGTA 480
AAGTGTACCC CATNCCCAAT GTNTGCTNGA NGCTCTGNCC TGCNTTANGT TCGGTCCTGG 540
GAAGACCTAT CAATTNAAGC TATGTTTCTG ACTGCCTCTT GCTCCCTGNA ACAANCNACC 600
CNNCNNTCCA AGGGGGGGNC GGCCCCCAAT CCCCCCAACC NTNAATTNAN TTTANCCCCN 660
CCCCCNGGCC CGGCCTTTTA CNANCNTCNN NNACNGGGNA AAACCNNNGC TTTNCCCAAC 720
NNAATCCNCC T 731
(2)关于SEQ ID NO:20的信息
(i)序列特征
(A)长度:754个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:20:
TTTTTTTTTT TTTTTTTTTT TAAAAACCCC CTCCATTNAA TGNAAACTTC CGAAATTGTC 60
CAACCCCCTC NTCCAAATNN CCNTTTCCGG GNGGGGGTTC CAAACCCAAN TTANNTTTGG 120
ANNTTAAATT AAATNTTNNT TGGNGGNNNA ANCCNAATGT NANGAAAGTT NAACCCANTA 180
TNANCTTNAA TNCCTGGAAA CCNGTNGNTT CCAAAAATNT TTAACCCTTA ANTCCCTCCG 240
AAATNGTTNA NGGAAAACCC AANTTCTCNT AAGGTTGTTT GAAGGNTNAA TNAAAANCCC 300
NNCCAATTGT TTTTNGCCAC GCCTGAATTA ATTGGNTTCC GNTGTTTTCC NTTAAAANAA 360
GGNNANCCCC GGTTANTNAA TCCCCCCNNC CCCAATTATA CCGANTTTTT TTNGAATTGG 420
GANCCCNCGG GAATTAACGG GGNNNNTCCC TNTTGGGGGG CNGGNNCCCC CCCCNTCGGG 480
GGTTNGGGNC AGGNCNNAAT TGTTTAAGGG TCCGAAAAAT CCCTCCNAGA AAAAAANCTC 540
CCAGGNTGAG NNTNGGGTTT NCCCCCCCCC CANGGCCCCT CTCGNANAGT TGGGGTTTGG 600
GGGGCCTGGG ATTTTNTTTC CCCTNTTNCC TCCCCCCCCC CCNGGGANAG AGGTTNGNGT 660
TTTGNTCNNC GGCCCCNCCN AAGANCTTTN CCGANTTNAN TTAAATCCNT GCCTNGGCGA 720
AGTCCNTTGN AGGGNTAAAN GGCCCCCTNN CGGG 754
(2)关于SEQ ID NO:21的信息
(i)序列特征
(A)长度:755个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:21:
ATCANCCCAT GACCCCNAAC NNGGGACCNC TCANCCGGNC NNNCNACCNC CGGCCNATCA 60
NNGTNAGNNC ACTNCNNTTN NATCACNCCC CNCCNACTAC GCCCNCNANC CNACGCNCTA 120
NNCANATNCC ACTGANNGCG CGANGTNGAN NGAGAAANCT NATACCANAG NCACCANACN 180
CCAGCTGTCC NANAANGCCT NNNATACNGG NNNATCCAAT NTGNANCCTC CNAAGTATTN 240
NNCNNCANAT GATTTTCCTN ANCCGATTAC CCNTNCCCCC TANCCCCTCC CCCCCAACNA 300
CGAAGGCNCT GGNCCNAAGG NNGCGNCNCC CCGCTAGNTC CCCNNCAAGT CNCNCNCCTA 360
AACTCANCCN NATTACNCGC TTCNTGAGTA TCACTCCCCG AATCTCACCC TACTCAACTC 420
AAAAANATCN GATACAAAAT AATNCAAGCC TGNTTATNAC ACTNTGACTG GGTCTCTATT 480
TTAGNGGTCC NTNAANCNTC CTAATACTTC CAGTCTNCCT TCNCCAATTT CCNAANGGCT 540
CTTTCNGACA GCATNTTTTG GTTCCCNNTT GGGTTCTTAN NGAATTGCCC TTCNTNGAAC 600
GGGCTCNTCT TTTCCTTCGG TTANCCTGGN TTCNNCCGGC CAGTTATTAT TTCCCNTTTT 660
AAATTCNTNC CNTTTANTTT TGGCNTTCNA AACCCCCGGC CTTGAAAACG GCCCCCTGGT 720
AAAAGGTTGT TTTGANAAAA TTTTTGTTTT GTTCC 755
(2)关于SEQ ID NO:22的信息
(i)序列特征
(A)长度:849个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:22:
TTTTTTTTTT TTTTTANGTG TNGTCGTGCA GGTAGAGGCT TACTACAANT GTGAANACGT 60
ACGCTNGGAN TAANGCGACC CGANTTCTAG GANNCNCCCT AAAATCANAC TGTGAAGATN 120
ATCCTGNNNA CGGAANGGTC ACCGGNNGAT NNTGCTAGGG TGNCCNCTCC CANNNCNTTN 180
CATAACTCNG NGGCCCTGCC CACCACCTTC GGCGGCCCNG NGNCCGGGCC CGGGTCATTN 240
GNNTTAACCN CACTNNGCNA NCGGTTTCCN NCCCCNNCNG ACCCNGGCGA TCCGGGGTNC 300
TCTGTCTTCC CCTGNAGNCN ANAAANTGGG CCNCGGNCCC CTTTACCCCT NNACAAGCCA 360
CNGCCNTCTA NCCNCNGCCC CCCCTCCANT NNGGGGGACT GCCNANNGCT CCGTTNCTNG 420
NNACCCCNNN GGGTNCCTCG GTTGTCGANT CNACCGNANG CCANGGATTC CNAAGGAAGG 480
TGCGTTNTTG GCCCCTACCC TTCGCTNCGG NNCACCCTTC CCGACNANGA NCCGCTCCCG 540
CNCNNCGNNG CCTCNCCTCG CAACACCCGC NCTCNTCNGT NCGGNNNCCC CCCCACCCGC 600
NCCCTCNCNC NGNCGNANCN CTCCNCCNCC GTCTCANNCA CCACCCCGCC CCGCCAGGCC 660
NTCANCCACN GGNNGACNNG NAGCNCNNTC GCNCCGCGCN GCGNCNCCCT CGCCNCNGAA 720
CTNCNTCNGG CCANTNNCGC TCAANCCNNA CNAAACGCCG CTGCGCGGCC CGNAGCGNCC 780
NCCTCCNCGA GTCCTCCCGN CTTCCNACCC ANGNNTTCCN CGAGGACACN NNACCCCGCC 840
NNCANGCGG 849
(2)关于SEQ ID NO:23的信息
(i)序列特征
(A)长度:872个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:23:
GCGCAAACTA TACTTCGCTC GNACTCGTGC GCCTCGCTNC TCTTTTCCTC CGCAACCATG 60
TCTGACNANC CCGATTNGGC NGATATCNAN AAGNTCGANC AGTCCAAACT GANTAACACA 120
CACACNCNAN AGANAAATCC NCTGCCTTCC ANAGTANACN ATTGAACNNG AGAACCANGC 180
NGGCGAATCG TAATNAGGCG TGCGCCGCCA ATNTGTCNCC GTTTATTNTN CCAGCNTCNC 240
CTNCCNACCC TACNTCTTCN NAGCTGTCNN ACCCCTNGTN CGNACCCCCC NAGGTCGGGA 300
TCGGGTTTNN NNTGACCGNG CNNCCCCTCC CCCCNTCCAT NACGANCCNC CCGCACCACC 360
NANNGCNCGC NCCCCGNNCT CTTCGCCNCC CTGTCCTNTN CCCCTGTNGC CTGGCNCNGN 420
ACCGCATTGA CCCTCGCCNN CTNCNNGAAA NCGNANACGT CCGGGTTGNN ANNANCGCTG 480
TGGGNNNGCG TCTGCNCCGC GTTCCTTCCN NCNNCTTCCA CCATCTTCNT TACNGGGTCT 540
CCNCGCCNTC TCNNNCACNC CCTGGGACGC TNTCCTNTGC CCCCCTTNAC TCCCCCCCTT 600
CGNCGTGNCC CGNCCCCACC NTCATTTNCA NACGNTCTTC ACAANNNCCT GGNTNNCTCC 660
CNANCNGNCN GTCANCCNAG GGAAGGGNGG GGNNCCNNTG NTTGACGTTG NGGNGANGTC 720
CGAANANTCC TCNCCNTCAN CNCTACCCCT CGGGCGNNCT CTCNGTTNCC AACTTANCAA 780
NTCTCCCCCG NGNGCNCNTC TCAGCCTCNC CCNCCCCNCT CTCTGCABTG TNCTCTGCTC 840
TNACCNNTAC GANTNTTCGN CNCCCTCTTT CC 872
(2)关于SEQ ID NO:24的信息
(i)序列特征
(A)长度:815个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:24:
GCATGCAAGC TTGAGTATTC TATAGNGTCA CCTAAATANC TTGGCNTAAT CATGGTCNTA 60
NCTGNCTTCC TGTGTCAAAT GTATACNAAN TANATATGAA TCTNATNTGA CAAGANNGTA 120
TCNTNCATTA GTAACAANTG TNNTGTCCAT CCTGTCNGAN CANATTCCCA TNNATTNCGN 180
CGCATTCNCN GCNCANTATN TAATNGGGAA NTCNNNTNNN NCACCNNCAT CTATCNTNCC 240
GCNCCCTGAC TGGNAGAGAT GGATNANTTC TNNTNTGACC NACATGTTCA TCTTGGATTN 300
AANANCCCCC CGCNGNCCAC CGGTTNGNNG CNAGCCNNTC CCAAGACCTC CTGTGGAGGT 360
AACCTGCGTC AGANNCATCA AACNTGGGAA ACCCGCNNCC ANGTNNAAGT NGNNNCANAN 420
GATCCCGTCC AGGNTTNACC ATCCCTTCNC AGCGCCCCCT TTNGTGCCTT ANAGNGNAGC 480
GTGTCCNANC CNCTCAACAT GANACGCGCC AGNCCANCCG CAATTNGGCA CAATGTCGNC 540
GAACCCCCTA GGGGGANTNA TNCAAANCCC CAGGATTGTC CNCNCANGAA ATCCCNCANC 600
CCCNCCCTAC CCNNCTTTGG GACNGTGACC AANTCCCGGA GTNCCAGTCC GGCCNGNCTC 660
CCCCACCGGT NNCCNTGGGG GGGTGAANCT CNGNNTCANC CNGNCGAGGN NTCGNAAGGA 720
ACCGGNCCTN GGNCGAANNG ANCNNTCNGA AGNGCCNCNT CGTATAACCC CCCCTCNCCA 780
NCCNACNGNT AGNTCCCCCC CNGGGTNCGG AANGG 815
(2)关于SEQ ID NO:25的信息
(i)序列特征
(A)长度:775个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:25:
CCGAGATGTC TCGCTCCGTG GCCTTAGCTG TGCTCGCGCT ACTCTCTCTT TCTGGCCTGG 60
AGGCTATCCA GCGTACTCCA AAGATTCAGG TTTACTCACG TCATCCAGCA GAGAATGGAA 120
AGTCAAATTT CCTGAATTGC TATGTGTCTG GGTTTCATCC ATCCGACATT GAANTTGACT 180
TACTGAAGAA TGGANAGAGA ATTGAAAA G TGGAGCATTC AGACTTGTCT TTCAGCAAGG 240
ACTGGTCTTT CTATCTCNTG TACTACACTG AATTCACCCC CACTGAAAAA GATGAGTATG 300
CCTGCCGTGT GAACCATGTG ACTTTGTCAC AGCCCAAGAT AGTTAAGTGG GATCGAGACA 360
TGTAAGCAGN CNNCATGGAA GTTTGAAGAT GCCGCATTTG GATTGGATGA ATTCCAAATT 420
CTGCTTGCTT GCNTTTTAAT ANTGATATGC NTATACACCC TACCCTTTAT GNCCCCAAAT 480
TGTAGGGGTT ACATNANTGT TCNCNTNGGA CATGATCTTC CTTTATAANT CCNCCNTTCG 540
AATTGCCCGT CNCCCNGTTN NGAATGTTTC CNNAACCACG GTTGGCTCCC CCAGGTCNCC 600
TCTTACGGAA GGGCCTGGGC CNCTTTNCAA GGTTGGGGGA ACCNAAAATT TCNCTTNTGC 660
CCNCCCNCCA CNNTCTTGNG NNCNCANTTT GGAACCCTTC CNATTCCCCT TGGCCTCNNA 720
NCCTTNNCTA ANAAAACTTN AAANCGTNGC NAAANNTTTN ACTTCCCCCC TTACC 775
(2)关于SEQ ID NO:26的信息
(i)序列特征
(A)长度:820个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:26:
ANATTANTAC AGTGTAATCT TTTCCCAGAG GTGTGTANAG GGAACGGGGC CTAGAGGCAT 60
CCCANAGATA NCTTATANCA ACAGTGCTTT GACCAAGAGC TGCTGGGCAC ATTTCCTGCA 120
GAAAAGGTGG CGGTCCCCAT CACTCCTCCT CTCCCATAGC CATCCCAGAG GGGTGAGTAG 180
CCATCANGCC TTCGGTGGGA GGGAGTCANG GAAACAACAN ACCACAGAGC ANACAGACCA 240
NTGATGACCA TGGGCGGGAG CGAGCCTCTT CCCTGNACCG GGGTGGCANA NGANAGCCTA 300
NCTGAGGGGT CACACTATAA ACGTTAACGA CCNAGATNAN CACCTGCTTC AAGTGCACCC 360
TTCCTACCTG ACNACCAGNG ACCNNNAACT GCNGCCTGGG GACAGCNCTG GGANCAGCTA 420
ACNNAGCACT CACCTGCCCC CCCATGGCCG TNCGCNTCCC TGGTCCTGNC AAGGGAAGCT 480
CCCTGTTGGA ATTNCGGGGA NACCAAGGGA NCCCCCTCCT CCANCTGTGA AGGAAAAANN 540
GATGGAATTT TNCCCTTCCG GCCNNTCCCC TCTTCCTTTA CACGCCCCCT NNTACTCNTC 600
TCCCTCTNTT NTCCTGNCNC ACTTTTNACC CCNNNATTTC CCTTNATTGA TCGGANNCTN 660
GANATTCCAC TNNCGCCTNC CNTCNATCNG NAANACNAAA NACTNTCTNA CCCNGGGGAT 720
GGGNNCCTCG NTCATCCTCT CTTTTTCNCT ACCNCCNNTT CTTTGCCTCT CCTTNGATCA 780
TCCAACCNTC GNTGGCCNTN CCCCCCCNNN TCCTTTNCCC 820
(2)关于SEQ ID NO:27的信息
(i)序列特征
(A)长度:818个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:27:
TCTGGGTGAT GGCCTCTTCC TCCTCAGGGA CCTCTGACTG CTCTGGGCCA AAGAATCTCT 60
TGTTTCTTCT CCGAGCCCCA GGCAGCGGTG ATTCAGCCCT GCCCAACCTG ATTCTGATGA 120
CTGCGGATGC TGTGACGGAC CCAAGGGGCA AATAGGGTCC CAGGGTCCAG GGAGGGGCGC 180
CTGCTGAGCA CTTCCGCCCC TCACCCTGCC CAGCCCCTGC CATGAGCTCT GGGCTGGGTC 240
TCCGCCTCCA GGGTTCTGCT CTTCCANGCA NGCCANCAAG TGGCGCTGGG CCACACTGGC 300
TTCTTCCTGC CCCNTCCCTG GCTCTGANTC TCTGTCTTCC TGTCCTGTGC ANGCNCCTTG 360
GATCTCAGTT TCCCTCNCTC ANNGAACTCT GTTTCTGANN TCTTCANTTA ACTNTGANTT 420
TATNACCNAN TGGNCTGTNC TGTCNNACTT TAATGGGCCN GACCGGCTAA TCCCTCCCTC 480
NCTCCCTTCC ANTTCNNNNA ACCNGCTTNC CNTCNTCTCC CCNTANCCCG CCNGGGAANC 540
CTCCTTTGCC CTNACCANGG GCCNNNACCG CCCNTNNCTN GGGGGGCNNG GTNNCTNCNC 600
CTGNTNNCCC CNCTCNCNNT TNCCTCGTCC CNNCNNCGCN NNGCANNTTC NCNGTCCCNN 660
TNNCTCTTCN NGTNTCGNAA NGNTCNCNTN TNNNNNGNCN NGNTNNTNCN TCCCTCTCNC 720
CNNNTGNANG TNNTTNNNNC NCNGNNCCCC NNNNCNNNNN NGGNNNTNNN TCTNCNCNGC 780
CCCNNCCCCC NGNATTAAGG CCTCCNNTCT CCGGCCNC 818
(2)关于SEQ ID NO:28的信息
(i)序列特征
(A)长度:731个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:28:
AGGAAGGGCG GAGGGATATT GTANGGGATT GAGGGATAGG AGNATAANGG GGGAGGTGTG 60
TCCCAACATG ANGGTGNNGT TCTCTTTTGA ANGAGGGTTG NGTTTTTANN CCNGGTGGGT 120
GATTNAACCC CATTGTATGG AGNNAAAGGN TTTNAGGGAT TTTTCGGCTC TTATCAGTAT 180
NTANATTCCT GTNAATCGGA AAATNATNTT TCNNCNGGAA AATNTTGCTC CCATCCGNAA 240
ATTNCTCCCG GGTAGTGCAT NTTNGGGGGN CNGCCANGTT TCCCAGGCTG CTANAATCGT 300
ACTAAAGNTT NAAGTGGGAN TNCAAATGAA AACCTNNCAC AGAGNATCCN TACCCGACTG 360
TNNNTTNCCT TCGCCCTNTG ACTCTGCNNG AGCCCAATAC CCNNGNGNAT GTCNCCCNGN 420
NNNGCGNCNC TGAAANNNNC TCGNGGCTNN GANCATCANG GGGTTTCGCA TCAAAAGCNN 480
CGTTTCNCAT NAAGGCACTT TNGCCTCATC CAACCNCTNG CCCTCNNCCA TTTNGCCGTC 540
NGGTTCNCCT ACGCTNNTNG CNCCTNNNTN GANATTTTNC CCGCCTNGGG NAANCCTCCT 600
GNAATGGGTA GGGNCTTNTC TTTTNACCNN GNGGTNTACT AATCNNCTNC ACGCNTNCTT 660
TCTCNACCCC CCCCCTTTTT CAATCCCANC GGCNAATGGG GTCTCCCCNN CGANGGGGGG 720
NNNCCCANNC C 731
(2)关于SEQ ID NO:29的信息
(i)序列特征
(A)长度:822个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:29:
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGGNCNC TTCTATGANT ANTNTTAGAT 60
CGCTCANACC TCACANCCTC CCNACNANGC CTATAANGAA NANNAATAGA NCTGTNCNNT 120
ATNTNTACNC TCATANNCCT CNNNACCCAC TCCCTCTTAA CCCNTACTGT GCCTATNGCN 180
TNNCTANTCT NTGCCGCCTN CNANCCACCN GTGGGCCNAC CNCNNGNATT CTCNATCTCC 240
TCNCCATNTN GCCTANANTA NGTNCATACC CTATACCTAC NCCAATGCTA NNNCTAANCN 300
TCCATNANTT ANNNTAACTA CCACTGACNT NGACTTTCNC ATNANCTCCT AATTTGAATC 360
TACTCTGACT CCCACNGCCT ANNNATTAGC ANCNTCCCCC NACNATNTCT CAACCAAATC 420
NTCAACAACC TATCTANCTG TTCNCCAACC NTTNCCTCCG ATCCCCNNAC AACCCCCCTC 480
CCAAATACCC NCCACCTGAC NCCTAACCCN CACCATCCCG GCAAGCCNAN GGNCATTTAN 540
CCACTGGAAT CACNATNGGA NAAAAAAAAC CCNAACTCTC TANCNCNNAT CTCCCTAANA 600
AATNCTCCTN NAATTTACTN NCANTNCCAT CAANCCCACN TGAAACNNAA CCCCTGTTTT 660
TANATCCCTT CTTTCGAAAA CCNACCCTTT ANNNCCCAAC CTTTNGGGCC CCCCCNCTNC 720
CCNAATGAAG GNCNCCCAAT CNANGAAACG NCCNTGAAAA ANCNAGGCNA ANANNNTCCG 780
CANATCCTAT CCCTTANTTN GGGGNCCCTT NCCCNGGGCC CC 822
(2)关于SEQ ID NO:30的信息
(i)序列特征
(A)长度:787个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:30:
CGGCCGCCTG CTCTGGCACA TGCCTCCTGA ATGGCATCAA AAGTGATGGA CTGCCCATTG 60
CTAGAGAAGA CCTTCTCTCC TACTGTCATT ATGGAGCCCT GCAGACTGAG GGCTCCCCTT 120
GTCTGCAGGA TTTGATGTCT GAAGTCGTGG AGTGTGGCTT GGAGCTCCTC ATCTACATNA 180
GCTGGAAGCC CTGGAGGGCC TCTCTCGCCA GCCTCCCCCT TCTCTCCACG CTCTCCANGG 240
ACACCAGGGG CTCCAGGCAG CCCATTATTC CCAGNANGAC ATGGTGTTTC TCCACGCGGA 300
CCCATGGGGC CTGNAAGGCC AGGGTCTCCT TTGACACCAT CTCTCCCGTC CTGCCTGGCA 360
GGCCGTGGGA TCCACTANTT CTANAACGGN CGCCACCNCG GTGGGAGCTC CAGCTTTTGT 420
TCCCNTTAAT GAAGGTTAAT TGCNCGCTTG GCGTAATCAT NGGTCANAAC TNTTTCCTGT 480
GTGAAATTGT TTNTCCCCTC NCNATTCCNC NCNACATACN AACCCGGAAN CATAAAGTGT 540
TAAAGCCTGG GGGTNGCCTN NNGAATNAAC TNAACTCAAT TAATTGCGTT GGCTCATGGC 600
CCGCTTTCCN TTCNGGAAAA CTGTCNTCCC CTGCNTTNNT GAATCGGCCA CCCCCCNGGG 660
AAAAGCGGTT TGCNTTTTNG GGGGNTCCTT CCNCTTCCCC CCTCNCTAAN CCCTNCGCCT 720
CGGTCGTTNC NGGTNGCGGG GAANGGGNAT NNNCTCCCNC NAAGGGGGNG AGNNNGNTAT 780
CCCCAAA 787
(2)关于SEQ ID NO:31的信息
(i)序列特征
(A)长度:799个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:31:
TTTTTTTTTT TTTTTTTGGC GATGCTACTG TTTAATTGCA GGAGGTGGGG GTGTGTGTAC 60
CATGTACCAG GGCTATTAGA AGCAAGAAGG AAGGAGGGAG GGCAGAGCGC CCTGCTGAGC 120
AACAAAGGAC TCCTGCAGCC TTCTCTGTCT GTCTCTTGGC GCAGGCACAT GGGGAGGCCT 180
CCCGCAGGGT GGGGGCCACC AGTCCAGGGG TGGGAGCACT ACANGGGGTG GGAGTGGGTG 240
GTGGCTGGTN CNAATGGCCT GNCACANATC CCTACGATTC TTGACACCTG GATTTCACCA 300
GGGGACCTTC TGTTCTCCCA NGGNAACTTC NTNNATCTCN AAAGAACACA ACTGTTTCTT 360
CNGCANTTCT GGCTGTTCAT GGAAAGCACA GGTGTCCNAT TTNGGCTGGG ACTTGGTACA 420
TATGGTTCCG GCCCACCTCT CCCNTCNAAN AAGTAATTCA CCCCCCCCCN CCNTCTNTTG 480
CCTGGGCCCT TAANTACCCA CACCGGAACT CANTTANTTA TTCATCTTNG GNTGGGCTTG 540
NTNATCNCCN CCTGAANGCG CCAAGTTGAA AGGCCACGCC GTNCCCNCTC CCCATAGNAN 600
NTTTTNNCNT CANCTAATGC CCCCCCNGGC AACNATCCAA TCCCCCCCCN TGGGGGCCCC 660
AGCCCANGGC CCCCGNCTCG GGNNNCCNGN CNCGNANTCC CCAGGNTCTC CCANTCNGNC 720
CCNNNGCNCC CCCGCACGCA GAACANAAGG NTNGAGCCNC CGCANNNNNN NGGTNNCNAC 780
CTCGCCCCCC CCNNCGNNG 799
(2)关于SEQ ID NO:32的信息
(i)序列特征
(A)长度:789个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:32:
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 60
TTTTNCCNAG GGCAGGTTTA TTGACAACCT CNCGGGACAC AANCAGGCTG GGGACAGGAC 120
GGCAACAGGC TCCGGCGGCG GCGGCGGCGG CCCTACCTGC GGTACCAAAT NTGCAGCCTC 180
CGCTCCCGCT TGATNTTCCT CTGCAGCTGC AGGATGCCNT AAAACAGGGC CTCGGCCNTN 240
GGTGGGCACC CTGGGATTTN AATTTCCACG GGCACAATGC GGTCGCANCC CCTCACCACC 300
NATTAGGAAT AGTGGTNTTA CCCNCCNCCG TTGGCNCACT CCCCNTGGAA ACCACTTNTC 360
GCGGCTCCGG CATCTGGTCT TAAACCTTGC AAACNCTGGG GCCCTCTTTT TGGTTANTNT 420
NCCNGCCACA ATCATNACTC AGACTGGCNC GGGCTGGCCC CAAAAAANCN CCCCAAAACC 480
GGNCCATGTC TTNNCGGGGT TGCTGCNATN TNCATCACCT CCCGGGCNCA NCAGGNCAAC 540
CCAAAAGTTC TTGNGGCCCN CAAAAAANCT CCGGGGGGNC CCAGTTTCAA CAAAGTCATC 600
CCCCTTGGCC CCCAAATCCT CCCCCCGNTT NCTGGGTTTG GGAACCCACG CCTCTNNCTT 660
TGGNNGGCAA GNTGGNTCCC CCTTCGGGCC CCCGGTGGGC CCNNCTCTAA NGAAAACNCC 720
NTCCTNNNCA CCATCCCCCC NNGNNACGNC TANCAANGNA TCCCTTTTTT TANAAACGGG 780
CCCCCCNCG 789
(2)关于SEQ ID NO:33的信息
(i)序列特征
(A)长度:793个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:33:
GACAGAACAT GTTGGATGGT GGAGCACCTT TCTATACGAC TTACAGGACA GCAGATGGGG 60
AATTCATGGC TGTTGGAGCA ATANAACCCC AGTTCTACGA GCTGCTGATC AAAGGACTTG 120
GACTAAAGTC TGATGAACTT CCCAATCAGA TGAGCATGGA TGATTGGCCA GAAATGAANA 180
AGAAGTTTGC AGATGTATTT GCAAAGAAGA CGAAGGCAGA GTGGTGTCAA ATCTTTGACG 240
GCACAGATGC CTGTGTGACT CCGGTTCTGA CTTTTGAGGA GGTTGTTCAT CATGATCACA 300
ACAANGAACG GGGCTCGTTT ATCACCANTG AGGAGCAGGA CGTGAGCCCC CGCCCTGCAC 360
CTCTGCTGTT AAACACCCCA GCCATCCCTT CTTTCAAAAG GGATCCACTA CTTCTAGAGC 420
GGNCGCCACC GCGGTGGAGC TCCAGCTTTT GTTCCCTTTA GTGAGGGTTA ATTGCGCGCT 480
TGGCGTAATC ATGGTCATAN CTGTTTCCTG TGTGAAATTG TTATCCGCTC ACAATTCCAC 540
ACAACATACG ANCCGGAAGC ATNAAATTTT AAAGCCTGGN GGTNGCCTAA TGANTGAACT 600
NACTCACATT AATTGGCTTT GCGCTCACTG CCCGCTTTCC AGTCCGGAAA ACCTGTCCTT 660
GCCAGCTGCC NTTAATGAAT CNGGCCACCC CCCGGGGAAA AGGCNGTTTG CTTNTTGGGG 720
CGCNCTTCCC GCTTTCTCGC TTCCTGAANT CCTTCCCCCC GGTCTTTCGG CTTGCGGCNA 780
ACGGTATCNA CCT 793
(2)关于SEQ ID NO:34的信息
(i)序列特征
(A)长度:756个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:34:
GCCGCGACCG GCATGTACGA GCAACTCAAG GGCGAGTGGA ACCGTAAAAG CCCCAATCTT 60
ANCAAGTGCG GGGAANAGCT GGGTCGACTC AAGCTAGTTC TTCTGGAGCT CAACTTCTTG 120
CCAACCACAG GGACCAAGCT GACCAAACAG CAGCTAATTC TGGCCCGTGA CATACTGGAG 180
ATCGGGGCCC AATGGAGCAT CCTACGCAAN GACATCCCCT CCTTCGAGCG CTACATGGCC 240
CAGCTCAAAT GCTACTACTT TGATTACAAN GAGCAGCTCC CCGAGTCAGC CTATATGCAC 300
CAGCTCTTGG GCCTCAACCT CCTCTTCCTG CTGTCCCAGA ACCGGGTGGC TGANTNCCAC 360
ACGGANTTGG ANCGGCTGCC TGCCCAANGA CATACANACC AATGTCTACA TCNACCACCA 420
GTGTCCTGGA GCAATACTGA TGGANGGCAG CTACCNCAAA GTNTTCCTGG CCNAGGGTAA 480
CATCCCCCGC CGAGAGCTAC ACCTTCTTCA TTGACATCCT GCTCGACACT ATCAGGGATG 540
AAAATCGCNG GGTTGCTCCA GAAAGGCTNC AANAANATCC TTTTCNCTGA AGGCCCCCGG 600
ATNCNCTAGT NCTAGAATCG GCCCGCCATC GCGGTGGANC CTCCAACCTT TCGTTNCCCT 660
TTACTGAGGG TTNATTGCCG CCCTTGGCGT TATCATGGTC ACNCCNGTTN CCTGTGTTGA 720
AATTNTTAAC CCCCCACAAT TCCACGCCNA CATTNG 756
(2)关于SEQ ID NO:35的信息
(i)序列特征
(A)长度:834个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:35:
GGGGATCTCT ANATCNACCT GNATGCATGG TTGTCGGTGT GGTCGCTGTC GATGAANATG 60
AACAGGATCT TGCCCTTGAA GCTCTCGGCT GCTGTNTTTA AGTTGCTCAG TCTGCCGTCA 120
TAGTCAGACA CNCTCTTGGG CAAAAAACAN CAGGATNTGA GTCTTGATTT CACCTCCAAT 180
AATCTTCNGG GCTGTCTGCT CGGTGAACTC GATGACNANG GGCAGCTGGT TGTGTNTGAT 240
AAANTCCANC ANGTTCTCCT TGGTGACCTC CCCTTCAAAG TTGTTCCGGC CTTCATCAAA 300
CTTCTNNAAN ANGANNANCC CANCTTTGTC GAGCTGGNAT TTGGANAACA CGTCACTGTT 360
GGAAACTGAT CCCAAATGGT ATGTCATCCA TCGCCTCTGC TGCCTGCAAA AAACTTGCTT 420
GGCNCAAATC CGACTCCCCN TCCTTGAAAG AAGCCNATCA CACCCCCCTC CCTGGACTCC 480
NNCAANGACT CTNCCGCTNC CCCNTCCNNG CAGGGTTGGT GGCANNCCGG GCCCNTGCGC 540
TTCTTCAGCC AGTTCACNAT NTTCATCAGC CCCTCTGCCA GCTGTTNTAT TCCTTGGGGG 600
GGAANCCGTC TCTCCCTTCC TGAANNAACT TTGACCGTNG GAATAGCCGC GCNTCNCCNT 660
ACNTNCTGGG CCGGGTTCAA ANTCCCTCCN TTGNCNNTCN CCTCGGGCCA TTCTGGATTT 720
NCCNAACTTT TTCCTTCCCC CNCCCCNCGG NGTTTGGNTT TTTCATNGGG CCCCAACTCT 780
GCTNTTGGCC ANTCCCCTGG GGGCNTNTAN CNCCCCCTNT GGTCCCNTNG GGCC 834
(2)关于SEQ ID NO:36的信息
(i)序列特征
(A)长度:814个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:36:
CGGNCGCTTT CCNGCCGCGC CCCGTTTCCA TGACNAAGGC TCCCTTCANG TTAAATACNN 60
CCTAGNAAAC ATTAATGGGT TGCTCTACTA ATACATCATA CNAACCAGTA AGCCTGCCCA 120
NAACGCCAAC TCAGGCCATT CCTACCAAAG GAAGAAAGGC TGGTCTCTCC ACCCCCTGTA 180
GGAAAGGCCT GCCTTGTAAG ACACCACAAT NCGGCTGAAT CTNAAGTCTT GTGTTTTACT 240
AATGGAAAAA AAAAATAAAC AANAGGTTTT GTTCTCATGG CTGCCCACCG CAGCCTGGCA 300
CTAAAACANC CCAGCGCTCA CTTCTGCTTG GANAAATATT CTTTGCTCTT TTGGACATCA 360
GGCTTGATGG TATCACTGCC ACNTTTCCAC CCAGCTGGGC NCCCTTCCCC CATNTTTGTC 420
ANTGANCTGG AAGGCCTGAA NCTTAGTCTC CAAAAGTCTC NGCCCACAAG ACCGGCCACC 480
AGGGGANGTC NTTTNCAGTG GATCTGCCAA ANANTACCCN TATCATCNNT GAATAAAAAG 540
GCCCCTGAAC GANATGCTTC CANCANCCTT TAAGACCCAT AATCCTNGAA CCATGGTGCC 600
CTTCCGGTCT GATCCNAAAG GAATGTTCCT GGGTCCCANT CCCTCCTTTG TTNCTTACGT 660
TGTNTTGGAC CCNTGCTNGN ATNACCCAAN TGANATCCCC NGAAGCACCC TNCCCCTGGC 720
ATTTGANTTT CNTAAATTCT CTGCCCTACN NCTGAAAGCA CNATTCCCTN GGCNCCNAAN 780
GGNGAACTCA AGAAGGTCTN NGAAAAACCA CNCN 814
(2)关于SEQ ID NO:37的信息
(i)序列特征
(A)长度:760个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:37:
GCATGCTGCT CTTCCTCAAA GTTGTTCTTG TTGCCATAAC AACCACCATA GGTAAAGCGG 60
GCGCAGTGTT CGCTGAAGGG GTTGTAGTAC CAGCGCGGGA TGCTCTCCTT GCAGAGTCCT 120
GTGTCTGGCA GGTCCACGCA ATGCCCTTTG TCACTGGGGA AATGGATGCG CTGGAGCTCG 180
TCNAANCCAC TCGTGTATTT TTCACANGCA GCCTCCTCCG AAGCNTCCGG GCAGTTGGGG 240
GTGTCGTCAC ACTCCACTAA ACTGTCGATN CANCAGCCCA TTGCTGCAGC GGAACTGGGT 300
GGGCTGACAG GTGCCAGAAC ACACTGGATN GGCCTTTCCA TGGAAGGGCC TGGGGGAAAT 360
CNCCTNANCC CAAACTGCCT CTCAAAGGCC ACCTTGCACA CCCCGACAGG CTAGAAATGC 420
ACTCTTCTTC CCAAAGGTAG TTGTTCTTGT TGCCCAAGCA NCCTCCANCA AACCAAAANC 480
TTGCAAAATC TGCTCCGTGG GGGTCATNNN TACCANGGTT GGGGAAANAA ACCCGGCNGN 540
GANCCNCCTT GTTTGAATGC NAAGGNAATA ATCCTCCTGT CTTGCTTGGG TGGAANAGCA 600
CAATTGAACT GTTAACNTTG GGCCGNGTTC CNCTNGGGTG GTCTGAAACT AATCACCGTC 660
ACTGGAAAAA GGTANGTGCC TTCCTTGAAT TCCCAAANTT CCCCTNGNTT TGGGTNNTTT 720
CTCCTCTNCC CTAAAAATCG TNTTCCCCCC CCNTANGGCG 760
(2)关于SEQ ID NO:38的信息
(i)序列特征
(A)长度:724个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:38:
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTAAAAA CCCCCTCCAT TGAATGAAAA 60
CTTCCNAAAT TGTCCAACCC CCTCNNCCAA ATNNCCATTT CCGGGGGGGG GTTCCAAACC 120
CAAATTAATT TTGGANTTTA AATTAAATNT TNATTNGGGG AANAANCCAA ATGTNAAGAA 180
AATTTAACCC ATTATNAACT TAAATNCCTN GAAACCCNTG GNTTCCAAAA ATTTTTAACC 240
CTTAAATCCC TCCGAAATTG NTAANGGAAA ACCAAATTCN CCTAAGGCTN TTTGAAGGTT 300
NGATTTAAAC CCCCTTNANT TNTTTTNACC CNNGNCTNAA NTATTTNGNT TCCGGTGTTT 360
TCCTNTTAAN CNTNGGTAAC TCCCGNTAAT GAANNNCCCT AANCCAATTA AACCGAATTT 420
TTTTTGAATT GGAAATTCCN NGGGAATTNA CCGGGGTTTT TCCCNTTTGG GGGCCATNCC 480
CCCNCTTTCG GGGTTTGGGN NTAGGTTGAA TTTTTNNANG NCCCAAAAAA NCCCCCAANA 540
AAAAAACTCC CAAGNNTTAA TTNGAATNTC CCCCTTCCCA GGCCTTTTGG GAAAGGNGGG 600
TTTNTGGGGG CCNGGGANTT CNTTCCCCCN TTNCCNCCCC CCCCCCNGGT AAANGGTTAT 660
NGNNTTTGGT TTTTGGGCCC CTTNANGGAC CTTCCGGATN GAAATTAAAT CCCCGGGNCG 720
GCCG 724
(2)关于SEQ ID NO:39的信息
(i)序列特征
(A)长度:751个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:39:
TTTTTTTTTT TTTTTCTTTG CTCACATTTA ATTTTTATTT TGATTTTTTT TAATGCTGCA 60
CAACACAATA TTTATTTCAT TTGTTTCTTT TATTTCATTT TATTTGTTTG CTGCTGCTGT 120
TTTATTTATT TTTACTGAAA GTGAGAGGGA ACTTTTGTGG CCTTTTTTCC TTTTTCTGTA 180
GGCCGCCTTA AGCTTTCTAA ATTTGGAACA TCTAAGCAAG CTGAANGGAA AAGGGGGTTT 240
CGCAAAATCA CTCGGGGGAA NGGAAAGGTT GCTTTGTTAA TCATGCCCTA TGGTGGGTGA 300
TTAACTGCTT GTACAATTAC NTTTCACTTT TAATTAATTG TGCTNAANGC TTTAATTANA 360
CTTGGGGGTT CCCTCCCCAN ACCAACCCCN CTGACAAAAA GTGCCNGCCC TCAAATNATG 420
TCCCGGCNNT CNTTGAAACA CACNGCNGAA NGTTCTCATT NTCCCCNCNC CAGGTNAAAA 480
TGAAGGGTTA CCATNTTTAA CNCCACCTCC ACNTGGCNNN GCCTGAATCC TCNAAAANCN 540
CCCTCAANCN AATTNCTNNG CCCCGGTCNC GCNTNNGTCC CNCCCGGGCT CCGGGAANTN 600
CACCCCCNGA ANNCNNTNNC NAACNAAATT CCGAAAATAT TCCCNNTCNC TCAATTCCCC 660
CNNAGACTNT CCTCNNCNAN CNCAATTTTC TTTTNNTCAC GAACNCGNNC CNNAAAATGN 720
NNNNCNCCTC CNCTNGTCCN NAATCNCCAN C 751
(2)关于SEQ ID NO:40的信息
(i)序列特征
(A)长度:753个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:40:
GTGGTATTTT CTGTAAGATC AGGTGTTCCT CCCTCGTAGG TTTAGAGGAA ACACCCTCAT 60
AGATGAAAAC CCCCCCGAGA CAGCAGCACT GCAACTGCCA AGCAGCCGGG GTAGGAGGGG 120
CGCCCTATGC ACAGCTGGGC CCTTGAGACA GCAGGGCTTC GATGTCAGGC TCGATGTCAA 180
TGGTCTGGAA GCGGCGGCTG TACCTGCGTA GGGGCACACC GTCAGGGCCC ACCAGGAACT 240
TCTCAAAGTT CCAGGCAACN TCGTTGCGAC ACACCGGAGA CCAGGTGATN AGCTTGGGGT 300
CGGTCATAAN CGCGGTGGCG TCGTCGCTGG GAGCTGGCAG GGCCTCCCGC AGGAAGGCNA 360
ATAAAAGGTG CGCCCCCGCA CCGTTCANCT CGCACTTCTC NAANACCATG ANGTTGGGCT 420
CNAACCCACC ACCANNCCGG ACTTCCTTGA NGGAATTCCC AAATCTCTTC GNTCTTGGGC 480
TTCTNCTGAT GCCCTANCTG GTTGCCCNGN ATGCCAANCA NCCCCAANCC CCGGGGTCCT 540
AAANCACCCN CCTCCTCNTT TCATCTGGGT TNTTNTCCCC GGACCNTGGT TCCTCTCAAG 600
GGANCCCATA TCTCNACCAN TACTCACCNT NCCCCCCCNT GNNACCCANC CTTCTANNGN 660
TTCCCNCCCG NCCTCTGGCC CNTCAAANAN GCTTNCACNA CCTGGGTCTG CCTTCCCCCC 720
TNCCCTATCT GNACCCCNCN TTTGTCTCAN TNT 753
(2)关于SEQ ID NO:41的信息
(i)序列特征
(A)长度:341个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:41:
ACTATATCCA TCACAACAGA CATGCTTCAT CCCATAGACT TCTTGACATA GCTTCAAATG 60
AGTGAACCCA TCCTTGATTT ATATACATAT ATGTTCTCAG TATTTTGGGA GCCTTTCCAC 120
TTCTTTAAAC CTTGTTCATT ATGAACACTG AAAATAGGAA TTTGTGAAGA GTTAAAAAGT 180
TATAGCTTGT TTACGTAGTA AGTTTTTGAA GTCTACATTC AATCCAGACA CTTAGTTGAG 240
TGTTAAACTG TGATTTTTAA AAAATATCAT TTGAGAATAT TCTTTCAGAG GTATTTTCAT 300
TTTTACTTTT TGATTAATTG TGTTTTATAT ATTAGGGTAG T 341
(2)关于SEQ ID NO:42的信息
(i)序列特征
(A)长度:101个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:42:
ACTTACTGAA TTTAGTTCTG TGCTCTTCCT TATTTAGTGT TGTATCATAA ATACTTTGAT 60
GTTTCAAACA TTCTAAATAA ATAATTTTCA GTGGCTTCAT A 101
(2)关于SEQ ID NO:43的信息
(i)序列特征
(A)长度:305个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:43:
ACATCTTTGT TACAGTCTAA GATGTGTTCT TAAATCACCA TTCCTTCCTG GTCCTCACCC 60
TCCAGGGTGG TCTCACACTG TAATTAGAGC TATTGAGGAG TCTTTACAGC AAATTAAGAT 120
TCAGATGCCT TGCTAAGTCT AGAGTTCTAG AGTTATGTTT CAGAAAGTCT AAGAAACCCA 180
CCTCTTGAGA GGTCAGTAAA GAGGACTTAA TATTTCATAT CTACAAAATG ACCACAGGAT 240
TGGATACAGA ACGAGAGTTA TCCTGGATAA CTCAGAGCTG AGTACCTGCC CGGGGGCCGC 300
TCGAA 305
(2)关于SEQ ID NO:44的信息
(i)序列特征
(A)长度:852个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:44:
ACATAAATAT CAGAGAAAAG TAGTCTTTGA AATATTTACG TCCAGGAGTT CTTTGTTTCT 60
GATTATTTGG TGTGTGTTTT GGTTTGTGTC CAAAGTATTG GCAGCTTCAG TTTTCATTTT 120
CTCTCCATCC TCGGGCATTC TTCCCAAATT TATATACCAG TCTTCGTCCA TCCACACGCT 180
CCAGAATTTC TCTTTTGTAG TAATATCTCA TAGCTCGGCT GAGCTTTTCA TAGGTCATGC 240
TGCTGTTGTT CTTCTTTTTA CCCCATAGCT GAGCCACTGC CTCTGATTTC AAGAACCTGA 300
AGACGCCCTC AGATCGGTCT TCCCATTTTA TTAATCCTGG GTTCTTGTCT GGGTTCAAGA 360
GGATGTCGCG GATGAATTCC CATAAGTGAG TCCCTCTCGG GTTGTGCTTT TTGGTGTGGC 420
ACTTGGCAGG GGGGTCTTGC TCCTTTTTCA TATCAGGTGA CTCTGCAACA GGAAGGTGAC 480
TGGTGGTTGT CATGGAGATC TGAGCCCGGC AGAAAGTTTT GCTGTCCAAC AAATCTACTG 540
TGCTACCATA GTTGGTGTCA TATAAATAGT TCTNGTCTTT CCAGGTGTTC ATGATGGAAG 600
GCTCAGTTTG TTCAGTCTTG ACAATGACAT TGTGTGTGGA CTGGAACAGG TCACTACTGC 660
ACTGGCCGTT CCACTTCAGA TGCTGCAAGT TGCTGTAGAG GAGNTGCCCC GCCGTCCCTG 720
CCGCCCGGGT GAACTCCTGC AAACTCATGC TGCAAAGGTG CTCGCCGTTG ATGTCGAACT 780
CNTGGAAAGG GATACAATTG GCATCCAGCT GGTTGGTGTC CAGGAGGTGA TGGAGCCACT 840
CCCACACCTG GT 852
(2)关于SEQ ID NO:45的信息
(i)序列特征
(A)长度:234个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:45:
ACAACAGACC CTTGCTCGCT AACGACCTCA TGCTCATCAA GTTGGACGAA TCCGTGTCCG 60
AGTCTGACAC CATCCGGAGC ATCAGCATTG CTTCGCAGTG CCCTACCGCG GGGAACTCTT 120
GCCTCGTTTC TGGCTGGGGT CTGCTGGCGA ACGGCAGAAT GCCTACCGTG CTGCAGTGCG 180
TGAACGTGTC GGTGGTGTCT GAGGAGGTCT GCAGTAAGCT CTATGACCCG CTGT 234
(2)关于SEQ ID NO:46的信息
(i)序列特征
(A)长度:590个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:46:
ACTTTTTATT TAAATGTTTA TAAGGCAGAT CTATGAGAAT GATAGAAAAC ATGGTGTGTA 60
ATTTGATAGC AATATTTTGG AGATTACAGA GTTTTAGTAA TTACCAATTA CACAGTTAAA 120
AAGAAGATAA TATATTCCAA GCANATACAA AATATCTAAT GAAAGATCAA GGCAGGAAAA 180
TGANTATAAC TAATTGACAA TGGAAAATCA ATTTTAATGT GAATTGCACA TTATCCTTTA 240
AAAGCTTTCA AAANAAANAA TTATTGCAGT CTANTTAATT CAAACAGTGT TAAATGGTAT 300
CAGGATAAAN AACTGAAGGG CANAAAGAAT TAATTTTCAC TTCATGTAAC NCACCCANAT 360
TTACAATGGC TTAAATGCAN GGAAAAAGCA GTGGAAGTAG GGAAGTANTC AAGGTCTTTC 420
TGGTCTCTAA TCTGCCTTAC TCTTTGGGTG TGGCTTTGAT CCTCTGGAGA CAGCTGCCAG 480
GGCTCCTGTT ATATCCACAA TCCCAGCAGC AAGATGAAGG GATGAAAAAG GACACATGCT 540
GCCTTCCTTT GAGGAGACTT CATCTCACTG GCCAACACTC AGTCACATGT 590
(2)关于SEQ ID NO:47的信息
(i)序列特征
(A)长度:774个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:47:
ACAAGGGGGC ATAATGAAGG AGTGGGGANA GATTTTAAAG AAGGAAAAAA AACGAGGCCC 60
TGAACAGAAT TTTCCTGNAC AACGGGGCTT CAAAATAATT TTCTTGGGGA GGTTCAAGAC 120
GCTTCACTGC TTGAAACTTA AATGGATGTG GGACANAATT TTCTGTAATG ACCCTGAGGG 180
CATTACAGAC GGGACTCTGG GAGGAAGGAT AAACAGAAAG GGGACAAAGG CTAATCCCAA 240
AACATCAAAG AAAGGAAGGT GGCGTCATAC CTCCCAGCCT ACACAGTTCT CCAGGGCTCT 300
CCTCATCCCT GGAGGACGAC AGTGGAGGAA CAACTGACCA TGTCCCCAGG CTCCTGTGTG 360
CTGGCTCCTG GTCTTCAGCC CCCAGCTCTG GAAGCCCACC CTCTGCTGAT CCTGCGTGGC 420
CCACACTCCT TGAACACACA TCCCCAGGTT ATATTCCTGG ACATGGCTGA ACCTCCTATT 480
CCTACTTCCG AGATGCCTTG CTCCCTGCAG CCTGTCAAAA TCCCACTCAC CCTCCAAACC 540
ACGGCATGGG AAGCCTTTCT GACTTGCCTG ATTACTCCAG CATCTTGGAA CAATCCCTGA 600
TTCCCCACTC CTTAGAGGCA AGATAGGGTG GTTAAGAGTA GGGCTGGACC ACTTGGAGCC 660
AGGCTGCTGG CTTCAAATTN TGGCTCATTT ACGAGCTATG GGACCTTGGG CAAGTNATCT 720
TCACTTCTAT GGGCNTCATT TTGTTCTACC TGCAAAATGG GGGATAATAA TAGT 774
(2)关于SEQ ID NO:48的信息
(i)序列特征
(A)长度:124个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:48:
CANAAATTGA AATTTTATAA AAAGGCATTT TTCTCTTATA TCCATAAAAT GATATAATTT 60
TTGCAANTAT ANAAATGTGT CATAAATTAT AATGTTCCTT AATTACAGCT CAACGCAACT 120
TGGT 124
(2)关于SEQ ID NO:49的信息
(i)序列特征
(A)长度:147个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:49:
GCCGATGCTA CTATTTTATT GCAGGAGGTG GGGGTGTTTT TATTATTCTC TCAACAGCTT 60
TGTGGCTACA GGTGGTGTCT GACTGCATNA AAAANTTTTT TACGGGTGAT TGCAAAAATT 120
TTAGGGCACC CATATCCCAA GCANTGT 147
(2)关于SEQ ID NO:50的信息
(i)序列特征
(A)长度:107个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:50:
ACATTAAATT AATAAAAGGA CTGTTGGGGT TCTGCTAAAA CACATGGCTT GATATATTGC 60
ATGGTTTGAG GTTAGGAGGA GTTAGGCATA TGTTTTGGGA GAGGGGT 107
(2)关于SEQ ID NO:51的信息
(i)序列特征
(A)长度:204个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:51:
GTCCTAGGAA GTCTAGGGGA CACACGACTC TGGGGTCACG GGGCCGACAC ACTTGCACGG 60
CGGGAAGGAA AGGCAGAGAA GTGACACCGT CAGGGGGAAA TGACAGAAAG GAAAATCAAG 120
GCCTTGCAAG GTCAGAAAGG GGACTCAGGG CTTCCACCAC AGCCCTGCCC CACTTGGCCA 180
CCTCCCTTTT GGGACCAGCA ATGT 204
(2)关于SEQ ID NO:52的信息
(i)序列特征
(A)长度:491个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:52:
ACAAAGATAA CATTTATCTT ATAACAAAAA TTTGATAGTT TTAAAGGTTA GTATTGTGTA 60
GGGTATTTTC CAAAAGACTA AAGAGATAAC TCAGGTAAAA AGTTAGAAAT GTATAAAACA 120
CCATCAGACA GGTTTTTAAA AAACAACATA TTACAAAATT AGACAATCAT CCTTAAAAAA 180
AAAACTTCTT GTATCAATTT CTTTTGTTCA AAATGACTGA CTTAANTATT TTTAAATATT 240
TCANAAACAC TTCCTCAAAA ATTTTCAANA TGGTAGCTTT CANATGTNCC CTCAGTCCCA 300
ATGTTGCTCA GATAAATAAA TCTCGTGAGA ACTTACCACC CACCACAAGC TTTCTGGGGC 360
ATGCAACAGT GTCTTTTCTT TNCTTTTTCT TTTTTTTTTT TTACAGGCAC AGAAACTCAT 420
CAATTTTATT TGGATAACAA AGGGTCTCCA AATTATATTG AAAAATAAAT CCAAGTTAAT 480
ATCACTCTTG T 491
(2)关于SEQ ID NO:53的信息
(i)序列特征
(A)长度:484碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:53
ACATAATTTA GCAGGGCTAA TTACCATAAG ATGCTATTTA TTAANAGGTN TATGATCTGA 60
GTATTAACAG TTGCTGAAGT TTGGTATTTT TATGCAGCAT TTTCTTTTTG CTTTGATAAC 120
ACTACAGAAC CCTTAAGGAC ACTGAAAATT AGTAAGTAAA GTTCAGAAAC ATTAGCTGCT 180
CAATCAAATC TCTACATAAC ACTATAGTAA TTAAAACGTT AAAAAAAAGT GTTGAAATCT 240
GCACTAGTAT ANACCGCTCC TGTCAGGATA ANACTGCTTT GGAACAGAAA GGGAAAAANC 300
AGCTTTGANT TTCTTTGTGC TGATANGAGG AAAGGCTGAA TTACCTTGTT GCCTCTCCCT 360
AATGATTGGC AGGTCNGGTA AATNCCAAAA CATATTCCAA CTCAACACTT CTTTTCCNCG 420
TANCTTGANT CTGTGTATTC CAGGANCAGG CGGATGGAAT GGGCCAGCCC NCGGATGTTC 480
CANT 434
(2)关于SEQ ID NO:54信息
(i)序列特征
(A)长度:151个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:54:
ACTAAACCTC GTGCTTGTGA ACTCCATACA GAAAACGGTG CCATCCCTGA ACACGGCTGG 60
CCACTGGGTA TACTGCTGAC AACCGCAACA ACAAAAACAC AAATCCTTGG CACTGGCTAG 120
TCTATGTCCT CTCAAGTGCC TTTTTGTTTG T 151
(2)关于SEQ ID NO:55的信息
(i)序列特征
(A)长度:91个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:55:
ACCTGGCTTG TCTCCGGGTG GTTCCCGGCG CCCCCCACGG TCCCCAGAAC GGACACTTTC 60
GCCCTCCAGT GGATACTCGA GCCAAAGTGG T 91
(2)关于SEQ ID NO:56的信息
(i)序列特征
(A)长度:133个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:56:
GGCGGATGTG CGTTGGTTAT ATACAAATAT GTCATTTTAT GTAAGGGACT TGAGTATACT 60
TGGATTTTTG GTATCTGTGG GTTGGGGGGA CGGTCCAGGA ACCAATACCC CATGGATACC 120
AAGGGACAAC TGT 133
(2)关于SEQ ID NO:57的信息
(i)序列特征
(A)长度:147个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:57:
ACTCTGGAGA ACCTGAGCCG CTGCTCCGCC TCTGGGATGA GGTGATGCAN GCNGTGGCGC 60
GACTGGGAGC TGAGCCCTTC CCTTTGCGCC TGCCTCAGAG GATTGTTGCC GACNTGCANA 120
TCTCANTGGG CTGGATNCAT GCAGGGT 147
(2)关于SEQ ID NO:58的信息
(i)序列特征
(A)长度:198个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:58:
ACAGGGATAT AGGTTTNAAG TTATTGTNAT TGTAAAATAC ATTGAATTTT CTGTATACTC 60
TGATTACATA CATTTATCCT TTAAAAAAGA TGTAAATCTT AATTTTTATG CCATCTATTA 120
ATTTACCAAT GAGTTACCTT GTAAATGAGA AGTCATGATA GCACTGAATT TTAACTAGTT 180
TTGACTTCTA AGTTTGGT 198
(2)关于SEQ ID NO:59的信息
(i)序列特征
(A)长度:330个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:59:
ACAACAAATG GGTTGTGAGG AAGTCTTATC AGCAAAACTG GTGATGGCTA CTGAAAAGAT 60
CCATTGAAAA TTATCATTAA TGATTTTAAA TGACAAGTTA TCAAAAACTC ACTCAATTTT 120
CACCTGTGCT AGCTTGCTAA AATGGGAGTT AACTCTAGAG CAAATATAGT ATCTTCTGAA 180
TACAGTCAAT AAATGACAAA GCCAGGGCCT ACAGGTGGTT TCCAGACTTT CCAGACCCAG 240
CAGAAGGAAT CTATTTTATC ACATGGATCT CCGTCTGTGC TCAAAATACC TAATGATATT 300
TTTCGTCTTT ATTGGACTTC TTTGAAGAGT 330
(2)关于SEQ ID NO:60的信息
(i)序列特征
(A)长度:175个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:60:
ACCGTGGGTG CCTTCTACAT TCCTGACGGC TCCTTCACCA ACATCTGGTT CTACTTCGGC 60
GTCGTGGGCT CCTTCCTCTT CATCCTCATC CAGCTGGTGC TGCTCATCGA CTTTGCGCAC 120
TCCTGGAACC AGCGGTGGCT GGGCAAGGCC GAGGAGTGCG ATTCCCGTGC CTGGT 175
(2)关于SEQ ID NO:61的信息
(i)序列特征
(A)长度:154个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:61:
ACCCCACTTT TCCTCCTGTG AGCAGTCTGG ACTTCTCACT GCTACATGAT GAGGGTGAGT 60
GGTTGTTGCT CTTCAACAGT ATCCTCCCCT TTCCGGATCT GCTGAGCCGG ACAGCAGTGC 120
TGGACTGCAC AGCCCCGGGG CTCCACATTG CTGT 154
(2)关于SEQ ID NO:62的信息
(i)序列特征
(A)长度:30个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:62:
CGCTCGAGCC CTATAGTGAG TCGTATTAGA 30
(2)关于SEQ ID NO:63的信息
(i)序列特征
(A)长度:89个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:63:
ACAAGTCATT TCAGCACCCT TTGCTCTTCA AAACTGACCA TCTTTTATAT TTAATGCTTC 60
CTGTATGAAT AAAAATGGTT ATGTCAAGT 89
(2)关于SEQ ID NO:64的信息
(i)序列特征
(A)长度:97个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:64:
ACCGGAGTAA CTGAGTCGGG ACGCTGAATC TGAATCCACC AATAAATAAA GGTTCTGCAG 60
AATCAGTGCA TCCAGGATTG GTCCTTGGAT CTGGGGT 97
(2)关于SEQ ID NO:65的信息
(i)序列特征
(A)长度:377个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:65:
ACAACAANAA NTCCCTTCTT TAGGCCACTG ATGGAAACCT GGAACCCCCT TTTGATGGCA 60
GCATGGCGTC CTAGGCCTTG ACACAGCGGC TGGGGTTTGG GCTNTCCCAA ACCGCACACC 120
CCAACCCTGG TCTACCCACA NTTCTGGCTA TGGGCTGTCT CTGCCACTGA ACATCAGGGT 130
TCGGTCATAA NATGAAATCC CAANGGGGAC AGAGGTCAGT AGAGGAAGCT CAATGAGAAA 240
GGTGCTGTTT GCTCAGCCAG AAAACAGCTG CCTGGCATTC GCCGCTGAAC TATGAACCCG 300
TGGGGGTGAA CTACCCCCAN GAGGAATCAT GCCTGGGCGA TGCAANGGTG CCAACAGGAG 360
GGGCGGGAGG AGCATGT 377
(2)关于SEQ ID NO:66的信息
(i)序列特征
(A)长度:305个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:66:
ACGCCTTTCC CTCAGAATTC AGGGAAGAGA CTGTCGCCTG CCTTCCTCCG TTGTTGCGTG 60
AGAACCCGTG TGCCCCTTCC CACCATATCC ACCCTCGCTC CATCTTTGAA CTCAAACACG 120
AGGAACTAAC TGCACCCTGG TCCTCTCCCC AGTCCCCAGT TCACCCTCCA TCCCTCACCT 180
TCCTCCACTC TAAGGGATAT CAACACTGCC CAGCACAGGG GCCCTGAATT TATGTGGTTT 240
TTATATATTT TTTAATAAGA TGCACTTTAT GTCATTTTTT AATAAAGTCT GAAGAATTAC 300
TGTTT 305
(2)关于SEQ ID NO:67的信息
(i)序列特征
(A)长度:385个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:67:
ACTACACACA CTCCACTTGC CCTTGTGAGA CACTTTGTCC CAGCACTTTA GGAATGCTGA 60
GGTCGGACCA GCCACATCTC ATGTGCAAGA TTGCCCAGCA GACATCAGGT CTGAGAGTTC 120
CCCTTTTAAA AAAGGGGACT TGCTTAAAAA AGAAGTCTAG CCACGATTGT GTAGAGCAGC 180
TGTGCTGTGC TGGAGATTCA CTTTTGAGAG AGTTCTCCTC TGAGACCTGA TCTTTAGAGG 240
CTGGGCAGTC TTGCACATGA GATGGGGCTG GTCTGATCTC AGCACTCCTT AGTCTGCTTG 300
CCTCTCCCAG GGCCCCAGCC TGGCCACACC TGCTTACAGG GCACTCTCAG ATGCCCATAC 360
CATAGTTTCT GTGCTAGTGG ACCGT 385
(2)关于SEQ ID NO:68的信息
(i)序列特征
(A)长度:73个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:68:
ACTTAACCAG ATATATTTTT ACCCCAGATG GGGATATTCT TTGTAAAAAA TGAAAATAAA 60
GTTTTTTTAA TGG 73
(2)关于SEQ ID NO:69的信息
(i)序列特征
(A)长度:536个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:69:
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGGGCTC TCACCCTCCT CTCCTGCAGC 60
TCCAGCTTTG TGCTCTGCCT CTGAGGAGAC CATGGCCCAG CATCTGAGTA CCCTGCTGCT 120
CCTGCTGGCC ACCCTAGCTG TGGCCCTGGC CTGGAGCCCC AAGGAGGAGG ATAGGATAAT 180
CCCGGGTGGC ATCTATAACG CAGACCTCAA TGATGAGTGG GTACAGCGTG CCCTTCACTT 240
CGCCATCAGC GAGTATAACA AGGCCACCAA AGATGACTAC TACAGACGTC CGCTGCGGGT 300
ACTAAGAGCC AGGCAACAGA CCGTTGGGGG GGTGAATTAC TTCTTCGACG TAGAGGTGGG 360
CCGAACCATA TGTACCAAGT CCCAGCCCAA CTTGGACACC TGTGCCTTCC ATGAACAGCC 420
AGAACTGCAG AAGAAACAGT TGTGCTCTTT CGAGATCTAC GAAGTTCCCT GGGGAGAACA 480
GAANGTCCCT GGGTGAAATC CAGGTGTCAA GAAATCCTAN GGATCTGTTG CCAGGC 536
(2)关于SEQ ID NO:70的信息
(i)序列特征
(A)长度:477个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:70:
ATGACCCCTA ACAGGGGCCC TCTCAGCCCT CCTAATGACC TCCGGCCTAG CCATGTGATT 60
TCACTTCCAC TCCATAACGC TCCTCATACT AGGCCTACTA ACCAACACAC TAACCATATA 120
CCAATGATGG CGCGATGTAA CACGAGAAAG CACATACCAA GGCCACCACA CACCACCTGT 180
CCAAAAAGGC CTTCGATACG GGATAATCCT ATTTATTACC TCAGAAGTTT TTTTCTTCGC 240
AGGGATTTTT CTGAGCCTTT TACCACTCCA GCCTAGCCCC TACCCCCCAA CTAGGAGGGC 300
ACTGGCCCCC AACAGGCATC ACCCCGCTAA ATCCCCTAGA AGTCCCACTC CTAAACACAT 360
CCGTATTACT CGCATCAGGA GTATCAATCA CCTGAGCTCA CCATAGTCTA ATAGAAAACA 420
ACCGAAACCA AATTATTCAA AGCACTGCTT ATTACAATTT TACTGGGTCT CTATTTT 477
(2)关于SEQ ID NO:71的信息
(i)序列特征
(A)长度:533个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:71:
AGAGCTATAG GTACAGTGTG ATCTCAGCTT TGCAAACACA TTTTCTACAT AGATAGTACT 60
AGGTATTAAT AGATATGTAA AGAAAGAAAT CACACCATTA ATAATGGTAA GATTGGTTTA 120
TGTGATTTTA GTGGTATTTT TGGCACCCTT ATATATGTTT TCCAAACTTT CAGCAGTGAT 180
ATTATTTCCA TAACTTAAAA AGTGAGTTTG AAAAAGAAAA TCTCCAGCAA GCATCTCATT 240
TAAATAAAGG TTTGTCATCT TTAAAAATAC AGCAATATGT GACTTTTTAA AAAAGCTGTC 300
AAATAGGTGT GACCCTACTA ATAATTATTA GAAATACATT TAAAAACATC GAGTACCTCA 360
AGTCAGTTTG CCTTGAAAAA TATCAAATAT AACTCTTAGA GAAATGTACA TAAAAGAATG 420
CTTCGTAATT TTGGAGTANG AGGTTCCCTC CTCAATTTTG TATTTTTAAA AAGTACATGG 480
TAAAAAAAAA AATTCACAAC AGTATATAAG GCTGTAAAAT GAAGAATTCT GCC 533
(2)关于SEQ ID NO:72的信息
(i)序列特征
(A)长度:511个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:72:
TATTACGGAA AAACACACCA CATAATTCAA CTANCAAAGA ANACTGCTTC AGGGCGTGTA 60
AAATGAAAGG CTTCCAGGCA GTTATCTGAT TAAAGAACAC TAAAAGAGGG ACAAGGCTAA 120
AAGCCGCAGG ATGTCTACAC TATANCAGGC GCTATTTGGG TTGGCTGGAG GAGCTGTGGA 180
AAACATGGAN AGATTGGTGC TGGANATCGC CGTGGCTATT CCTCATTGTT ATTACANAGT 240
GAGGTTCTCT GTGTGCCCAC TGGTTTGAAA ACCGTTCTNC AATAATGATA GAATAGTACA 300
CACATGAGAA CTGAAATGGC CCAAACCCAG AAAGAAAGCC CAACTAGATC CTCAGAANAC 360
GCTTCTAGGG ACAATAACCG ATGAAGAAAA GATGGCCTCC TTGTGCCCCC GTCTGTTATG 420
ATTTCTCTCC ATTGCAGCNA NAAACCCGTT CTTCTAAGCA AACNCAGGTG ATGATGGCNA 480
AAATACACCC CCTCTTGAAG NACCNGGAGG A 511
(2)关于SEQ ID NO:的信息
(i)序列特征
(A)长度:499个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:73:
CAGTGCCAGC ACTGGTGCCA GTACCAGTAC CAATAACAGT GCCAGTGCCA GTGCCAGCAC 60
CAGTGGTGGC TTCAGTGCTG GTGCCAGCCT GACCGCCACT CTCACATTTG GGCTCTTCGC 120
TGGCCTTGGT GGAGCTGGTG CCAGCACCAG TGGCAGCTCT GGTGCCTGTG GTTTCTCCTA 180
CAAGTGAGAT TTTAGATATT GTTAATCCTG CCAGTCTTTC TCTTCAAGCC AGGGTGCATC 240
CTCAGAAACC TACTCAACAC AGCACTCTAG GCAGCCACTA TCAATCAATT GAAGTTGACA 300
CTCTGCATTA AATCTATTTG CCATTTCTGA AAAAAAAAAA AAAAAAAGGG CGGCCGCTCG 360
ANTCTAGAGG GCCCGTTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT ANTTGCCAGC 420
CATCTGTTGT TTGCCCCTCC CCCGNTGCCT TCCTTGACCC TGGAAAGTGC CACTCCCACT 480
GTCCTTTCCT AANTAAAAT 499
(2)关于SEQ ID NO:74的信息
(i)序列特征
(A)长度:537个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:74:
TTTCATAGGA GAACACACTG AGGAGATACT TGAAGAATTT GGATTCAGCC GCGAAGAGAT 60
TTATCAGCTT AACTCAGATA AAATCATTGA AAGTAATAAG GTAAAAGCTA GTCTCTAACT 120
TCCAGGCCCA CGGCTCAAGT GAATTTGAAT ACTGCATTTA CAGTGTAGAG TAACACATAA 180
CATTGTATGC ATGGAAACAT GGAGGAACAG TATTACAGTG TCCTACCACT CTAATCAAGA 240
AAAGAATTAC AGACTCTGAT TCTACAGTGA TGATTGAATT CTAAAAATGG TAATCATTAG 300
GGCTTTTGAT TTATAANACT TTGGGTACTT ATACTAAATT ATGGTAGTTA TACTGCCTTC 360
CAGTTTGCTT GATATATTTG TTGATATTAA GATTCTTGAC TTATATTTTG AATGGGTTCT 420
ACTGAAAAAN GAATGATATA TTCTTGAAGA CATCGATATA CATTTATTTA CACTCTTGAT 480
TCTACAATGT AGAAAATGAA GGAAATGCCC CAAATTGTAT GGTGATAAAA GTCCCGT 537
(2)关于SEQ ID NO:75的信息
(i)序列特征
(A)长度:467个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:75:
CAAANACAAT TGTTCAAAAG ATGCAAATGA TACACTACTG CTGCAGCTCA CAAACACCTC 60
TGCATATTAC ACGTACCTCC TCCTGCTCCT CAAGTAGTGT GGTCTATTTT GCCATCATCA 120
CCTGCTGTCT GCTTAGAAGA ACGGCTTTCT GCTGCAANGG AGAGAAATCA TAACAGACGG 180
TGGCACAAGG AGGCCATCTT TTCCTCATCG GTTATTGTCC CTAGAAGCGT CTTCTGAGGA 240
TCTAGTTGGG CTTTCTTTCT GGGTTTGGGC CATTTCANTT CTCATGTGTG TACTATTCTA 300
TCATTATTGT ATAACGGTTT TCAAACCNGT GGGCACNCAG AGAACCTCAC TCTGTAATAA 360
CAATGAGGAA TAGCCACGGT GATCTCCAGC ACCAAATCTC TCCATGTTNT TCCAGAGCTC 420
CTCCAGCCAA CCCAAATAGC CGCTGCTATN GTGTAGAACA TCCCTGN 467
(2)关于SEQ ID NO:76的信息
(i)序列特征
(A)长度:400个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:76:
AAGCTGACAG CATTCGGGCC GAGATGTCTC GCTCCGTGGC CTTAGCTGTG CTCGCGCTAC 60
TCTCTCTTTC TGGCCTGGAG GCTATCCAGC GTACTCCAAA GATTCAGGTT TACTCACGTC 120
ATCCAGCAGA GAATGGAAAG TCAAATTTCC TGAATTGCTA TGTGTCTGGG TTTCATCCAT 180
CCGACATTGA AGTTGACTTA CTGAAGAATG GAGAGAGAAT TGAAAAAGTG GAGCATTCAG 240
ACTTGTCTTT CAGCAAGGAC TGGTCTTTCT ATCTCTTGTA CTACACTGAA TTCACCCCCA 300
CTGAAAAAGA TGAGTATGCC TGCCGTGTGA ACCATGTGAC TTTGTCACAG CCCAAGATNG 360
TTNAGTGGGA TCGANACATG TAAGCAGCAN CATGGGAGGT 400
(2)关于SEQ ID NO:77的信息
(i)序列特征
(A)长度:248个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:77:
CTGGAGTGCC TTGGTGTTTC AAGCCCCTGC AGGAAGCAGA ATGCACCTTC TGAGGCACCT 60
CCAGCTGCCC CGGCGGGGGA TGCGAGGCTC GGAGCACCCT TGCCCGGCTG TGATTGCTGC 120
CAGGCACTGT TCATCTCAGC TTTTCTGTCC CTTTGCTCCC GGCAAGCGCT TCTGCTGAAA 180
GTTCATATCT GGAGCCTGAT GTCTTAACGA ATAAAGGTCC CATGCTCCAC CCGAAAAAAA 240
AAAAAAAA 248
(2)关于SEQ ID NO:78的信息
(i)序列特征
(A)长度:201个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:78:
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGCCCAA CACAATGGCT ACCTTTAACA 60
TCACCCAGAC CCCGCCCTGC CCGTGCCCCA CGCTGCTGCT AACGACAGTA TGATGCTTAC 120
TCTGCTACTC GGAAACTATT TTTATGTAAT TAATGTATGC TTTCTTGTTT ATAAATGCCT 180
GATTTAAAAA AAAAAAAAAA A 201
(2)关于SEQ ID NO:79的信息
(i)序列特征
(A)长度:552个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:79:
TCCTTTTGTT AGGTTTTTGA GACAACCCTA GACCTAAACT GTGTCACAGA CTTCTGAATG 60
TTTAGGCAGT GCTAGTAATT TCCTCGTAAT GATTCTGTTA TTACTTTCCT ATTCTTTATT 120
CCTCTTTCTT CTGAAGATTA ATGAAGTTGA AAATTGAGGT GGATAAATAC AAAAAGGTAG 180
TGTGATAGTA TAAGTATCTA AGTGCAGATG AAAGTGTGTT ATATATATCC ATTCAAAATT 240
ATGCAAGTTA GTAATTACTC AGGGTTAACT AAATTACTTT AATATGCTGT TGAACCTACT 300
CTGTTCCTTG GCTAGAAAAA ATTATAAACA GGACTTTGTT AGTTTGGGAA GCCAAATTGA 360
TAATATTCTA TGTTCTAAAA GTTGGGCTAT ACATAAANTA TNAAGAAATA TGGAATTTTA 420
TTCCCAGGAA TATGGGGTTC ATTTATGAAT ANTACCCGGG ANAGAAGTTT TGANTNAAAC 480
CNGTTTTGGT TAATACGTTA ATATGTCCTN AATNAACAAG GCNTGACTTA TTTCCAAAAA 540
AAAAAAAAAA AA 552
(2)关于SEQ ID NO:80的信息
(i)序列特征
(A)长度:476个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:80:
ACAGGGATTT GAGATGCTAA GGCCCCAGAG ATCGTTTGAT CCAACCCTCT TATTTTCAGA 60
GGGGAAAATG GGGCCTAGAA GTTACAGAGC ATCTAGCTGG TGCGCTGGCA CCCCTGGCCT 120
CACACAGACT CCCGAGTAGC TGGGACTACA GGCACACAGT CACTGAAGCA GGCCCTGTTT 180
GCAATTCACG TTGCCACCTC CAACTTAAAC ATTCTTCATA TGTGATGTCC TTAGTCACTA 240
AGGTTAAACT TTCCCACCCA GAAAAGGCAA CTTAGATAAA ATCTTAGAGT ACTTTCATAC 300
TCTTCTAAGT CCTCTTCCAG CCTCACTTTG AGTCCTCCTT GGGGGTTGAT AGGAANTNTC 360
TCTTGGCTTT CTCAATAAAA TCTCTATCCA TCTCATGTTT AATTTGGTAC GCNTAAAAAT 420
GCTGAAAAAA TTAAAATGTT CTGGTTTCNC TTTAAAAAAA AAAAAAAAAA AAAAAA 476
(2)关于SEQ ID NO:81的信息
(i)序列特征
(A)长度:232个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:81:
TTTTTTTTTG TATGCCNTCN CTGTGGNGTT ATTGTTGCTG CCACCCTGGA GGAGCCCAGT 60
TTCTTCTGTA TCTTTCTTTT CTGGGGGATC TTCCTGGCTC TGCCCCTCCA TTCCCAGCCT 120
CTCATCCCCA TCTTGCACTT TTGCTAGGGT TGGAGGCGCT TTCCTGGTAG CCCCTCAGAG 180
ACTCAGTCAG CGGGAATAAG TCCTAGGGGT GGGGGGTGTG GCAAGCCGGC CT 232
(2)关于SEQ ID NO:82的信息
(i)序列特征
(A)长度:383个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:82:
AGGCGGGAGC AGAAGCTAAA GCCAAAGCCC AAGAAGAGTG GCAGTGCCAG CACTGGTGCC 60
AGTACCAGTA CCAATAACAT GCCAGTGCCA GTGCCAGCAC CAGTGGTGGC TTCAGTGCTG 120
GTGCCAGCCT GACCGCCACT CTCACATTTG GGCTCTTCGC TGGCCTTGGT GGAGCTGGTG 180
CCAGCACCAG TGGCAGCTCT GGTGCCTGTG GTTTCTCCTA CAAGTGAGAT TTTAGATATT 240
GTTAATCCTG CCAGTCTTTC TCTTCAAGCC AGGGTGCATC CTCAGAAACC TACTCAACAC 300
AGCACTCTNG GCAGCCACTA TCAATCAATT GAAGTTGACA CTCTGCATTA AATCTATTTG 360
CCATTTCAAA AAAAAAAAAA AAA 383
(2)关于SEQ ID NO:83的信息
(i)序列特征
(A)长度:494个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:83:
ACCGAATTGG GACCGCTGGC TTATAAGCGA TCATGTCCTC CAGTATTACC TCAACGAGCA 60
GGGAGATCGA GTCTATACGC TGAAGAAATT TGACCCGATG GGACAACAGA CCTGCTCAGC 120
CCATCCTGCT CGGTTCTCCC CAGATGACAA ATACTCTCGA CACCGAATCA CCATCAAGAA 180
ACGCTTCAAG GTGCTCATGA CCCAGCAACC GCGCCCTGTC CTCTGAGGGT CCTTAAACTG 240
ATGTCTTTTC TGCCACCTGT TACCCCTCGG AGACTCCGTA ACCAAACTCT TCGGACTGTG 300
AGCCCTGATG CCTTTTTGCC AGCCATACTC TTTGGCNTCC AGTCTCTCGT GGCGATTGAT 360
TATGCTTGTG TGAGGCAATC ATGGTGGCAT CACCCATNAA GGGAACACAT TTGANTTTTT 420
TTTCNCATAT TTTAAATTAC NACCAGAATA NTTCAGAATA AATGAATTGA AAAACTCTTA 480
AAAAAAAAAA AAAA 494
(2)关于SEQ ID NO:84的信息
(i)序列特征
(A)长度:380个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:84:
GCTGGTAGCC TATGGCGTGG CCACGGANGG GCTCCTGAGG CACGGGACAG TGACTTCCCA 60
AGTATCCTGC GCCGCGTCTT CTACCGTCCC TACCTGCAGA TCTTCGGGCA GATTCCCCAG 120
GAGGACATGG ACGTGGCCCT CATGGAGCAC AGCAACTGCT CGTCGGAGCC CGGCTTCTGG 180
GCACACCCTC CTGGGGCCCA GGCGGGCACC TGCGTCTCCC AGTATGCCAA CTGGCTGGTG 240
GTGCTGCTCC TCGTCATCTT CCTGCTCGTG GCCAACATCC TGCTGGTCAC TTGCTCATTG 300
CCATGTTCAG TTACACATTC GGCAAAGTAC AGGGCAACAG CNATCTCTAC TGGGAAGGCC 360
AGCGTTNCCG CCTCATCCGG 380
(2)关于SEQ ID NO:85的信息
(i)序列特征
(A)长度:481个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:85:
GAGTTAGCTC CTCCACAACC TTGATGAGGT CGTCTGCAGT GGCCTCTCGC TTCATACCGC 60
TNCCATCGTC ATACTGTAGG TTTGCCACCA CCTCCTGCAT CTTGGGGCGG CTAATATCCA 120
GGAAACTCTC AATCAAGTCA CCGTCNATNA AACCTGTGGC TGGTTCTGTC TTCCGCTCGG 180
TGTGAAAGGA TCTCCAGAAG GAGTGCTCGA TCTTCCCCAC ACTTTTGATG ACTTTATTGA 240
GTCGATTCTG CATGTCCAGC AGGAGGTTGT ACCAGCTCTC TGACAGTGAG GTCACCAGCC 30C
CTATCATGCC NTTGAACGTG CCGAAGAACA CCGAGCCTTG TGTGGGGGGT GNAGTCTCAC 360
CCAGATTCTG CATTACCAGA NAGCCGTGGC AAAAGANATT GACAACTCGC CCAGGNNGAA 420
AAAGAACACC TCCTGGAAGT GCTNGCCGCT CCTCGTCCNT TGGTGGNNGC GCNTNCCTTT 480
T 481
(2)关于SEQ ID NO:86的信息
(i)序列特征
(A)长度:472个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:86:
AACATCTTCC TGTATAATGC TGTGTAATAT CGATCCGATN TTGTCTGCTG AGAATTCATT 60
ACTTGGAAAA GCAACTTNAA GCCTGGACAC TGGTATTAAA ATTCACAATA TGCAACACTT 120
TAAACAGTGT GTCAATCTGC TCCCTTACTT TGTCATCACC AGTCTGGGAA TAAGGGTATG 180
CCCTATTCAC ACCTGTTAAA AGGGCGCTAA GCATTTTTGA TTCAACATCT TTTTTTTTGA 240
CACAAGTCCG AAAAAAGCAA AAGTAAACAG TTNTTAATTT GTTAGCCAAT TCACTTTCTT 300
CATGGGACAG AGCCATTTGA TTTAAAAAGC AAATTGCATA ATATTGAGCT TTGGGAGCTG 360
ATATNTGAGC GGAAGANTAG CCTTTCTACT TCACCAGACA CAACTCCTTT CATATTGGGA 420
TGTTNACNAA AGTTATGTCT CTTACAGATG GGATGCTTTT GTGGCAATTC TG 472
(2)关于SEQ ID NO:87的信息
(i)序列特征
(A)长度:413个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:87:
AGAAACCAGT ATCTCTNAAA ACAACCTCTC ATACCTTGTG GACCTAATTT TGTGTGCGTG 60
TGTGTGTGCG CGCATATTAT ATAGACAGGC ACATCTTTTT TACTTTTGTA AAAGCTTATG 120
CCTCTTTGGT ATCTATATCT GTGAAAGTTT TAATGATCTG CCATAATGTC TTGGGGACCT 180
TTGTCTTCTG TGTAAATGGT ACTAGAGAAA ACACCTATNT TATGAGTCAA TCTAGTTNGT 240
TTTATTCGAC ATGAAGGAAA TTTCCAGATN ACAACACTNA CAAACTCTCC CTTGACTAGG 300
GGGGACAAAG AAAAGCANAA CTGAACATNA GAAACAATTN CCTGGTGAGA AATTNCATAA 360
ACAGAAATTG GGTNGTATAT TGAAANANNG CATCATTNAA ACGTTTTTTT TTT 413
(2)关于SEQ ID NO:88的信息
(i)序列特征
(A)长度:448个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:88:
CGCAGCGGGT CCTCTCTATC TAGCTCCAGC CTCTCGCCTG CCCCACTCCC CGCGTCCCGC 60
GTCCTAGCCN ACCATGGCCG GGCCCCTGCG CGCCCCGCTG CTCCTGCTGG CCATCCTGGC 120
CGTGGCCCTG GCCGTGAGCC CCGCGGCCGG CTCCAGTCCC GGCAAGCCGC CGCGCCTGGT 180
GGGAGGCCCA TGGACCCCGC GTGGAAGAAG AAGGTGTGCG GCGTGCACTG GACTTTGCCG 240
TCGGCNANTA CAACAAACCC GCAACNACTT TTACCNAGCN CGCGCTGCAG GTTGTGCCGC 300
CCCAANCAAA TTGTTACTNG GGGTAANTAA TTCTTGGAAG TTGAACCTGG GCCAAACNNG 360
TTTACCAGAA CCNAGCCAAT TNGAACAATT NCCCCTCCAT AACAGCCCCT TTTAAAAAGG 420
GAANCANTCC TGNTCTTTTC CAAATTTT 448
(2)关于SEQ ID NO:89的信息
(i)序列特征
(A)长度:463个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:89:
GAATTTTGTG CACTGGCCAC TGTGATGGAA CCATTGGGCC AGGATGCTTT GAGTTTATCA 60
GTAGTGATTC TGCCAAAGTT GGTGTTGTAA CATGAGTATG TAAAATGTCA AAAAATTAGC 120
AGAGGTCTAG GTCTGCATAT CAGCAGACAG TTTGTCCGTG TATTTTGTAG CCTTGAAGTT 180
CTCAGTGACA AGTTNNTTCT GATGCGAAGT TCTNATTCCA GTGTTTTAGT CCTTTGCATC 240
TTTNATGTTN AGACTTGCCT CTNTNAAATT GCTTTTGTNT TCTGCAGGTA CTATCTGTGG 300
TTTAACAAAA TAGAANNACT TCTCTGCTTN GAANATTTGA ATATCTTACA TCTNAAAATN 360
AATTCTCTCC CCATANNAAA ACCCANGCCC TTGGGANAAT TTGAAAAANG GNTCCTTCNN 420
AATTCNNANA ANTTCAGNTN TCATACAACA NAACNGGANC CCC 463
(2)关于SEQ ID NO:90的信息
(i)序列特征
(A)长度:400个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:90:
AGGGATTGAA GGTCTNTTNT ACTGTCGGAC TGTTCANCCA CCAACTCTAC AAGTTGCTGT 60
CTTCCACTCA CTGTCTGTAA GCNTNTTAAC CCAGACTGTA TCTTCATAAA TAGAACAAAT 120
TCTTCACCAG TCACATCTTC TAGGACCTTT TTGGATTCAG TTAGTATAAG CTCTTCCACT 180
TCCTTTGTTA AGACTTCATC TGGTAAAGTC TTAAGTTTTG TAGAAAGGAA TTTAATTGCT 240
CGTTCTCTAA CAATGTCCTC TCCTTGAAGT ATTTGGCTGA ACAACCCACC TNAAGTCCCT 300
TTGTGCATCC ATTTTAAATA TACTTAATAG GGCATTGGTN CACTAGGTTA AATTCTGCAA 360
GAGTCATCTG TCTGCAAAAG TTGCGTTAGT ATATCTGCCA 400
(2)关于SEQ ID NO:91的信息
(i)序列特征
(A)长度:480个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:91:
GAGCTCGGAT CCAATAATCT TTGTCTGAGG GCAGCACACA TATNCAGTGC CATGGNAACT 60
GGTCTACCCC ACATGGGAGC AGCATGCCGT AGNTATATAA GGTCATTCCC TGAGTCAGAC 120
ATGCCTCTTT GACTACCGTG TGCCAGTGCT GGTGATTCTC ACACACCTCC NNCCGCTCTT 180
TGTGGAAAAA CTGGCACTTG NCTGGAACTA GCAAGACATC ACTTACAAAT TCACCCACGA 240
GACACTTGAA AGGTGTAACA AAGCGACTCT TGCATTGCTT TTTGTCCCTC CGGCACCAGT 300
TGTCAATACT AACCCGCTGG TTTGCCTCCA TCACATTTGT GATCTGTAGC TCTGGATACA 360
TCTCCTGACA GTACTGAAGA ACTTCTTCTT TTGTTTCAAA AGCAACTCTT GGTGCCTGTT 420
NGATCAGGTT CCCATTTCCC AGTCCGAATG TTCACATGGC ATATNTTACT TCCCACAAAA 480
(2)关于SEQ ID NO:92的信息
(i)序列特征
(A)长度:477个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:92:
ATACAGCCCA NATCCCACCA CGAAGATGCG CTTGTTGACT GAGAACCTGA TGCGGTCACT 60
GGTCCCGCTG TAGCCCCAGC GACTCTCCAC CTGCTGGAAG CGGTTGATGC TGCACTCCTT 120
CCCACGCAGG CAGCAGCGGG GCCGGTCAAT GAACTCCACT CGTGGCTTGG GGTTGACGGT 180
TAANTGCAGG AAGAGGCTGA CCACCTCGCG GTCCACCAGG ATGCCCGACT GTGCGGGACC 240
TGCAGCGAAA CTCCTCGATG GTCATGAGCG GGAAGCGAAT GANGCCCAGG GCCTTGCCCA 300
GAACCTTCCG CCTGTTCTCT GGCGTCACCT GCAGCTGCTG CCGCTNACAC TCGGCCTCGG 360
ACCAGCGGAC AAACGGCGTT GAACAGCCGC ACCTCACGGA TGCCCANTGT GTCGCGCTCC 420
AGGAACGGCN CCAGCGTGTC CAGGTCAATG TCGGTGAANC CTCCGCGGGT AATGGCG 477
(2)关于SEQ ID NO:93的信息
(i)序列特征
(A)长度:377个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:93:
GAACGGCTGG ACCTTGCCTC GCATTGTGCT GCTGGCAGGA ATACCTTGGC AAGCAGCTCC 60
AGTCCGAGCA GCCCCAGACC GCTGCCGCCC GAAGCTAAGC CTGCCTCTGG CCTTCCCCTC 120
CGCCTCAATG CAGAACCANT AGTGGGAGCA CTGTGTTTAG AGTTAAGAGT GAACACTGTN 180
TGATTTTACT TGGGAATTTC CTCTGTTATA TAGCTTTTCC CAATGCTAAT TTCCAAACAA 240
CAACAACAAA ATAACATGTT TGCCTGTTNA GTTGTATAAA AGTANGTGAT TCTGTATNTA 300
AAGAAAATAT TACTGTTACA TATACTGCTT GCAANTTCTG TATTTATTGG TNCTCTGGAA 360
ATAAATATAT TATTAAA 377
(2)关于SEQ ID NO:94的信息
(i)序列特征
(A)长度:495个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:94:
CCCTTTGAGG GGTTAGGGTC CAGTTCCCAG TGGAAGAAAC AGGCCAGGAG AANTGCGTGC 60
CGAGCTGANG CAGATTTCCC ACAGTGACCC CAGAGCCCTG GGCTATAGTC TCTGACCCCT 120
CCAAGGAAAG ACCACCTTCT GGGGACATGG GCTGGAGGGC AGGACCTAGA GGCACCAAGG 180
GAAGGCCCCA TTCCGGGGCT GTTCCCCGAG GAGGAAGGGA AGGGGCTCTG TGTGCCCCCC 240
ACGAGGAANA GGCCCTGANT CCTGGGATCA NACACCCCTT CACGTGTATC CCCACACAAA 300
TGCAAGCTCA CCAAGGTCCC CTCTCAGTCC CTTCCCTACA CCCTGAACGG NCACTGGCCC 360
ACACCCACCC AGANCANCCA CCCGCCATGG GGAATGTNCT CAAGGAATCG CNGGGCAACG 420
TGGACTCTNG TCCCNNAAGG GGGCAGAATC TCCAATAGAN GGANNGAACC CTTGCTNANA 480
AAAAAAAANA AAAAA 495
(2)关于SEQ ID NO:95的信息
(i)序列特征
(A)长度:472个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:95:
GGTTACTTGG TTTCATTGCC ACCACTTAGT GGATGTCATT TAGAACCATT TTGTCTGCTC 60
CCTCTGGAAG CCTTGCGCAG AGCGGACTTT GTAATTGTTG GAGAATAACT GCTGAATTTT 120
TAGCTGTTTT GAGTTGATTC GCACCACTGC ACCACAACTC AATATGAAAA CTATTTNACT 180
TATTTATTAT CTTGTGAAAA GTATACAATG AAAATTTTGT TCATACTGTA TTTATCAAGT 240
ATGATGAAAA GCAATAGATA TATATTCTTT TATTATGTTN AATTATGATT GCCATTATTA 300
ATCGGCAAAA TGTGGAGTGT ATGTTCTTTT CACAGTAATA TATGCCTTTT GTAACTTCAC 360
TTGGTTATTT TATTGTAAAT GAATTACAAA ATTCTTAATT TAAGAAAATG GTANGTTATA 420
TTTANTTCAN TAATTTCTTT CCTTGTTTAC GTTAATTTTG AAAAGAATGC AT 472
(2)关于SEQ ID NO:96的信息
(i)序列特征
(A)长度:476个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:96:
CTGAAGCATT TCTTCAAACT TNTCTACTTT TGTCATTGAT ACCTGTAGTA AGTTGACAAT 60
GTGGTGAAAT TTCAAAATTA TATGTAACTT CTACTAGTTT TACTTTCTCC CCCAAGTCTT 120
TTTTAACTCA TGATTTTTAC ACACACAATC CAGAACTTAT TATATAGCCT CTAAGTCTTT 180
ATTCTTCACA GTAGATGATG AAAGAGTCCT CCAGTGTCTT GNGCANAATG TTCTAGNTAT 240
AGCTGGATAC ATACNGTGGG AGTTCTATAA ACTCATACCT CAGTGGGACT NAACCAAAAT 300
TGTGTTAGTC TCAATTCCTA CCACACTGAG GGAGCCTCCC AAATCACTAT ATTCTTATCT 360
GCAGGTACTC CTCCAGAAAA ACNGACAGGG CAGGCTTGCA TGAAAAAGTN ACATCTGCGT 420
TACAAAGTCT ATCTTCCTCA NANGTCTGTN AAGGAACAAT TTAATCTTCT AGCTTT 476
(2)关于SEQ ID NO:97的信息
(i)序列特征
(A)长度:479个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:97:
ACTCTTTCTA ATGCTGATAT GATCTTGAGT ATAAGAATGC ATATGTCACT AGAATGGATA 60
AAATAATGCT GCAAACTTAA TGTTCTTATG CAAAATGGAA CGCTAATGAA ACACAGCTTA 120
CAATCGCAAA TCAAAACTCA CAAGTGCTCA TCTGTTGTAG ATTTAGTGTA ATAAGACTTA 180
GATTGTGCTC CTTCGGATAT GATTGTTTCT CANATCTTGG GCAATNTTCC TTAGTCAAAT 240
CAGGCTACTA GAATTCTGTT ATTGGATATN TGAGAGCATG AAATTTTTAA NAATACACTT 300
GTGATTATNA AATTAATCAC AAATTTCACT TATACCTGCT ATCAGCAGCT AGAAAAACAT 360
NTNNTTTTTA NATCAAAGTA TTTTGTGTTT GGAANTGTNN AAATGAAATC TGAATGTGGG 420
TTCNATCTTA TTTTTTCCCN GACNACTANT TNCTTTTTTA GGGNCTATTC TGANCCATC 479
(2)关于SEQ ID NO:98的信息
(i)序列特征
(A)长度:461个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:98:
AGTGACTTGT CCTCCAACAA AACCCCTTGA TCAAGTTTGT GGCACTGACA ATCAGACCTA 60
TGCTAGTTCC TGTCATCTAT TCGCTACTAA ATGCAGACTG GAGGGGACCA AAAAGGGGCA 120
TCAACTCCAG CTGGATTATT TTGGAGCCTG CAAATCTATT CCTACTTGTA CGGACTTTGA 180
AGTGATTCAG TTTCCTCTAC GGATGAGAGA CTGGCTCAAG AATATCCTCA TGCAGCTTTA 240
TGAAGCCACT CTGAACACGC TGGTTATCTA GATGAGAACA GAGAAATAAA GTCAGAAAAT 300
TTACCTGGAG AAAAGAGGCT TTGGCTGGGG ACCATCCCAT TGAACCTTCT CTTAAGGACT 360
TTAAGAAAAA CTACCACATG TTGTGTATCC TGGTGCCGGC CGTTTATGAA CTGACCACCC 420
TTTGGAATAA TCTTGACGCT CCTGAACTTG CTCCTCTGCG A 461
(2)关于SEQ ID NO:99的信息
(i)序列特征
(A)长度:171个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:99:
GTGGCCGCGC GCAGGTGTTT CCTCGTACCG CAGGGCCCCC TCCCTTCCCC AGGCGTCCCT 60
CGGCGCCTCT GCGGGCCCGA GGAGGAGCGG CTGGCGGGTG GGGGGAGTGT GACCCACCCT 120
CGGTGAGAAA AGCCTTCTCT AGCGATCTGA GAGGCGTGCC TTGGGGGTAC C 171
(2)关于SEQ ID NO:100的信息
(i)序列特征
(A)长度:269个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:100:
CGGCCGCAAG TGCAACTCCA GCTGGGGCCG TGCGGACGAA GATTCTGCCA GCAGTTGGTC 60
CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC 120
AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA 180
CAGCCGGAAC AGAGCCCGGT GAAGCGGGAG GCCTCGGGGA GCCCCTCGGG AAGGGCGGCC 240
CGAGAGATAC GCAGGTGCAG GTGGCCGCC 269
(2)关于SEQ ID NO:101的信息
(i)序列特征
(A)长度:405个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:101:
TTTTTTTTTT TTTTGGAATC TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA 60
GCTAGCAAGG TAACAGGGTA GGGCATGGTT ACATGTTCAG GTCAACTTCC TTTGTCGTGG 120
TTGATTGGTT TGTCTTTATG GGGGCGGGGT GGGGTAGGGG AAACGAAGCA AATAACATGG 180
AGTGGGTGCA CCCTCCCTGT AGAACCTGGT TACAAAGCTT GGGGCAGTTC ACCTGGTCTG 240
TGACCGTCAT TTTCTTGACA TCAATGTTAT TAGAAGTCAG GATATCTTTT AGAGAGTCCA 300
CTGTTCTGGA GGGAGATTAG GGTTTCTTGC CAAATCCAAC AAAATCCACT GAAAAAGTTG 360
GATGATCAGT ACGAATACCG AGGCATATTC TCATATCGGT GGCCA 405
(2)关于SEQ ID NO:102的信息
(i)序列特征
(A)长度:470个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:102
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 60
GGCACTTAAT CCATTTTTAT TTCAAAATGT CTACAAATTT AATCCCATTA TACGGTATTT 120
TCAAAATCTA AATTATTCAA ATTAGCCAAA TCCTTACCAA ATAATACCCA AAAATCAAAA 180
ATATACTTCT TTCAGCAAAC TTGTTACATA AATTAAAAAA ATATATACGG CTGGTGTTTT 240
CAAAGTACAA TTATCTTAAC ACTGCAAACA TTTTAAGGAA CTAAAATAAA AAAAAACACT 300
CCGCAAAGGT TAAAGGGAAC AACAAATTCT TTTACAACAC CATTATAAAA ATCATATCTC 360
AAATCTTAGG GGAATATATA CTTCACACGG GATCTTAACT TTTACTCACT TTGTTTATTT 420
TTTTAAACCA TTGTTTGGGC CCAACACAAT GGAATCCCCC CTGGACTAGT 470
(2)关于SEQ ID NO:103的信息
(i)序列特征
(A)长度:581个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:103:
TTTTTTTTTT TTTTTTTTGA CCCCGCTCTT ATAAAAAACA AGTTACCATT TTATTTTACT 60
TACACATATT TATTTTATAA TTGGTATTAG ATATTCAAAA GGCAGCTTTT AAAATCAAAC 120
TAAATGGAAA CTGCCTTAGA TACATAATTC TTAGGAATTA GCTTAAAATC TGCCTAAAGT 180
GAAAATCTTC TCTAGCTCTT TTGACTGTAA ATTTTTGACT CTTGTAAAAC ATCCAAATTC 240
ATTTTTCTTG TCTTTAAAAT TATCTAATCT TTCCATTTTT TCCCTATTCC AAGTCAATTT 300
GCTTCTCTAG CCTCATTTCC TAGCTCTTAT CTACTATTAG TAAGTGGCTT TTTTCCTAAA 360
AGGGAAAACA GGAAGAGAAA TGGCACACAA AACAAACATT TTATATTCAT ATTTCTACCT 420
ACGTTAATAA AATAGCATTT TGTGAAGCCA GCTCAAAAGA AGGCTTAGAT CCTTTTATGT 480
CCATTTTAGT CACTAAACGA TATCAAAGTG CCAGAATGCA AAAGGTTTGT GAACATTTAT 540
TCAAAAGCTA ATATAAGATA TTTCACATAC TCATCTTTCT G 581
(2)关于SEQ ID NO:104的信息
(i)序列特征
(A)长度:578个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:104:
TTTTTTTTTT TTTTTTTTTT TTTTTCTCTT CTTTTTTTTT GAAATGAGGA TCGAGTTTTT 60
CACTCTCTAG ATAGGGCATG AAGAAAACTC ATCTTTCCAG CTTTAAAATA ACAATCAAAT 120
CTCTTATGCT ATATCATATT TTAAGTTAAA CTAATGAGTC ACTGGCTTAT CTTCTCCTGA 180
AGGAAATCTG TTCATTCTTC TCATTCATAT AGTTATATCA AGTACTACCT TGCATATTGA 240
GAGGTTTTTC TTCTCTATTT ACACATATAT TTCCATGTGA ATTTGTATCA AACCTTTATT 300
TTCATGCAAA CTAGAAAATA ATGTTTCTTT TGCATAAGAG AAGAGAACAA TATAGCATTA 360
CAAAACTGCT CAAATTGTTT GTTAAGTTAT CCATTATAAT TAGTTGGCAG GAGCTAATAC 420
AAATCACATT TACGACAGCA ATAATAAAAC TGAAGTACCA GTTAAATATC CAAAATAATT 480
AAAGGAACAT TTTTAGCCTG GGTATAATTA GCTAATTCAC TTTACAAGCA TTTATTAGAA 540
TGAATTCACA TGTTATTATT CCTAGCCCAA CACAATGG 578
(2)关于SEQ ID NO:105的信息
(i)序列特征
(A)长度:538个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:105:
TTTTTTTTTT TTTTTCAGTA ATAATCAGAA CAATATTTAT TTTTATATTT AAAATTCATA 60
GAAAAGTGCC TTACATTTAA TAAAAGTTTG TTTCTCAAAG TGATCAGAGG AATTAGATAT 120
GTCTTGAACA CCAATATTAA TTTGAGGAAA ATACACCAAA ATACATTAAG TAAATTATTT 180
AAGATCATAG AGCTTGTAAG TGAAAAGATA AAATTTGACC TCAGAAACTC TGAGCATTAA 240
AAATCCACTA TTAGCAAATA AATTACTATG GACTTCTTGC TTTAATTTTG TGATGAATAT 300
GGGGTGTCAC TGGTAAACCA ACACATTCTG AAGGATACAT TACTTAGTGA TAGATTCTTA 360
TGTACTTTGC TAATACGTGG ATATGAGTTG ACAAGTTTCT CTTTCTTCAA TCTTTTAAGG 420
GGCGAGAAAT GAGGAAGAAA AGAAAAGGAT TACGCATACT GTTCTTTCTA TGGAAGGATT 480
AGATATGTTT CCTTTGCCAA TATTAAAAAA ATAATAATGT TTACTACTAG TGAAACCC 538
(2)关于SEQ ID NO:106的信息
(i)序列特征
(A)长度:473个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:106:
TTTTTTTTTT TTTTTTAGTC AAGTTTCTAT TTTTATTATA ATTAAAGTCT TGGTCATTTC 60
ATTTATTAGC TCTGCAACTT ACATATTTAA ATTAAAGAAA CGTTTTAGAC AACTGTACAA 120
TTTATAAATG TAAGGTGCCA TTATTGAGTA ATATATTCCT CCAAGAGTGG ATGTGTCCCT 180
TCTCCCACCA ACTAATGAAC AGCAACATTA GTTTAATTTT ATTAGTAGAT ATACACTGCT 240
GCAAACGCTA ATTCTCTTCT CCATCCCCAT GTGATATTGT GTATATGTGT GAGTTGGTAG 300
AATGCATCAC AATCTACAAT CAACAGCAAG ATGAAGCTAG GCTGGGCTTT CGGTGAAAAT 360
AGACTGTGTC TGTCTGAATC AAATGATCTG ACCTATCCTC GGTGGCAAGA ACTCTTCGAA 420
CCGCTTCCTC AAAGGCGCTG CCACATTTGT GGCTCTTTGC ACTTGTTTCA AAA 473
(2)关于SEQ ID NO:107的信息
(i)序列特征
(A)长度:1621个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:107:
CGCCATGGCA CTGCAGGGCA TCTCGGTCAT GGAGCTGTCC GGCCTGGCCC CGGGCCCGTT 60
CTGTGCTATG GTCCTGGCTG ACTTCGGGGC GCGTGTGGTA CGCGTGGACC GGCCCGGCTC 120
CCGCTACGAC GTGAGCCGCT TGGGCCGGGG CAAGCGCTCG CTAGTGCTGG ACCTGAAGCA 180
GCCGCGGGGA GCCGCCGTGC TGCGGCGTCT GTGCAAGCGG TCGGATGTGC TGCTGGAGCC 240
CTTCCGCCGC GGTGTCATGG AGAAACTCCA GCTGGGCCCA GAGATTCTGC AGCGGGAAAA 300
TCCAAGGCTT ATTTATGCCA GGCTGAGTGG ATTTGGCCAG TCAGGAAGCT TCTGCCGGTT 360
AGCTGGCCAC GATATCAACT ATTTGGCTTT GTCAGGTGTT CTCTCAAAAA TTGGCAGAAG 420
TGGTGAGAAT CCGTATGCCC CGCTGAATCT CCTGGCTGAC TTTGCTGGTG GTGGCCTTAT 480
GTGTGCACTG GGCATTATAA TGGCTCTTTT TGACCGCACA CGCACTGACA AGGGTCAGGT 540
CATTGATGCA AATATGGTGG AAGGAACAGC ATATTTAAGT TCTTTTCTGT GGAAAACTCA 600
GAAATCGAGT CTGTGGGAAG CACCTCGAGG ACAGAACATG TTGGATGGTG GAGCACCTTT 660
CTATACGACT TACAGGACAG CAGATGGGGA ATTCATGGCT GTTGGAGCAA TAGAACCCCA 720
GTTCTACGAG CTGCTGATCA AAGGACTTGG ACTAAAGTCT GATGAACTTC CCAATCAGAT 780
GAGCATGGAT GATTGGCCAG AAATGAAGAA GAAGTTTGCA GATGTATTTG CAAAGAAGAC 840
GAAGGCAGAG TGGTGTCAAA TCTTTGACGG CACAGATGCC TGTGTGACTC CGGTTCTGAC 900
TTTTGAGGAG GTTGTTCATC ATGATCACAA CAAGGAACGG GGCTCGTTTA TCACCAGTGA 960
GGAGCAGGAC GTGAGCCCCC GCCCTGCACC TCTGCTGTTA AACACCCCAG CCATCCCTTC 1020
TTTCAAAAGG GATCCTTTCA TAGGAGAACA CACTGAGGAG ATACTTGAAG AATTTGGATT 1080
CAGCCGCGAA GAGATTTATC AGCTTAACTC AGATAAAATC ATTGAAAGTA ATAAGGTAAA 1140
AGCTAGTCTC TAACTTCCAG GCCCACGGCT CAAGTGAATT TGAATACTGC ATTTACAGTG 1200
TAGAGTAACA CATAACATTG TATGCATGGA AACATGGAGG AACAGTATTA CAGTGTCCTA 1260
CCACTCTAAT CAAGAAAAGA ATTACAGACT CTGATTCTAC AGTGATGATT GAATTCTAAA 1320
AATGGTTATC ATTAGGGCTT TTGATTTATA AAACTTTGGG TACTTATACT AAATTATGGT 1380
AGTTATTCTG CCTTCCAGTT TGCTTGATAT ATTTGTTGAT ATTAAGATTC TTGACTTATA 1440
TTTTGAATGG GTTCTAGTGA AAAAGGAATG ATATATTCTT GAAGACATCG ATATACATTT 1500
ATTTACACTC TTGATTCTAC AATGTAGAAA ATGAGGAAAT GCCACAAATT GTATGGTGAT 1560
AAAAGTCACG TGAAACAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1620
A 1621
(2)关于SEQ ID NO:108的信息
(i)序列特征
(A)长度:382个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:蛋白质
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:108:
Met Ala Leu Gln Gly Ile Ser Val Met Glu Leu Ser Gly Leu Ala Pro
1 5 10 15
Gly Pro Phe Cys Ala Met Val Leu Ala Asp Phe Gly Ala Arg Val Val
20 25 30
Arg Val Asp Arg Pro Gly Ser Arg Tyr Asp Val Ser Arg Leu Gly Arg
35 40 45
Gly Lys Arg Ser Leu Val Leu Asp Leu Lys Gln Pro Arg Gly Ala Ala
50 55 60
Val Leu Arg Arg Leu Cys Lys Arg Ser Asp Val Leu Leu Glu Pro Phe
65 70 75 80
Arg Arg Gly Val Met Glu Lys Leu Gln Leu Gly Pro Glu Ile Leu Gln
85 90 95
Arg Glu Asn Pro Arg Leu Ile Tyr Ala Arg Leu Ser Gly Phe Gly Gln
100 105 110
Ser Gly Ser Phe Cys Arg Leu Ala Gly His Asp Ile Asn Tyr Leu Ala
115 120 125
Leu Ser Gly Val Leu Ser Lys Ile Gly Arg Ser Gly Glu Asn Pro Tyr
130 135 140
Ala Pro Leu Asn Leu Leu Ala Asp Phe Ala Gly Gly Gly Leu Met Cys
145 150 155 160
Ala Leu Gly Ile Ile Met Ala Leu Phe Asp Arg Thr Arg Thr Asp Lys
165 170 175
Gly Gln Val Ile Asp Ala Asn Met Val Glu Gly Thr Ala Tyr Leu Ser
180 185 190
Ser Phe Leu Trp Lys Thr Gln Lys Ser Ser Leu Trp Glu Ala Pro Arg
195 200 205
Gly Gln Asn Met Leu Asp Gly Gly Ala Pro Phe Tyr Thr Thr Tyr Arg
210 215 220
Thr Ala Asp Gly Glu Phe Met Ala Val Gly Ala Ile Glu Pro Gln Phe
225 230 235 240
Tyr Glu Leu Leu Ile Lys Gly Leu Gly Leu Lys Ser Asp Glu Leu Pro
245 250 255
Asn Gln Met Ser Met Asp Asp Trp Pro Glu Met Lys Lys Lys Phe Ala
260 265 270
Asp Val Phe Ala Lys Lys Thr Lys Ala Glu Trp Cys Gln Ile Phe Asp
275 280 285
Gly Thr Asp Ala Cys Val Thr Pro Val Leu Thr Phe Glu Glu Val Val
290 295 300
His His Asp His Asn Lys Glu Arg Gly Ser Phe Ile Thr Ser Glu Glu
305 310 315 320
Gln Asp Val Ser Pro Arg Pro Ala Pro Leu Leu Leu Asn Thr Pro Ala
325 330 335
Ile Pro Ser Phe Lys Arg Asp Pro Phe Ile Gly Glu His Thr Glu Glu
340 345 350
Ile Leu Glu Glu Phe Gly Phe Ser Arg Glu Glu Ile Tyr Gln Leu Asn
355 360 365
Ser Asp Lys Ile Ile Glu Ser Asn Lys Val Lys Ala Ser Leu
370 375 380
(2)关于SEQ ID NO:109的信息
(i)序列特征
(A)长度:1524个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:109:
GGCACGAGGC TGCGCCAGGG CCTGAGCGGA GGCGGGGGCA GCCTCGCCAG CGGGGGCCCC 60
GGGCCTGGCC ATGCCTCACT GAGCCAGCGC CTGCGCCTCT ACCTCGCCGA CAGCTGGAAC 120
CAGTGCGACC TAGTGGCTCT CACCTGCTTC CTCCTGGGCG TGGGCTGCCG GCTGACCCCG 180
GGTTTGTACC ACCTGGGCCG CACTGTCCTC TGCATCGACT TCATGGTTTT CACGGTGCGG 240
CTGCTTCACA TCTTCACGGT CAACAAACAG CTGGGGCCCA AGATCGTCAT CGTGAGCAAG 300
ATGATGAAGG ACGTGTTCTT CTTCCTCTTC TTCCTCGGCG TGTGGCTGGT AGCCTATGGC 360
GTGGCCACGG AGGGGCTCCT GAGGCCACGG GACAGTGACT TCCCAAGTAT CCTGCGCCGC 420
GTCTTCTACC GTCCCTACCT GCAGATCTTC GGGCAGATTC CCCAGGAGGA CATGGACGTG 480
GCCCTCATGG AGCACAGCAA CTGCTCGTCG GAGCCCGGCT TCTGGGCACA CCCTCCTGGG 540
GCCCAGGCGG GCACCTGCGT CTCCCAGTAT GCCAACTGGC TGGTGGTGCT GCTCCTCGTC 600
ATCTTCCTGC TCGTGGCCAA CATCCTGCTG GTCAACTTGC TCATTGCCAT GTTCAGTTAC 660
ACATTCGGCA AAGTACAGGG CAACAGCGAT CTCTACTGGA AGGCGCAGCG TTACCGCCTC 720
ATCCGGGAAT TCCACTCTCG GCCCGCGCTG GCCCCGCCCT TTATCGTCAT CTCCCACTTG 780
CGCCTCCTGC TCAGGCAATT GTGCAGGCGA CCCCGGAGCC CCCAGCCGTC CTCCCCGGCC 840
CTCGAGCATT TCCGGGTTTA CCTTTCTAAG GAAGCCGAGC GGAAGCTGCT AACGTGGGAA 900
TCGGTGCATA AGGAGAACTT TCTGCTGGCA CGCGCTAGGG ACAAGCGGGA GAGCGACTCC 960
GAGCGTCTGA AGCGCACGTC CCAGAAGGTG GACTTGGCAC TGAAACAGCT GGGACACATC 1020
CGCGAGTACG AACAGCGCCT GAAAGTGCTG GAGCGGGAGG TCCAGCAGTG TAGCCGCGTC 1080
CTGGGGTGGG TGGCCGAGGC CCTGAGCCGC TCTGCCTTGC TGCCCCCAGG TGGGCCGCCA 1140
CCCCCTGACC TGCCTGGGTC CAAAGACTGA GCCCTGCTGG CGGACTTCAA GGAGAAGCCC 1200
CCACAGGGGA TTTTGCTCCT AGAGTAAGGC TCATCTGGGC CTCGGCCCCC GCACCTGGTG 1260
GCCTTGTCCT TGAGGTGAGC CCCATGTCCA TCTGGGCCAC TGTCAGGACC ACCTTTGGGA 1320
GTGTCATCCT TACAAACCAC AGCATGCCCG GCTCCTCCCA GAACCAGTCC CAGCCTGGGA 1380
GGATCAAGGC CTGGATCCCG GGCCGTTATC CATCTGGAGG CTGCAGGGTC CTTGGGGTAA 1440
CAGGGACCAC AGACCCCTCA CCACTCACAG ATTCCTCACA CTGGGGAAAT AAAGCCATTT 1500
CAGAGGAAAA AAAAAAAAAA AAAA 1524
(2)关于SEQ ID NO:110的信息
(i)序列特征
(A)长度:3410个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:110:
GGGAACCAGC CTGCACGCGC TGGCTCCGGG TGACAGCCGC GCGCCTCGGC CAGGATCTGA 60
GTGATGAGAC GTGTCCCCAC TGAGGTGCCC CACAGCAGCA GGTGTTGAGC ATGGGCTGAG 120
AAGCTGGACC GGCACCAAAG GGCTGGCAGA AATGGGCGCC TGGCTGATTC CTAGGCAGTT 180
GGCGGCAGCA AGGAGGAGAG GCCGCAGCTT CTGGAGCAGA GCCGAGACGA AGCAGTTCTG 240
GAGTGCCTGA ACGGCCCCCT GAGCCCTACC CGCCTGGCCC ACTATGGTCC AGAGGCTGTG 300
GGTGAGCCGC CTGCTGCGGC ACCGGAAAGC CCAGCTCTTG CTGGTCAACC TGCTAACCTT 360
TGGCCTGGAG GTGTGTTTGG CCGCAGGCAT CACCTATGTG CCGCCTCTGC TGCTGGAAGT 420
GGGGGTAGAG GAGAAGTTCA TGACCATGGT GCTGGGCATT GGTCCAGTGC TGGGCCTGGT 480
CTGTGTCCCG CTCCTAGGCT CAGCCAGTGA CCACTGGCGT GGACGCTATG GCCGCCGCCG 540
GCCCTTCATC TGGGCACTGT CCTTGGGCAT CCTGCTGAGC CTCTTTCTCA TCCCAAGGGC 600
CGGCTGGCTA GCAGGGCTGC TGTGCCCGGA TCCCAGGCCC CTGGAGCTGG CACTGCTCAT 660
CCTGGGCGTG GGGCTGCTGG ACTTCTGTGG CCAGGTGTGC TTCACTCCAC TGGAGGCCCT 720
GCTCTCTGAC CTCTTCCGGG ACCCGGACCA CTGTCGCCAG GCCTACTCTG TCTATGCCTT 780
CATGATCAGT CTTGGGGGCT GCCTGGGCTA CCTCCTGCCT GCCATTGACT GGGACACCAG 840
TGCCCTGGCC CCCTACCTGG GCACCCAGGA GGAGTGCCTC TTTGGCCTGC TCACCCTCAT 900
CTTCCTCACC TGCGTAGCAG CCACACTGCT GGTGGCTGAG GAGGCAGCGC TGGGCCCCAC 960
CGAGCCAGCA GAAGGGCTGT CGGCCCCCTC CTTGTCGCCC CACTGCTGTC CATGCCGGGC 1020
CCGCTTGGCT TTCCGGAACC TGGGCGCCCT GCTTCCCCGG CTGCACCAGC TGTGCTGCCG 1080
CATGCCCCGC ACCCTGCGCC GGCTCTTCGT GGCTGAGCTG TGCAGCTGGA TGGCACTCAT 1140
GACCTTCACG CTGTTTTACA CGGATTTCGT GGGCGAGGGG CTGTACCAGG GCGTGCCCAG 1200
AGCTGAGCCG GGCACCGAGG CCCGGAGACA CTATGATGAA GGCGTTCGGA TGGGCAGCCT 1260
GGGGCTGTTC CTGCAGTGCG CCATCTCCCT GGTCTTCTCT CTGGTCATGG ACCGGCTGGT 1320
GCAGCGATTC GGCACTCGAG CAGTCTATTT GGCCAGTGTG GCAGCTTTCC CTGTGGCTGC 1380
CGGTGCCACA TGCCTGTCCC ACAGTGTGGC CGTGGTGACA GCTTCAGCCG CCCTCACCGG 1440
GTTCACCTTC TCAGCCCTGC AGATCCTGCC CTACACACTG GCCTCCCTCT ACCACCGGGA 1500
GAAGCAGGTG TTCCTGCCCA AATACCGAGG GGACACTGGA GGTGCTAGCA GTGAGGACAG 1560
CCTGATGACC AGCTTCCTGC CAGGCCCTAA GCCTGGAGCT CCCTTCCCTA ATGGACACGT 1620
GGGTGCTGGA GGCAGTGGCC TGCTCCCACC TCCACCCGCG CTCTGCGGGG CCTCTGCCTG 1680
TGATGTCTCC GTACGTGTGG TGGTGGGTGA GCCCACCGAG GCCAGGGTGG TTCCGGGCCG 1740
GGGCATCTGC CTGGACCTCG CCATCCTGGA TAGTGCCTTC CTGCTGTCCC AGGTGGCCCC 1800
ATCCCTGTTT ATGGGCTCCA TTGTCCAGCT CAGCCAGTCT GTCACTGCCT ATATGGTGTC 1860
TGCCGCAGGC CTGGGTCTGG TCGCCATTTA CTTTGCTACA CAGGTAGTAT TTGACAAGAG 1920
CGACTTGGCC AAATACTCAG CGTAGAAAAC TTCCAGCACA TTGGGGTGGA GGGCCTGCCT 1980
CACTGGGTCC CAGCTCCCCG CTCCTGTTAG CCCCATGGGG CTGCCGGGCT GGCCGCCAGT 2040
TTCTGTTGCT GCCAAAGTAA TGTGGCTCTC TGCTGCCACC CTGTGCTGCT GAGGTGCGTA 2100
GCTGCACAGC TGGGGGCTGG GGCGTCCCTC TCCTCTCTCC CCAGTCTCTA GGGCTGCCTG 2160
ACTGGAGGCC TTCCAAGGGG GTTTCAGTCT GGACTTATAC AGGGAGGCCA GAAGGGCTCC 2220
ATGCACTGGA ATGCGGGGAC TCTGCAGGTG GATTACCCAG GCTCAGGGTT AACAGCTAGC 2280
CTCCTAGTTG AGACACACCT AGAGAAGGGT TTTTGGGAGC TGAATAAACT CAGTCACCTG 2340
GTTTCCCATC TCTAAGCCCC TTAACCTGCA GCTTCGTTTA ATGTAGCTCT TGCATGGGAG 2400
TTTCTAGGAT GAAACACTCC TCCATGGGAT TTGAACATAT GACTTATTTG TAGGGGAAGA 2460
GTCCTGAGGG GCAACACACA AGAACCAGGT CCCCTCAGCC CACAGCACTG TCTTTTTGCT 2520
GATCCACCCC CCTCTTACCT TTTATCAGGA TGTGGCCTGT TGGTCCTTCT GTTGCCATCA 2580
CAGAGACACA GGCATTTAAA TATTTAACTT ATTTATTTAA CAAAGTAGAA GGGAATCCAT 2640
TGCTAGCTTT TCTGTGTTGG TGTCTAATAT TTGGGTAGGG TGGGGGATCC CCAACAATCA 2700
GGTCCCCTGA GATAGCTGGT CATTGGGCTG ATCATTGCCA GAATCTTCTT CTCCTGGGGT 2760
CTGGCCCCCC AAAATGCCTA ACCCAGGACC TTGGAAATTC TACTCATCCC AAATGATAAT 2820
TCCAAATGCT GTTACCCAAG GTTAGGGTGT TGAAGGAAGG TAGAGGGTGG GGCTTCAGGT 2880
CTCAACGGCT TCCCTAACCA CCCCTCTTCT CTTGGCCCAG CCTGGTTCCC CCCACTTCCA 2940
CTCCCCTCTA CTCTCTCTAG GACTGGGCTG ATGAAGGCAC TGCCCAAAAT TTCCCCTACC 3000
CCCAACTTTC CCCTACCCCC AACTTTCCCC ACCAGCTCCA CAACCCTGTT TGGAGCTACT 3060
GCAGGACCAG AAGCACAAAG TGCGGTTTCC CAAGCCTTTG TCCATCTCAG CCCCCAGAGT 3120
ATATCTGTGC TTGGGGAATC TCACACAGAA ACTCAGGAGC ACCCCCTGCC TGAGCTAAGG 3180
GAGGTCTTAT CTCTCAGGGG GGGTTTAAGT GCCGTTTGCA ATAATGTCGT CTTATTTATT 3240
TAGCGGGGTG AATATTTTAT ACTGTAAGTG AGCAATCAGA GTATAATGTT TATGGTGACA 3300
AAATTAAAGG CTTTCTTATA TGTTTAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3360
AAAAAAAARA AAAAAAAAAA AAAAAAAAAA AAAAAAATAA AAAAAAAAAA 3410
(2)关于SEQ ID NO:111的信息
(i)序列特征
(A)长度:1289个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:111:
AGCCAGGCGT CCCTCTGCCT GCCCACTCAG TGGCAACACC CGGGAGCTGT TTTGTCCTTT 60
GTGGAGCCTC AGCAGTTCCC TCTTTCAGAA CTCACTGCCA AGAGCCCTGA ACAGGAGCCA 120
CCATGCAGTG CTTCAGCTTC ATTAAGACCA TGATGATCCT CTTCAATTTG CTCATCTTTC 180
TGTGTGGTGC AGCCCTGTTG GCAGTGGGCA TCTGGGTGTC AATCGATGGG GCATCCTTTC 240
TGAAGATCTT CGGGCCACTG TCGTCCAGTG CCATGCAGTT TGTCAACGTG GGCTACTTCC 300
TCATCGCAGC CGGCGTTGTG GTCTTTGCTC TTGGTTTCCT GGGCTGCTAT GGTGCTAAGA 360
CTGAGAGCAA GTGTGCCCTC GTGACGTTCT TCTTCATCCT CCTCCTCATC TTCATTGCTG 420
AGGTTGCAGC TGCTGTGGTC GCCTTGGTGT ACACCACAAT GGCTGAGCAC TTCCTGACGT 480
TGCTGGTAGT GCCTGCCATC AAGAAAGATT ATGGTTCCCA GGAAGACTTC ACTCAAGTGT 540
GGAACACCAC CATGAAAGGG CTCAAGTGCT GTGGCTTCAC CAACTATACG GATTTTGAGG 600
ACTCACCCTA CTTCAAAGAG AACAGTGCCT TTCCCCCATT CTGTTGCAAT GACAACGTCA 660
CCAACACAGC CAATGAAACC TGCACCAAGC AAAAGGCTCA CGACCAAAAA GTAGAGGGTT 720
GCTTCAATCA GCTTTTGTAT GACATCCGAA CTAATGCAGT CACCGTGGGT GGTGTGGCAG 780
CTGGAATTGG GGGCCTCGAG CTGGCTGCCA TGATTGTGTC CATGTATCTG TACTGCAATC 840
TACAATAAGT CCACTTCTGC CTCTGCCACT ACTGCTGCCA CATGGGAACT GTGAAGAGGC 900
ACCCTGGCAA GCAGCAGTGA TTGGGGGAGG GGACAGGATC TAACAATGTC ACTTGGGCCA 960
GAATGGACCT GCCCTTTCTG CTCCAGACTT GGGGCTAGAT AGGGACCACT CCTTTTAGCG 1020
ATGCCTGACT TTCCTTCCAT TGGTGGGTGG ATGGGTGGGG GGCATTCCAG AGCCTCTAAG 1080
GTAGCCAGTT CTGTTGCCCA TTCCCCCAGT CTATTAAACC CTTGATATGC CCCCTAGGCC 1140
TAGTGGTGAT CCCAGTGCTC TACTGGGGGA TGAGAGAAAG GCATTTTATA GCCTGGGCAT 1200
AAGTGAAATC AGCAGAGCCT CTGGGTGGAT GTGTAGAAGG CACTTCAAAA TGCATAAACC 1260
TGTTACAATG TTAAAAAAAA AAAAAAAAAA 1289
(2)关于SEQ ID NO:112的信息
(i)序列特征
(A)长度:315个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:蛋白质
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:112:
Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val Asn Lys Gln
1 5 10 15
Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys Asp Val Phe
20 25 30
Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr Gly Val Ala
35 40 45
Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro Ser Ile Leu
50 55 60
Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly Gln Ile Pro
65 70 75 80
Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn Cys Ser Ser
85 90 95
Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala Gly Thr Cys
100 105 110
Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu Val Ile Phe
115 120 125
Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile Ala Met Phe
130 135 140
Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu Tyr Trp Lys
145 150 155 160
Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg Pro Ala Leu
165 170 175
Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu Leu Arg Gln
180 185 190
Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro Ala Leu Glu
195 200 205
His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys Leu Leu Thr
210 215 220
Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg Ala Arg Asp
225 230 235 240
Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser Gln Lys Val
245 250 255
Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr Glu Gln Arg
260 265 270
Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg Val Leu Gly
275 280 285
Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro Pro Gly Gly
290 295 300
Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp
305 310 315
(2)关于SEQ ID NO:113的信息
(i)序列特征
(A)长度:553个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:蛋白质
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:113:
Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala
1 5 10 15
Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu
20 25 30
Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val
35 40 45
Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly
50 55 60
Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly
65 70 75 80
Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile
85 90 95
Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu
100 105 110
Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly
115 120 125
Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu
130 135 140
Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala
145 150 155 160
Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr
165 170 175
Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu
180 185 190
Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu
195 200 205
Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly
210 215 220
Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His
225 230 235 240
Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly Ala Leu
245 250 255
Leu Pro Arg Leu His Gln Leu Cys Cys Arg Met Pro Arg Thr Leu Arg
260 265 270
Arg Leu Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met Thr Phe
275 280 285
Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gln Gly Val
290 295 300
Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly
305 310 315 320
Val Arg Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu
325 330 335
Val Phe Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg
340 345 350
Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala
355 360 365
Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu
370 375 380
Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala
385 390 395 400
Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly
405 410 415
Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu
420 425 430
Pro Gly Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala
435 440 445
Gly Gly Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser
450 455 460
Ala Cys Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala
465 470 475 480
Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp
485 490 495
Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser
500 505 510
Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala
515 520 525
Gly Leu Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp
530 535 540
Lys Ser Asp Leu Ala Lys Tyr Ser Ala
545 550
(2)关于SEQ ID NO:114的信息
(i)序列特征
(A)长度:241个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:蛋白质
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:114:
Met Gln Cys Phe Ser Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu
1 5 10 15
Leu Ile Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly Ile Trp Val
20 25 30
Ser Ile Asp Gly Ala Ser Phe Leu Lys Ile Phe Gly Pro Leu Ser Ser
35 40 45
Ser Ala Met Gln Phe Val Asn Val Gly Tyr Phe Leu Ile Ala Ala Gly
50 55 60
Val Val Val Phe Ala Leu Gly Phe Leu Gly Cys Tyr Gly Ala Lys Thr
65 70 75 80
Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile
85 90 95
Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr
100 105 110
Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys
115 120 125
Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met
130 135 140
Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp
145 150 155 160
Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn
165 170 175
Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala
180 185 190
His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile
195 200 205
Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly
210 215 220
Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu
225 230 235 240
Gln
(2)关于SEQ ID NO:115的信息
(i)序列特征
(A)长度:366个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:115:
GCTCTTTCTC TCCCCTCCTC TGAATTTAAT TCTTTCAACT TGCAATTTGC AAGGATTACA 60
CATTTCACTG TGATGTATAT TGTGTTGCAA AAAAAAAAAA GTGTCTTTGT TTAAAATTAC 120
TTGGTTTGTG AATCCATCTT GCTTTTTCCC CATTGGAACT AGTCATTAAC CCATCTCTGA 180
ACTGGTAGAA AAACATCTGA AGAGCTAGTC TATCAGCATC TGACAGGTGA ATTGGATGGT 240
TCTCAGAACC ATTTCACCCA GACAGCCTGT TTCTATCCTG TTTAATAAAT TAGTTTGGGT 300
TCTCTACATG CATAACAAAC CCTGCTCCAA TCTGTCACAT AAAAGTCTGT GACTTGAAGT 360
TTAGTC 366
(2)关于SEQ ID NO:116的信息
(i)序列特征
(A)长度:282个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:116:
ACAAAGATGA ACCATTTCCT ATATTATAGC AAAATTAAAA TCTACCCGTA TTCTAATATT 60
GAGAAATGAG ATNAAACACA ATNTTATAAA GTCTACTTAG AGAAGATCAA GTGACCTCAA 120
AGACTTTACT ATTTTCATAT TTTAAGACAC ATGATTTATC CTATTTTAGT AACCTGGTTC 180
ATACGTTAAA CAAAGGATAA TGTGAACAGC AGAGAGGATT TGTTGGCAGA AAATCTATGT 240
TCAATCTNGA ACTATCTANA TCACAGACAT TTCTATTCCT TT 282
(2)关于SEQ ID NO:117的信息
(i)序列特征
(A)长度:305个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:117:
ACACATGTCG CTTCACTGCC TTCTTAGATG CTTCTGGTCA ACATANAGGA ACAGGGACCA 60
TATTTATCCT CCCTCCTGAA ACAATTGCAA AATAANACAA AATATATGAA ACAATTGCAA 120
AATAAGGCAA AATATATGAA ACAACAGGTC TCGAGATATT GGAAATCAGT CAATGAAGGA 180
TACTGATCCC TGATCACTGT CCTAATGCAG GATGTGGGAA ACAGATGAGG TCACCTCTGT 240
GACTGCCCCA GCTTACTGCC TGTAGAGAGT TTCTANGCTG CAGTTCAGAC AGGGAGAAAT 300
TGGGT 305
(2)关于SEQ ID NO:118的信息
(i)序列特征
(A)长度:71个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:118:
ACCAAGGTGT NTGAATCTCT GACGTGGGGA TCTCTGATTC CCGCACAATC TGAGTGGAAA 60
AANTCCTGGG T 71
(2)关于SEQ ID NO:119信息
(i)序列特征
(A)长度:212个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:119:
ACTCCGGTTG GTGTCAGCAG CACGTGGCAT TGAACATNGC AATGTGGAGC CCAAACCACA 60
GAAAATGGGG TGAAATTGGC CAACTTTCTA TNAACTTATG TTGGCAANTT TGCCACCAAC 120
AGTAAGCTGG CCCTTCTAAT AAAAGAAAAT TGAAAGGTTT CTCACTAANC GGAATTAANT 180
AATGGANTCA AGANACTCCC AGGCCTCAGC GT 212
(2)关于SEQ ID NO:120的信息
(i)序列特征
(A)长度:90个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:120:
ACTCGTTGCA NATCAGGGGC CCCCCAGAGT CACCGTTGCA GGAGTCCTTC TGGTCTTGCC 60
CTCCGCCGGC GCAGAACATG CTGGGGTGGT 90
(2)关于SEQ ID NO:121的信息
(i)序列特征
(A)长度:218个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:121:
TGTANCGTGA ANACGACAGA NAGGGTTGTC AAAAATGGAG AANCCTTGAA GTCATTTTGA 60
GAATAAGATT TGCTAAAAGA TTTGGGGCTA AAACATGGTT ATTGGGAGAC ATTTCTGAAG 120
ATATNCANGT AAATTANGGA ATGAATTCAT GGTTCTTTTG GGAATTCCTT TACGATNGCC 180
AGCATANACT TCATGTGGGG ATANCAGCTA CCCTTGTA 218
(2)关于SEQ ID NO:122的信息
(i)序列特征
(A)长度:171个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:122:
TAGGGGTGTA TGCAACTGTA AGGACAAAAA TTGAGACTCA ACTGGCTTAA CCAATAAAGG 60
CATTTGTTAG CTCATGGAAC AGGAAGTCGG ATGGTGGGGC ATCTTCAGTG CTGCATGAGT 120
CACCACCCCG GCGGGGTCAT CTGTGCCACA GGTCCCTGTT GACAGTGCGG T 171
(2)关于SEQ ID NO:123的信息
(i)序列特征
(A)长度:76个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:123:
TGTAGCGTGA AGACNACAGA ATGGTGTGTG CTGTGCTATC CAGGAACACA TTTATTATCA 60
TTATCAANTA TTGTGT 76
(2)关于SEQ ID NO:124的信息
(i)序列特征
(A)长度:131个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:124:
ACCTTTCCCC AAGGCCAATG TCCTGTGTGC TAACTGGCCG GCTGCAGGAC AGCTGCAATT 60
CAATGTGCTG GGTCATATGG AGGGGAGGAG ACTCTAAAAT AGCCAATTTT ATTCTCTTGG 120
TTAAGATTTG T 131
(2)关于SEQ ID NO:125的信息
(i)序列特征
(A)长度:432个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:125:
ACTTTATCTA CTGGCTATGA AATAGATGGT GGAAAATTGC GTTACCAACT ATACCACTGG 60
CTTGAAAAAG AGGTGATAGC TCTTCAGAGG ACTTGTGACT TTTGCTCAGA TGCTGAAGAA 120
CTACAGTCTG CATTTGGCAG AAATGAAGAT GAATTTGGAT TAAATGAGGA TGCTGAAGAT 180
TTGCCTCACC AAACAAAAGT GAAACAACTG AGAGAAAATT TTCAGGAAAA AAGACAGTGG 240
CTCTTGAAGT ATCAGTCACT TTTGAGAATG TTTCTTAGTT ACTGCATACT TCATGGATCC 300
CATGGTGGGG GTCTTGCATC TGTAAGAATG GAATTGATTT TGCTTTTGCA AGAATCTCAG 360
CAGGAAACAT CAGAACCACT ATTTTCTAGC CCTCTGTCAG AGCAAACCTC AGTGCCTCTC 420
CTCTTTGCTT GT 432
(2)关于SEQ ID NO:126的信息
(i)序列特征
(A)长度:112个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:126:
ACACAACTTG AATAGTAAAA TAGAAACTGA GCTGAAATTT CTAATTCACT TTCTAACCAT 60
AGTAAGAATG ATATTTCCCC CCAGGGATCA CCAAATATTT ATAAAAATTT GT 112
(2)关于SEQ ID NO:127的信息
(i)序列特征
(A)长度:54个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:127:
ACCACGAAAC CACAAACAAG ATGGAAGCAT CAATCCACTT GCCAAGCACA GCAG 54
(2)关于SEQ ID NO:128的信息
(i)序列特征
(A)长度:323个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:128:
ACCTCATTAG TAATTGTTTT GTTGTTTCAT TTTTTTCTAA TGTCTCCCCT CTACCAGCTC 60
ACCTGAGATA ACAGAATGAA AATGGAAGGA CAGCCAGATT TCTCCTTTGC TCTCTGCTCA 120
TTCTCTCTGA AGTCTAGGTT ACCCATTTTG GGGACCCATT ATAGGCAATA AACACAGTTC 180
CCAAAGCATT TGGACAGTTT CTTGTTGTGT TTTAGAATGG TTTTCCTTTT TCTTAGCCTT 240
TTCCTGCAAA AGGCTCACTC AGTCCCTTGC TTGCTCAGTG GACTGGGCTC CCCAGGGCCT 300
AGGCTGCCTT CTTTTCCATG TCC 323
(2)关于SEQ ID NO:129的信息
(i)序列特征
(A)长度:192个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:129:
ACATACATGT GTGTATATTT TTAAATATCA CTTTTGTATC ACTCTGACTT TTTAGCATAC 60
TGAAAACACA CTAACATAAT TTNTGTGAAC CATGATCAGA TACAACCCAA ATCATTCATC 120
TAGCACATTC ATCTGTGATA NAAAGATAGG TGAGTTTCAT TTCCTTCACG TTGGCCAATG 180
GATAAACAAA GT 192
(2)关于SEQ ID NO:130的信息
(i)序列特征
(A)长度:362个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:130:
CCCTTTTTTA TGGAATGAGT AGACTGTATG TTTGAANATT TANCCACAAC CTCTTTGACA 60
TATAATGACG CAACAAAAAG GTGCTGTTTA GTCCTATGGT TCAGTTTATG CCCCTGACAA 120
GTTTCCATTG TGTTTTGCCG ATCTTCTGGC TAATCGTGGT ATCCTCCATG TTATTAGTAA 180
TTCTGTATTC CATTTTGTTA ACGCCTGGTA GATGTAACCT GCTANGAGGC TAACTTTATA 240
CTTATTTAAA AGCTCTTATT TTGTGGTCAT TAAAATGGCA ATTTATGTGC AGCACTTTAT 300
TGCAGCAGGA AGCACGTGTG GGTTGGTTGT AAAGCTCTTT GCTAATCTTA AAAAGTAATG 360
GG 362
(2)关于SEQ ID NO:131的信息
(i)序列特征
(A)长度:332个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:131:
CTTTTTGAAA GATCGTGTCC ACTCCTGTGG ACATCTTGTT TTAATGGAGT TTCCCATGCA 60
GTANGACTGG TATGGTTGCA GCTGTCCAGA TAAAAACATT TGAAGAGCTC CAAAATGAGA 120
GTTCTCCCAG GTTCGCCCTG CTGCTCCAAG TCTCAGCAGC AGCCTCTTTT AGGAGGCATC 180
TTCTGAACTA GATTAAGGCA GCTTGTAAAT CTGATGTGAT TTGGTTTATT ATCCAACTAA 240
CTTCCATCTG TTATCACTGG AGAAAGCCCA GACTCCCCAN GACNGGTACG GATTGTGGGC 300
ATANAAGGAT TGGGTGAAGC TGGCGTTGTG GT 332
(2)关于SEQ ID NO:132的信息
(i)序列特征
(A)长度:322个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:132:
ACTTTTGCCA TTTTGTATAT ATAAACAATC TTGGGACATT CTCCTGAAAA CTAGGTGTCC 60
AGTGGCTAAG AGAACTCGAT TTCAAGCAAT TCTGAAAGGA AAACCAGCAT GACACAGAAT 120
CTCAAATTCC CAAACAGGGG CTCTGTGGGA AAAATGAGGG AGGACCTTTG TATCTCGGGT 180
TTTAGCAAGT TAAAATGAAN ATGACAGGAA AGGCTTATTT ATCAACAAAG AGAAGAGTTG 240
GGATGCTTCT AAAAAAAACT TTGGTAGAGA AAATAGGAAT GCTNAATCCT AGGGAAGCCT 300
GTAACAATCT ACAATTGGTC CA 322
(2)关于SEQ ID NO:133的信息
(i)序列特征
(A)长度:278个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:133:
ACAAGCCTTC ACAAGTTTAA CTAAATTGGG ATTAATCTTT CTGTANTTAT CTGCATAATT 60
CTTGTTTTTC TTTCCATCTG GCTCCTGGGT TGACAATTTG TGGAAACAAC TCTATTGCTA 120
CTATTTAAAA AAAATCACAA ATCTTTCCCT TTAAGCTATG TTNAATTCAA ACTATTCCTG 180
CTATTCCTGT TTTGTCAAAG AAATTATATT TTTCAAAATA TGTMTATTTG TTTGATGGGT 240
CCCACGAAAC ACTAATAAAA ACCACAGAGA CCAGCCTG 278
(2)关于SEQ ID NO:134的信息
(i)序列特征
(A)长度:121个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:134:
GTTTANAAAA CTTGTTTAGC TCCATAGAGG AAAGAATGTT AAACTTTGTA TTTTAAAACA 60
TGATTCTCTG AGGTTAAACT TGGTTTTCAA ATGTTATTTT TACTTGTATT TTGCTTTTGG 120
T 121
(2)关于SEQ ID NO:135的信息
(i)序列特征
(A)长度:350个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(x i)序列描述:SEQ ID NO:135:
ACTTANAACC ATGCCTAGCA CATCAGAATC CCTCAAAGAA CATCAGTATA ATCCTATACC 60
ATANCAAGTG GTGACTGGTT AAGCGTGCGA CAAAGGTCAG CTGGCACATT ACTTGTGTGC 120
AAACTTGATA CTTTTGTTCT AAGTAGGAAC TAGTATACAG TNCCTAGGAN TGGTACTCCA 180
GGGTGCCCCC CAACTCCTGC AGCCGCTCCT CTGTGCCAGN CCCTGNAAGG AACTTTCGCT 240
CCACCTCAAT CAAGCCCTGG GCCATGCTAC CTGCAATTGG CTGAACAAAC GTTTGCTGAG 300
TTCCCAAGGA TGCAAAGCCT GGTGCTCAAC TCCTGGGGCG TCAACTCAGT 350
(2)关于SEQ ID NO:136的信息
(i)序列特征
(A)长度:399个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:136:
TGTACCGTGA AGACGACAGA AGTTGCATGG CAGGGACAGG GCAGGGCCGA GGCCAGGGTT 60
GCTGTGATTG TATCCGAATA NTCCTCGTGA GAAAAGATAA TGAGATGACG TGAGCAGCCT 120
GCAGACTTGT GTCTGCCTTC AANAAGCCAG ACAGGAAGGC CCTGCCTGCC TTGGCTCTGA 180
CCTGGCGGCC AGCCAGCCAG CCACAGGTGG GCTTCTTCCT TTTGTGGTGA CAACNCCAAG 240
AAAACTGCAG AGGCCCAGGG TCAGGTGTNA GTGGGTANGT GACCATAAAA CACCAGGTGC 300
TCCCAGGAAC CCGGGCAAAG GCCATCCCCA CCTACAGCCA GCATGCCCAC TGGCGTGATG 360
GGTGCAGANG GATGAAGCAG CCAGNTGTTC TGCTGTGGT 399
(2)关于SEQ ID NO:137的信息
(i)序列特征
(A)长度:165个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:137:
ACTGGTGTGG TNGGGGGTGA TGCTGGTGGT ANAAGTTGAN GTGACTTCAN GATGGTGTGT 60
GGAGGAAGTG TGTGAACGTA GGGATGTAGA NGTTTTGGCC GTGCTAAATG AGCTTCGGGA 120
TTGGCTGGTC CCACTGGTGG TCACTGTCAT TGGTGGGGTT CCTGT 165
(2)关于SEQ ID NO:138的信息
(i)序列特征
(A)长度:338个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:138:
ACTCACTGGA ATGCCACATT CACAACAGAA TCAGAGGTCT GTGAAAACAT TAATGGCTCC 60
TTAACTTCTC CAGTAAGAAT CAGGGACTTG AAATGGAAAC GTTAACAGCC ACATGCCCAA 120
TGCTGGGCAG TCTCCCATGC CTTCCACAGT GAAAGGGCTT GAGAAAAATC ACATCCAATG 180
TCATGTGTTT CCAGCCACAC CAAAAGGTGC TTGGGGTGGA GGGCTGGGGG CATANANGGT 240
CANGCCTCAG GAAGCCTCAA GTTCCATTCA GCTTTGCCAC TGTACATTCC CCATNTTTAA 300
AAAAACTGAT GCCTTTTTTT TTTTTTTTTG TAAAATTC 338
(2)关于SEQ ID NO:139的信息
(i)序列特征
(A)长度:382个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:139:
GGGAATCTTG GTTTTTGGCA TCTGGTTTGC CTATAGCCGA GGCCACTTTG ACAGAACAAA 60
GAAAGGGACT TCGAGTAAGA AGGTGATTTA CAGCCAGCCT AGTGCCCGAA GTGAAGGAGA 120
ATTCAAACAG ACCTCGTCAT TCCTGGTGTG AGCCTGGTCG GCTCACCGCC TATCATCTGC 180
ATTTGCCTTA CTCAGGTGCT ACCGGACTCT GGCCCCTGAT GTCTGTAGTT TCACAGGATG 240
CCTTATTTGT CTTCTACACC CCACAGGGCC CCCTACTTCT TCGGATGTGT TTTTAATAAT 300
GTCAGCTATG TGCCCCATCC TCCTTCATGC CCTCCCTCCC TTTCCTACCA CTGCTGAGTG 360
GCCTGGAACT TGTTTAAAGT GT 382
(2)关于SEQ ID NO:140的信息
(i)序列特征
(A)长度:200个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:140:
ACCAAANCTT CTTTCTGTTG TGTTNGATTT TACTATAGGG GTTTNGCTTN TTCTAAANAT 60
ACTTTTCATT TAACANCTTT TGTTAAGTGT CAGGCTGCAC TTTGCTCCAT ANAATTATTG 120
TTTTCACATT TCAACTTGTA TGTGTTTGTC TCTTANAGCA TTGGTGAAAT CACATATTTT 130
ATATTCAGCA TAAAGGAGAA 200
(2)关于SEQ ID NO:141的信息
(i)序列特征
(A)长度:335个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:141:
ACTTTATTTT CAAAACACTC ATATGTTGCA AAAAACACAT AGAAAAATAA AGTTTGGTGG 60
GGGTGCTGAC TAAACTTCAA GTCACAGACT TTTATGTGAC AGATTGGAGC AGGGTTTGTT 120
ATGCATGTAG AGAACCCAAA CTAATTTATT AAACAGGATA GAAACAGGCT GTCTGGGTGA 180
AATGGTTCTG AGAACCATCC AATTCACCTG TCAGATGCTG ATANACTAGC TCTTCAGATG 240
TTTTTCTACC AGTTCAGAGA TNGGTTAATG ACTANTTCCA ATGGGGAAAA AGCAAGATGG 300
ATTCACAAAC CAAGTAATTT TAAACAAAGA CACTT 335
(2)关于SEQ ID NO:142的信息
(i)序列特征
(A)长度:459个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:142:
ACCAGGTTAA TATTGCCACA TATATCCTTT CCAATTGCGG GCTAAACAGA CGTGTATTTA 60
GGGTTGTTTA AAGACAACCC AGCTTAATAT CAAGAGAAAT TGTGACCTTT CATGGAGTAT 120
CTGATGGAGA AAACACTGAG TTTTGACAAA TCTTATTTTA TTCAGATAGC AGTCTGATCA 180
CACATGGTCC AACAACACTC AAATAATAAA TCAAATATNA TCAGATGTTA AAGATTGGTC 240
TTCAAACATC ATAGCCAATG ATGCCCCGCT TGCCTATAAT CTCTCCGACA TAAAACCACA 300
TCAACACCTC AGTGGCCACC AAACCATTCA GCACAGCTTC CTTAACTGTG AGCTGTTTGA 360
AGCTACCAGT CTGAGCACTA TTGACTATNT TTTTCANGCT CTGAATAGCT CTAGGGATCT 420
CAGCANGGGT GGGAGGAACC AGCTCAACCT TGGCGTANT 459
(2)关于SEQ ID NO:143的信息
(i)序列特征
(A)长度:140个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:143:
ACATTTCCTT CCACCAAGTC AGGACTCCTG GCTTCTGTGG GAGTTCTTAT CACCTGAGGG 60
AAATCCAAAC AGTCTCTCCT AGAAAGGAAT AGTGTCACCA ACCCCACCCA TCTCCCTGAG 120
ACCATCCGAC TTCCCTGTGT 140
(2)关于SEQ ID NO:144的信息
(i)序列特征
(A)长度:164个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:144:
ACTTCAGTAA CAACATACAA TAACAACATT AAGTGTATAT TGCCATCTTT GTCATTTTCT 60
ATCTATACCA CTCTCCCTTC TGAAAACAAN AATCACTANC CAATCACTTA TACAAATTTG 120
AGGCAATTAA TCCATATTTG TTTTCAATAA GGAAAAAAAG ATGT 164
(2)关于SEQ ID NO:145的信息
(i)序列特征
(A)长度:303个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:145:
ACGTAGACCA TCCAACTTTG TATTTGTAAT GGCAAACATC CAGNAGCAAT TCCTAAACAA 60
ACTGGAGGGT ATTTATACCC AATTATCCCA TTCATTAACA TGCCCTCCTC CTCAGGCTAT 120
GCAGGACAGC TATCATAAGT CGGCCCAGGC ATCCAGATAC TACCATTTGT ATAAACTTCA 180
GTAGGGGAGT CCATCCAAGT GACAGGTCTA ATCAAAGGAG GAAATGGAAC ATAAGCCCAG 240
TAGTAAAATN TTGCTTAGCT GAAACAGCCA CAAAAGACTT ACCGCCGTGG TGATTACCAT 300
CAA 303
(2)关于SEQ ID NO:146的信息
(i)序列特征
(A)长度:327个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:146:
ACTGCAGCTC AATTAGAAGT GGTCTCTGAC TTTCATCANC TTCTCCCTGG GCTCCATGAC 60
ACTGGCCTGG AGTGACTCAT TGCTCTGGTT GGTTGAGAGA GCTCCTTTGC CAACAGGCCT 120
CCAAGTCAGG GCTGGGATTT GTTTCCTTTC CACATTCTAG CAACAATATG CTGGCCACTT 180
CCTGAACAGG GAGGGTGGGA GGAGCCAGCA TGGAACAAGC TGCCACTTTC TAAAGTAGCC 240
AGACTTGCCC CTGGGCCTGT CACACCTACT GATGACCTTC TGTGCCTGCA GGATGGAATG 300
TAGGGGTGAG CTGTGTGACT CTATGGT 327
(2)关于SEQ ID NO:147的信息
(i)序列特征
(A)长度:173个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:147:
ACATTGTTTT TTTGAGATAA AGCATTGANA GAGCTCTCCT TAACGTGACA CAATGGAAGG 60
ACTGGAACAC ATACCCACAT CTTTGTTCTG AGGGATAATT TTCTGATAAA GTCTTGCTGT 120
ATATTCAAGC ACATATGTTA TATATTATTC AGTTCCATGT TTATAGCCTA GTT 173
(2)关于SEQ ID NO:148的信息
(i)序列特征
(A)长度:477个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:148:
ACAACCACTT TATCTCATCG AATTTTTAAC CCAAACTCAC TCACTGTGCC TTTCTATCCT 60
ATGGGATATA TTATTTGATG CTCCATTTCA TCACACATAT ATGAATAATA CACTCATACT 120
GCCCTACTAC CTGCTGCAAT AATCACATTC CCTTCCTGTC CTGACCCTGA AGCCATTGGG 180
GTGGTCCTAG TGGCCATCAG TCCANGCCTG CACCTTGAGC CCTTGAGCTC CATTGCTCAC 240
NCCANCCCAC CTCACCGACC CCATCCTCTT ACACAGCTAC CTCCTTGCTC TCTAACCCCA 300
TAGATTATNT CCAAATTCAG TCAATTAAGT TACTATTAAC ACTCTACCCG ACATGTCCAG 360
CACCACTGGT AAGCCTTCTC CAGCCAACAC ACACACACAC ACACNCACAC ACACACATAT 420
CCAGGCACAG GCTACCTCAT CTTCACAATC ACCCCTTTAA TTACCATGCT ATGGTGG 477
(2)关于SEQ ID NO:149的信息
(i)序列特征
(A)长度:207个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:149:
ACAGTTGTAT TATAATATCA AGAAATAAAC TTGCAATGAG AGCATTTAAG AGGGAAGAAC 60
TAACGTATTT TAGAGAGCCA AGGAAGGTTT CTGTGGGGAG TGG3ATGTAA GGTGGGGCCT 120
GATGATAAAT AAGAGTCAGC CAGGTAAGTG GGTGGTGTGG TATGGGCACA GTGAAGAACA 180
TTTCAGGCAG AGGGAACAGC AGTGAAA 207
(2)关于SEQ ID NO:150的信息
(i)序列特征
(A)长度:111个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:150:
ACCTTGATTT CATTGCTGCT CTGATGGAAA CCCAACTATC TAATTTAGCT AAAACATGGG 60
CACTTAAATG TGGTCAGTGT TTGGACTTGT TAACTANTGG CATCTTTGGG T 111
(2)关于SEQ ID NO:151的信息
(i)序列特征
(A)长度:196个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:151:
AGCGCGGCAG GTCATATTGA ACATTCCAGA TACCTATCAT TACTCGATGC TGTTGATAAC 60
AGCAAGATGG CTTTGAACTC AGGGTCACCA CCAGCTATTG GACCTTACTA TGAAAACCAT 120
GGATACCAAC CGGAAAACCC CTATCCCGCA CAGCCCACTG TGGTCCCCAC TGTCTACGAG 180
GTGCATCCGG CTCAGT 196
(2)关于SEQ ID NO:152的信息
(i)序列特征
(A)长度:132个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:152:
ACAGCACTTT CACATGTAAG AAGGGAGAAA TTCCTAAATG TAGGAGAAAG ATAACAGAAC 60
CTTCCCCTTT TCATCTAGTG GTGGAAACCT GATGCTTTAT GTTGACAGGA ATAGAACCAG 120
GAGGGAGTTT GT 132
(2)关于SEQ ID NO:153的信息
(i)序列特征
(A)长度:285个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:153:
ACAANACCCA NGANAGGCCA CTGGCCGTGG TGTCATGGCC TCCAAACATG AAAGTGTCAG 60
CTTCTGCTCT TATGTCCTCA TCTGACAACT CTTTACCATT TTTATCCTCG CTCAGCAGGA 120
GCACATCAAT AAAGTCCAAA GTCTTGGACT TGGCCTTGGC TTGGAGGAAG TCATCAACAC 180
CCTGGCTAGT GAGGGTGCGG CGCCGCTCCT GGATGACGGC ATCTGTGAAG TCGTGCACCA 240
GTCTGCAGGC CCTGTGGAAG CGCCGTCCAC ACGGAGTNAG GAATT 285
(2)关于SEQ ID NO:154的信息
(i)序列特征
(A)长度:333个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:154:
ACCACAGTCC TGTTGGGCCA GGGCTTCATG ACCCTTTCTG TGAAAAGCCA TATTATCACC 60
ACCCCAAATT TTTCCTTAAA TATCTTTAAC TGAAGGGGTC AGCCTCTTGA CTGCAAAGAC 120
CCTAAGCCGG TTACACAGCT AACTCCCACT GGCCCTGATT TGTGAAATTG CTGCTGCCTG 180
ATTGGCACAG GAGTCGAAGG TGTTCAGCTC CCCTCCTCCG TGGAACGAGA CTCTGATTTG 240
AGTTTCACAA ATTCTCGGGC CACCTCGTCA TTGCTCCTCT GAAATAAAAT CCGGAGAATG 300
GTCAGGCCTG TCTCATCCAT ATGGATCTTC CGG 333
(2)关于SEQ ID NO:155的信息
(i)序列特征
(A)长度:308个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:155:
ACTGGAAATA ATAAAACCCA CATCACAGTG TTGTGTCAAA GATCATCAGG GCATGGATGG 60
GAAAGTGCTT TGGGAACTGT AAAGTGCCTA ACACATGATC GATGATTTTT GTTATAATAT 120
TTGAATCACG GTGCATACAA ACTCTCCTGC CTGCTCCTCC TGGGCCCCAG CCCCAGCCCC 180
ATCACAGCTC ACTGCTCTGT TCATCCAGGC CCAGCATGTA GTGGCTGATT CTTCTTGGCT 240
GCTTTTAGCC TCCANAAGTT TCTCTGAAGC CAACCAAACC TCTANGTGTA AGGCATGCTG 300
GCCCTGGT 308
(2)关于SEQ ID NO:156的信息
(i)序列特征
(A)长度:295个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:156:
ACCTTGCTCG GTGCTTGGAA CATATTAGGA ACTCAAAATA TGAGATGATA ACAGTGCCTA 60
TTATTGATTA CTGAGAGAAC TGTTAGACAT TTAGTTGAAG ATTTTCTACA CAGGAACTGA 120
GAATAGGAGA TTATGTTTGG CCCTCATATT CTCTCCTATC CTCCTTGCCT CATTCTATGT 180
CTAATATATT CTCAAT AAA TAAGGTTAGC ATAATCAGGA AATCGACCAA ATACCAATAT 240
AAAACCAGAT GTCTATCCTT AAGATTTTCA AATAGAAAAC AAATTAACAG ACTAT 295
(2)关于SEQ ID NO:157的信息
(i)序列特征
(A)长度:126个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:157:
ACAAGTTTAA ATAGTGCTGT CACTGTGCAT GTGCTGAAAT GTGAAATCCA CCACATTTCT 60
GAAGAGCAAA ACAAATTCTG TCATGTAATC TCTATCTTGG GTCGTGGGTA TATCTGTCCC 120
CTTAGT 126
(2)关于SEQ ID NO:158的信息
(i)序列特征
(A)长度:442个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:158:
ACCCACTGGT CTTGGAAACA CCCATCCTTA ATACGATGAT TTTTCTGTCG TGTGAAAATG 60
AANCCAGCAG GCTGCCCCTA GTCAGTCCTT CCTTCCAGAG AAAAAGAGAT TTGAGAAAGT 120
GCCTGGGTAA TTCACCATTA ATTTCCTCCC CCAAACTCTC TGAGTCTTCC CTTAATATTT 180
CTGGTGGTTC TGACCAAAGC AGGTCATGGT TTGTTGAGCA TTTGGGATCC CAGTGAAGTA 240
NATGTTTGTA GCCTTGCATA CTTAGCCCTT CCCACGCACA AACGGAGTGG CAGAGTGGTG 300
CCAACCCTGT TTTCCCAGTC CACGTAGACA GATTCACAGT GCGGAATTCT GGAAGCTGGA 360
NACAGACGGG CTCTTTGCAG AGCCGGGACT CTGAGANGGA CATGAGGGCC TCTGCCTCTG 420
TGTTCATTCT CTGATGTCCT GT 442
(2)关于SEQ ID NO:159的信息
(i)序列特征
(A)长度:498个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:159:
ACTTCCAGGT AACGTTGTTG TTTCCGTTGA GCCTGAACTG ATGGGTGACG TTGTAGGTTC 60
TCCAACAAGA ACTGAGGTTG CAGAGCGGGT AGGGAAGAGT GCTGTTCCAG TTGCACCTGG 120
GCTGCTGTGG ACTGTTGTTG ATTCCTCACT ACGGCCCAAG GTTGTGGAAC TGGCANAAAG 180
GTGTGTTGTT GGANTTGAGC TCGGGCGGCT GTGGTAGGTT GTGGGCTCTT CAACAGGGGC 240
TGCTGTGGTG CCGGGANGTG AANGTGTTGT GTCACTTGAG CTTGGCCAGC TCTGGAAAGT 300
ANTANATTCT TCCTGAAGGC CAGCGCTTGT GGAGCTGGCA NGGGTCANTG TTGTGTGTAA 360
CGAACCAGTG CTGCTGTGGG TGGGTGTANA TCCTCCACAA AGCCTGAAGT TATGGTGTCN 420
TCAGGTAANA ATGTGGTTTC AGTGTCCCTG GGCNGCTGTG GAAGGTTGTA NATTGTCACC 480
AAGGGAATAA GCTGTGGT 498
(2)关于SEQ ID NO:160的信息
(i)序列特征
(A)长度:380个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:160:
ACCTGCATCC AGCTTCCCTG CCAAACTCAC AAGGAGACAT CAACCTCTAG ACAGGGAAAC 60
AGCTTCAGGA TACTTCCAGG AGACAGAGCC ACCAGCAGCA AAACAAATAT TCCCATGCCT 120
GGAGCATGGC ATAGAGGAAG CTGANAAATG TGGGGTCTGA GGAAGCCATT TGAGTCTGGC 180
CACTAGACAT CTCATCAGCC ACTTGTGTGA AGAGATGCCC CATGACCCCA GATGCCTCTC 240
CCACCCTTAC CTCCATCTCA CACACTTGAG CTTTCCACTC TGTATAATTC TAACATCCTG 300
GAGAAAAATG GCAGTTTGAC CGAACCTGTT CACAACGGTA GAGGCTGATT TCTAACGAAA 360
CTTGTAGAAT GAAGCCTGGA 380
(2)关于SEQ ID NO:161的信息
(i)序列特征
(A)长度:114个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:161:
ACTCCACATC CCCTCTGAGC AGGCGGTTGT CGTTCAAGGT GTATTTGGCC TTGCCTGTCA 60
CACTGTCCAC TGGCCCCTTA TCCACTTGGT GCTTAATCCC TCGAAAGAGC ATGT 114
(2)关于SEQ ID NO:162的信息
(i)序列特征
(A)长度:177个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:162:
ACTTTCTGAA TCGAATCAAA TGATACTTAG TGTAGTTTTA ATATCCTCAT ATATATCAAA 60
GTTTTACTAC TCTGATAATT TTGTAAACCA GGTAACCAGA ACATCCAGTC ATACAGCTTT 120
TGGTGATATA TAACTTGGCA ATAACCCAGT CTGGTGATAC ATAAAACTAC TCACTGT 177
(2)关于SEQ ID NO:163的信息
(i)序列特征
(A)长度:137个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:163:
CATTTATACA GACAGGCGTG AAGACATTCA CGACAAAAAC GCGAAATTCT ATCCCGTGAC 60
CANAGAAGGC AGCTACGGCT ACTCCTACAT CCTGGCGTGG GTGGCCTTCG CCTGCACCTT 120
CATCAGCGGC ATGATGT 137
(2)关于SEQ ID NO:164的信息
(i)序列特征
(A)长度:469个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:164:
CTTATCACAA TGAATGTTCT CCTGGGCAGC GTTGTGATCT TTGCCACCTT CGTGACTTTA 60
TGCAATGCAT CATGCTATTT CATACCTAAT GAGGGAGTTC CAGGAGATTC AACCAGGAAA 120
TGCATGGATC TCAAAGGAAA CAAACACCCA ATAAACTCGG AGTGGCAGAC TGACAACTGT 180
GAGACATGCA CTTGCTACGA AACAGAAATT TCATGTTGCA CCCTTGTTTC TACACCTGTG 240
GGTTATGACA AAGACAACTG CCAAAGAATC TTCAAGAAGG AGGACTGCAA GTATATCGTG 300
GTGGAGAAGA AGGACCCAAA AAAGACCTGT TCTGTCAGTG AATGGATAAT CTAATGTGCT 360
TCTAGTAGGC ACAGGGCTCC CAGGCCAGGC CTCATTCTCC TCTGGCCTCT AATAGTCAAT 420
GATTGTGTAG CCATGCCTAT CAGTAAAAAG ATNTTTGAGC AAACACTTT 469
(2)关于SEQ ID NO:165的信息
(i)序列特征
(A)长度:195个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:165:
ACAGTTTTTT ATANATATCG ACATTGCCGG CACTTGTGTT CAGTTTCATA AAGCTGGTGG 60
ATCCGCTGTC ATCCACTATT CCTTGGCTAG AGTAAAAATT ATTCTTATAG CCCATGTCCC 120
TGCAGGCCGC CCGCCCGTAG TTCTCGTTCC AGTCGTCTTG GCACACAGGG TGCCAGGACT 180
TCCTCTGAGA TGAGT 195
(2)关于SEQ ID NO:166的信息
(i)序列特征
(A)长度:383个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:166:
ACATCTTAGT AGTGTGGCAC ATCAGGGGGC CATCAGGGTC ACAGTCACTC ATAGCCTCGC 60
CGAGGTCGGA GTCCACACCA CCGGTGTAGG TGTGCTCAAT CTTGGGCTTG GCGCCCACCT 120
TTGGAGAAGG GATATGCTGC ACACACATGT CCACAAAGCC TGTGAACTCG CCAAAGAATT 180
TTTGCAGACC AGCCTGAGCA AGGGGCGGAT GTTCAGCTTC AGCTCCTCCT TCGTCAGGTG 240
GATGCCAACC TCGTCTANGG TCCGTGGGAA GCTGGTGTCC ACNTCACCTA CAACCTGGGC 300
GANGATCTTA TAAAGAGGCT CCNAGATAAA CTCCACGAAA CTTCTCTGGG AGCTGCTAGT 360
NGGGGCCTTT TTGGTGAACT TTC 383
(2)关于SEQ ID NO:167的信息
(i)序列特征
(A)长度:247个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:167:
ACAGAGCCAG ACCTTGGCCA TAAATGAANC AGAGATTAAG ACTAAACCCC AAGTCGANAT 60
TGGAGCAGAA ACTGGAGCAA GAAGTGGGCC TGGGGCTGAA GTAGAGACCA AGGCCACTGC 120
TATANCCATA CACAGAGCCA ACTCTCAGGC CAAGGCNATG GTTGGGGCAG ANCCAGAGAC 180
TCAATCTGAN TCCAAAGTGG TGGCTGGAAC ACTGGTCATG ACANAGGCAG TGACTCTGAC 240
TGANGTC 247
(2)关于SEQ ID NO:168的信息
(i)序列特征
(A)长度:273个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:168:
ACTTCTAAGT TTTCTAGAAG TGGAAGGATT GTANTCATCC TGAAAATGGG TTTACTTCAA 60
AATCCCTCAN CCTTGTTCTT CACNACTGTC TATACTGANA GTGTCATGTT TCCACAAAGG 120
GCTGACACCT GAGCCTGNAT TTTCACTCAT CCCTGAGAAG CCCTTTCCAG TAGGGTGGGC 180
AATTCCCAAC TTCCTTGCCA CAAGCTTCCC AGGCTTTCTC CCCTGGAAAA CTCCAGCTTG 240
AGTCCCAGAT ACACTCATGG GCTGCCCTGG GCA 273
(2)关于SEQ ID NO:169的信息
(i)序列特征
(A)长度:431个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:169:
ACAGCCTTGG CTTCCCCAAA CTCCACAGTC TCAGTGCAGA AAGATCATCT TCCAGCAGTC 60
AGCTCAGACC AGGGTCAAAG GATGTGACAT CAACAGTTTC TGGTTTCAGA ACAGGTTCTA 120
CTACTGTCAA ATGACCCCCC ATACTTCCTC AAAGGCTGTG GTAAGTTTTG CACAGGTGAG 180
GGCAGCAGAA AGGGGGTANT TACTGATGGA CACCATCTTC TCTGTATACT CCACACTGAC 240
CTTGCCATGG GCAAAGGCCC CTACCACAAA AACAATAGGA TCACTGCTGG GCACCAGCTC 300
ACGCACATCA CTGACAACCG GGATGGAAAA AGAANTGCCA ACTTTCATAC ATCCAACTGG 360
AAAGTGATCT GATACTGGAT TCTTAATTAC CTTCAAAAGC TTCTGGGGGC CATCAGCTGC 420
TCGAACACTG A 431
(2)关于SEQ ID NO:170的信息
(i)序列特征
(A)长度:266个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:170:
ACCTGTGGGC TGGGCTGTTA TGCCTGTGCC GGCTGCTGAA AGGGAGTTCA GAGGTGGAGC 60
TCAAGGAGCT CTGCAGGCAT TTTGCCAANC CTCTCCANAG CANAGGGAGC AACCTACACT 120
CCCCGCTAGA AAGACACCAG ATTGGAGTCC TGGGAGGGGG AGTTGGGGTG GGCATTTGAT 180
GTATACTTGT CACCTGAATG AANGAGCCAG AGAGGAANGA GACGAANATG ANATTGGCCT 240
TCAAAGCTAG GGGTCTGGCA GGTGGA 266
(2)关于SEQ ID NO:171的信息
(i)序列特征
(A)长度:1248个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:171:
GGCAGCCAAA TCATAAACGG CGAGGACTGC AGCCCGCACT CGCAGCCCTG GCAGGCGGCA 60
CTGGTCATGG AAAACGAATT GTTCTGCTCG GGCGTCCTGG TGCATCCGCA GTGGGTGCTG 120
TCAGCCGCAC ACTGTTTCCA GAAGTGAGTG CAGAGCTCCT ACACCATCGG GCTGGGCCTG 180
CACAGTCTTG AGGCCGACCA AGAGCCAGGG AGCCAGATGG TGGAGGCCAG CCTCTCCGTA 240
CGGCACCCAG AGTACAACAG ACCCTTGCTC GCTAACGACC TCATGCTCAT CAAGTTGGAC 300
GAATCCGTGT CCGAGTCTGA CACCATCCGG AGCATCAGCA TTGCTTCGCA GTGCCCTACC 360
GCGGGGAACT CTTGCCTCGT TTCTGGCTGG GGTCTGCTGG CGAACGGCAG AATGCCTACC 420
GTGCTGCAGT GCGTGAACGT GTCGGTGGTG TCTGAGGAGG TCTGCAGTAA GCTCTATGAC 480
CCGCTGTACC ACCCCAGCAT GTTCTGCGCC GGCGGAGGGC AAGACCAGAA GGACTCCTGC 540
AACGGTGACT CTGGGGGGCC CCTGATCTGC AACGGGTACT TGCAGGGCCT TGTGTCTTTC 600
GGAAAAGCCC CGTGTGGCCA AGTTGGCGTG CCAGGTGTCT ACACCAACCT CTGCAAATTC 660
ACTGAGTGGA TAGAGAAAAC CGTCCAGGCC AGTTAACTCT GGGGACTGGG AACCCATGAA 720
ATTGACCCCC AAATACATCC TGCGGAAGGA ATTCAGGAAT ATCTGTTCCC AGCCCCTCCT 780
CCCTCAGGCC CAGGAGTCCA GGCCCCCAGC CCCTCCTCCC TCAAACCAAG GGTACAGATC 840
CCCAGCCCCT CCTCCCTCAG ACCCAGGAGT CCAGACCCCC CAGCCCCTCC TCCCTCAGAC 900
CCAGGAGTCC AGCCCCTCCT CCCTCAGACC CAGGAGTCCA GACCCCCCAG CCCCTCCTCC 960
CTCAGACCCA GGGGTCCAGG CCCCCAACCC CTCCTCCCTC AGACTCAGAG GTCCAAGCCC 1020
CCAACCCNTC ATTCCCCAGA CCCAGAGGTC CAGGTCCCAG CCCCTCNTCC CTCAGACCCA 1080
GCGGTCCAAT GCCACCTAGA CTNTCCCTGT ACACAGTGCC CCCTTGTGGC ACGTTGACCC 1140
AACCTTACCA GTTGGTTTTT CATTTTTNGT CCCTTTCCCC TAGATCCAGA AATAAAGTTT 1200
AAGAGAAGNG CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA 1248
(2)关于SEQ ID NO:172的信息
(i)序列特征
(A)长度:159个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:蛋白质
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:172:
Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
1 5 10 15
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
20 25 30
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
35 40 45
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
50 55 60
Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
65 70 75 80
Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe
85 90 95
Cys Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser
100 105 110
Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe
115 120 125
Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn
130 135 140
Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
145 150 155
(2)关于SEQ ID NO:173的信息
(i)序列特征
(A)长度:1265个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:173:
GGCAGCCCGC ACTCGCAGCC CTGGCAGGCG GCACTGGTCA TGGAAAACGA ATTGTTCTGC 60
TCGGGCGTCC TGGTGCATCC GCAGTGGGTG CTGTCAGCCG CACACTGTTT CCAGAACTCC 120
TACACCATCG GGCTGGGCCT GCACAGTCTT GAGGCCGACC AAGAGCCAGG GAGCCAGATG 180
GTGGAGGCCA GCCTCTCCGT ACGGCACCCA GAGTACAACA GACCCTTGCT CGCTAACGAC 240
CTCATGCTCA TCAAGTTGGA CGAATCCGTG TCCGAGTCTG ACACCATCCG GAGCATCAGC 300
ATTGCTTCGC AGTGCCCTAC CGCGGGGAAC TCTTGCCTCG TTTCTGGCTG GGGTCTGCTG 360
GCGAACGGTG AGCTCACGGG TGTGTGTCTG CCCTCTTCAA GGAGGTCCTC TGCCCAGTCG 420
CGGGGGCTGA CCCAGAGCTC TGCGTCCCAG GCAGAATGCC TACCGTGCTG CAGTGCGTGA 480
ACGTGTCGGT GGTGTCTGAG GAGGTCTGCA GTAAGCTCTA TGACCCGCTG TACCACCCCA 540
GCATGTTCTG CGCCGGCGGA GGGCAAGACC AGAAGGACTC CTGCAACGGT GACTCTGGGG 600
GGCCCCTGAT CTGCAACGGG TACTTGCAGG GCCTTGTGTC TTTCGGAAAA GCCCCGTGTG 660
GCCAAGTTGG CGTGCCAGGT GTCTACACCA ACCTCTGCAA ATTCACTGAG TGGATAGAGA 720
AAACCGTCCA GGCCAGTTAA CTCTGGGGAC TGGGAACCCA TGAAATTGAC CCCCAAATAC 780
ATCCTGCGGA AGGAATTCAG GAATATCTGT TCCCAGCCCC TCCTCCCTCA GGCCCAGGAG 840
TCCAGGCCCC CAGCCCCTCC TCCCTCAAAC CAAGGGTACA GATCCCCAGC CCCTCCTCCC 900
TCAGACCCAG GAGTCCAGAC CCCCCAGCCC CTCCTCCCTC AGACCCAGGA GTCCAGCCCC 960
TCCTCCNTCA GACCCAGGAG TCCAGACCCC CCAGCCCCTC CTCCCTCAGA CCCAGGGGTT 1020
GAGGCCCCCA ACCCCTCCTC CTTCAGAGTC AGAGGTCCAA GCCCCCAACC CCTCGTTCCC 1080
CAGACCCAGA GGTNNAGGTC CCAGCCCCTC TTCCNTCAGA CCCAGNGGTC CAATGCCACC 1140
TAGATTTTCC CTGNACACAG TGCCCCCTTG TGGNANGTTG ACCCAACCTT ACCAGTTGGT 1200
TTTTCATTTT TNGTCCCTTT CCCCTAGATC CAGAAATAAA GTTTAAGAGA NGNGCAAAAA 1260
AAAAA 1265
(2)关于SEQ ID NO:174的信息
(i)序列特征
(A)长度:1459个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:174:
GGTCAGCCGC ACACTGTTTC CAGAAGTGAG TGCAGAGCTC CTACACCATC GGGCTGGGCC 60
TGCACAGTCT TGAGGCCGAC CAAGAGCCAG GGAGCCAGAT GGTGGAGGCC AGCCTCTCCG 120
TACGGCACCC AGAGTACAAC AGACCCTTGC TCGCTAACGA CCTCATGCTC ATCAAGTTGG 180
ACGAATCCGT GTCCGAGTCT GACACCATCC GGAGCATCAG CATTGCTTCG CAGTGCCCTA 240
CCGCGGGGAA CTCTTGCCTC GTTTCTGGCT GGGGTCTGCT GGCGAACGGT GAGCTCACGG 300
GTGTGTGTCT GCCCTCTTCA AGGAGGTCCT CTGCCCAGTC GCGGGGGCTG ACCCAGAGCT 360
CTGCGTCCCA GGCAGAATGC CTACCGTGCT GCAGTGCGTG AACGTGTCGG TGGTGTCTGA 420
NGAGGTCTGC ANTAAGCTCT ATGACCCGCT GTACCACCCC ANCATGTTCT GCGCCGGCGG 480
AGGGCAAGAC CAGAAGGACT CCTGCAACGT GAGAGAGGGG AAAGGGGAGG GCAGGCGACT 540
CAGGGAAGGG TGGAGAAGGG GGAGACAGAG ACACACAGGG CCGCATGGCG AGATGCAGAG 600
ATGGAGAGAC ACACAGGGAG ACAGTGACAA CTAGAGAGAG AAACTGAGAG AAACAGAGAA 660
ATAAACACAG GAATAAAGAG AAGCAAAGGA AGAGAGAAAC AGAAACAGAC ATGGGGAGGC 720
AGAAACACAC ACACATAGAA ATGCAGTTGA CCTTCCAACA GCATGGGGCC TGAGGGCGGT 780
GACCTCCACC CAATAGAAAA TCCTCTTATA ACTTTTGACT CCCCAAAAAC CTGACTAGAA 840
ATAGCCTACT GTTGACGGGG AGCCTTACCA ATAACATAAA TAGTCGATTT ATGCATACGT 900
TTTATGCATT CATGATATAC CTTTGTTGGA ATTTTTTGAT ATTTCTAAGC TACACAGTTC 960
GTCTGTGAAT TTTTTTAAAT TGTTGCAACT CTCCTAAAAT TTTTCTGATG TGTTTATTGA 1020
AAAAATCCAA GTATAAGTGG ACTTGTGCAT TCAAACCAGG GTTGTTCAAG GGTCAACTGT 1080
GTACCCAGAG GGAAACAGTG ACACAGATTC ATAGAGGTGA AACACGAAGA GAAACAGGAA 1140
AAATCAAGAC TCTACAAAGA GGCTGGGCAG GGTGGCTCAT GCCTGTAATC CCAGCACTTT 1200
GGGAGGCGAG GCAGGCAGAT CACTTGAGGT AAGGAGTTCA AGACCAGCCT GGCCAAAATG 1260
GTGAAATCCT GTCTGTACTA AAAATACAAA AGTTAGCTGG ATATGGTGGC AGGCGCCTGT 1320
AATCCCAGCT ACTTGGGAGG CTGAGGCAGG AGAATTGCTT GAATATGGGA GGCAGAGGTT 1380
GAAGTGAGTT GAGATCACAC CACTATACTC CAGCTGGGGC AACAGAGTAA GACTCTGTCT 1440
CAAAAAAAAA AAAAAAAAA 1459
(2)关于SEQ ID NO:175的信息
(i)序列特征
(A)长度:1167个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:175:
GCGCAGCCCT GGCAGGCGGC ACTGGTCATG GAAAACGAAT TGTTCTGCTC GGGCGTCCTG 60
GTGCATCCGC AGTGGGTGCT GTCAGCCGCA CACTGTTTCC AGAACTCCTA CACCATCGGG 120
CTGGGCCTGC ACAGTCTTGA GGCCGACCAA GAGCCAGGGA GCCAGATGGT GGAGGCCAGC 180
CTCTCCGTAC GGCACCCAGA GTACAACAGA CTCTTGCTCG CTAACGACCT CATGCTCATC 240
AAGTTGGACG AATCCGTGTC CGAGTCTGAC ACCATCCGGA GCATCAGCAT TGCTTCGCAG 300
TGCCCTACCG CGGGGAACTC TTGCCTCGTN TCTGGCTGGG GTCTGCTGGC GAACGGCAGA 360
ATGCCTACCG TGCTGCACTG CGTGAACGTG TCGGTGGTGT CTGAGGANGT CTGCAGTAAG 420
CTCTATGACC CGCTGTACCA CCCCAGCATG TTCTGCGCCG GCGGAGGGCA AGACCAGAAG 480
GACTCCTGCA ACGGTGACTC TGGGGGGCCC CTGATCTGCA ACGGGTACTT GCAGGGCCTT 540
GTGTCTTTCG GAAAAGCCCC GTGTGGCCAA CTTGGCGTGC CAGGTGTCTA CACCAACCTC 600
TGCAAATTCA CTGAGTGGAT AGAGAAAACC GTCCAGNCCA GTTAACTCTG GGGACTGGGA 660
ACCCATGAAA TTGACCCCCA AATACATCCT GCGGAANGAA TTCAGGAATA TCTGTTCCCA 720
GCCCCTCCTC CCTCAGGCCC AGGAGTCCAG GCCCCCAGCC CCTCCTCCCT CAAACCAAGG 780
GTACAGATCC CCAGCCCCTC CTCCCTCAGA CCCAGGAGTC CAGACCCCCC AGCCCCTCNT 840
CCNTCAGACC CAGGAGTCCA GCCCCTCCTC CNTCAGACGC AGGAGTCCAG ACCCCCCAGC 900
CCNTCNTCCG TCAGACCCAG GGGTGCAGGC CCCCAACCCC TCNTCCNTCA GAGTCAGAGG 960
TCCAAGCCCC CAACCCCTCG TTCCCCAGAC CCAGAGGTNC AGGTCCCAGC CCCTCCTCCC 1020
TCAGACCCAG CGGTCCAATG CCACCTAGAN TNTCCCTGTA CACAGTGCCC CCTTGTGGCA 1080
NGTTGACCCA ACCTTACCAG TTGGTTTTTC ATTTTTTGTC CCTTTCCCCT AGATCCAGAA 1140
ATAAAGTNTA AGAGAAGCGC AAAAAAA 1167
(2)关于SEQ ID NO:176的信息
(i)序列特征
(A)长度:205个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:蛋白质
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:176:
Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
1 5 10 15
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
20 25 30
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
35 40 45
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Leu Leu Leu
50 55 60
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65 70 75 80
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
85 90 95
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met
100 105 110
Pro Thr Val Leu His Cys Val Asn Val Ser Val Val Ser Glu Xaa Val
115 120 125
Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala
130 135 140
Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly
145 150 155 160
Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys
165 170 175
Ala Pro Cys Gly Gln Leu Gly Val Pro Gly Val Tyr Thr Asn Leu Cys
180 185 190
Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Xaa Ser
195 200 205
(2)关于SEQ ID NO:177的信息
(i)序列特征
(A)长度:1119个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:177:
GCGCACTCGC AGCCCTGGCA GGCGGCACTG GTCATGGAAA ACGAATTGTT CTGCTCGGGC 60
GTCCTGGTGC ATCCGCAGTG GGTGCTGTCA GCCGCACACT GTTTCCAGAA CTCCTACACC l20
ATCGGGCTGG GCCTGCACAG TCTTGAGGCC GACCAAGAGC CAGGGAGCCA GATGGTGGAG 180
GCCAGCCTCT CCGTACGGCA CCCAGAGTAC AACAGACCCT TGCTCGCTAA CGACCTCATG 240
CTCATCAAGT TGGACGAATC CGTGTCCGAG TCTGACACCA TCCGGAGCAT CAGCATTGCT 300
TCGCAGTGCC CTACCGCGGG GAACTCTTGC CTCGTTTCTG GCTGGGGTCT GCTGGCGAAC 360
GATGCTGTGA TTGCCATCCA GTCCCAGACT GTGGGAGGCT GGGAGTGTGA GAAGCTTTCC 420
CAACCCTGGC AGGGTTGTAC CATTTCGGCA ACTTCCAGTG CAAGGACGTC CTGCTGCATC 480
CTCACTGGGT GCTCACTACT GCTCACTGCA TCACCCGGAA CACTGTGATC AACTAGCCAG 540
CACCATAGTT CTCCGAAGTC AGACTATCAT GATTACTGTG TTGACTGTGC TGTCTATTGT 600
ACTAACCATG CCGATGTTTA GGTGAAATTA GCGTCACTTG GCCTCAACCA TCTTGGTATC 660
CAGTTATCCT CACTGAATTG AGATTTCCTG CTTCAGTGTC AGCCATTCCC ACATAATTTC 720
TGACCTACAG AGGTGAGGGA TCATATAGCT CTTCAAGGAT GCTGGTACTC CCCTCACAAA 780
TTCATTTCTC CTGTTGTAGT GAAAGGTGCG CCCTCTGGAG CCTCCCAGGG TGGGTGTGCA 840
GGTCACAATG ATGAATGTAT GATCGTGTTC CCATTACCCA AAGCCTTTAA ATCCCTCATG 900
CTCAGTACAC CAGGGCAGGT CTAGCATTTC TTCATTTAGT GTATGCTGTC CATTCATGCA 960
ACCACCTCAG GACTCCTGGA TTCTCTGCCT AGTTGAGCTC CTGCATGCTG CCTCCTTGGG 1020
GAGGTGAGGG AGAGGGCCCA TGGTTCAATG GGATCTGTGC AGTTGTAACA CATTAGGTGC 1080
TTAATAAACA GAAGCTGTGA TGTTAAAAAA AAAAAAAAAA 1119
(2)关于SEQ ID NO:178的信息
(i)序列特征
(A)长度:164个氨基酸
(B)类型:氨基酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:蛋白质
(vi)最初来源
(A)生物:Homo sapiens
(xi)序列描述:SEQ ID NO:178:
Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
1 5 10 15
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
20 25 30
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
35 40 45
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
50 55 60
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65 70 75 80
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
85 90 95
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Asp Ala Val
100 105 110
Ile Ala Ile Gln Ser Xaa Thr Val Gly Gly Trp Glu Cys Glu Lys Leu
115 120 125
Ser Gln Pro Trp Gln Gly Cys Thr Ile Ser Ala Thr Ser Ser Ala Arg
130 135 140
Thr Ser Cys Cys Ile Leu Thr Gly Cys Ser Leu Leu Leu Thr Ala Ser
145 150 155 160
Pro Gly Thr Leu
(2)关于SEQ ID NO:179的信息
(i)序列特征
(A)长度:250个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:179:
CTGGAGTGCC TTGGTGTTTC AAGCCCCTGC AGGAAGCAGA ATGCACCTTC TGAGGCACCT 60
CCAGCTGCCC CCGGCCGGGG GATGCGAGGC TCGGAGCACC CTTGCCCGGC TGTGATTGCT 120
GCCAGGCACT GTTCATCTCA GCTTTTCTGT CCCTTTGCTC CCGGCAAGCG CTTCTGCTGA 180
AAGTTCATAT CTGGAGCCTG ATGTCTTAAC GAATAAAGGT CCCATGCTCC ACCCGAAAAA 240
AAAAAAAAAA 250
(2)关于SEQ ID NO:180的信息
(i)序列特征
(A)长度:202个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:180:
ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGCCCAA CACAATGGCT ACCTTTAACA 60
TCACCCAGAC CCCGCCCCTG CCCGTGCCCC ACGCTGCTGC TAACGACAGT ATGATGCTTA 120
CTCTGCTACT CGGAAACTAT TTTTATGTAA TTAATGTATG CTTTCTTGTT TATAAATGCC 180
TGATTTAAAA AAAAAAAAAA AA 202
(2)关于SEQ ID NO:181的信息
(i)序列特征
(A)长度:558个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:181:
TCCYTTTGKT NAGGTTTKKG AGACAMCCCK AGACCTWAAN CTGTGTCACA GACTTCYNGG 60
AATGTTTAGG CAGTGCTAGT AATTTCYTCG TAATGATTCT GTTATTACTT TCCTNATTCT 120
TTATTCCTCT TTCTTCTGAA GATTAATGAA GTTGAAAATT GAGGTGGATA AATACAAAAA 180
GGTAGTGTGA TAGTATAAGT ATCTAAGTGC AGATGAAAGT GTGTTATATA TATCCATTCA 240
AAATTATGCA AGTTAGTAAT TACTCAGGGT TAACTAAATT ACTTTAATAT GCTGTTGAAC 300
CTACTCTGTT CCTTGGCTAG AAAAAATTAT AAACAGGACT TTGTTAGTTT GGGAAGCCAA 360
ATTGATAATA TTCTATGTTC TAAAAGTTGG GCTATACATA AATTATTAAG AAATATGGAW 420
TTTTATTCCC AGGAATATGG KGTTCATTTT ATGAATATTA CSCRGGATAG AWGTWTGAGT 480
AAAAYCAGTT TTGGTWAATA YGTWAATATG TCMTAAATAA ACAAKGCTTT GACTTATTTC 540
CAAAAAAAAA AAAAAAAA 558
(2)关于SEQ ID NO:182的信息
(i)序列特征
(A)长度:479个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:182:
ACAGGGWTTK GRGGATGCTA AGSCCCCRGA RWTYGTTTGA TCCAACCCTG GCTTWTTTTC 60
AGAGGGGAAA ATGGGGCCTA GAAGTTACAG MSCATYTAGY TGGTGCGMTG GCACCCCTGG 120
CSTCACACAG ASTCCCGAGT AGCTGGGACT ACAGGCACAC AGTCACTGAA GCAGGCCCTG 180
TTWGCAATTC ACGTTGCCAC CTCCAACTTA AACATTCTTC ATATGTGATG TCCTTAGTCA 240
CTAAGGTTAA ACTTTCCCAC CCAGAAAAGG CAACTTAGAT AAAATCTTAG AGTACTTTCA 300
TACTMTTCTA AGTCCTCTTC CAGCCTCACT KKGAGTCCTM CYTGGGGGTT GATAGGAANT 360
NTCTCTTGGC TTTCTCAATA AARTCTCTAT YCATCTCATG TTTAATTTGG TACGCATARA 420
AWTGSTGARA AAATTAAAAT GTTCTGGTTY MACTTTAAAA ARAAAAAAAA AAAAAAAAA 479
(2)关于SEQ ID NO:183的信息
(i)序列特征
(A)长度:384个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:183:
AGGCGGGAGC AGAAGCTAAA GCCAAAGCCC AAGAAGAGTG GCAGTGCCAG CACTGGTGCC 60
AGTACCAGTA CCAATAACAG TGCCAGTGCC AGTGCCAGCA CCAGTGGTGG CTTCAGTGCT 120
GGTGCCAGCC TGACCGCCAC TCTCACATTT GGGCTCTTCG CTGGCCTTGG TGGAGCTGGT 180
GCCAGCACCA GTGGCAGCTC TGGTGCCTGT GGTTTCTCCT ACAAGTGAGA TTTTAGATAT 240
TGTTAATCCT GCCAGTCTTT CTCTTCAAGC CAGGGTGCAT CCTCAGAAAC CTACTCAACA 300
CAGCACTCTA GGCAGCCACT ATCAATCAAT TGAAGTTGAC ACTCTGCATT ARATCTATTT 360
GCCATTTCAA AAAAAAAAAA AAAA 384
(2)关于SEQ ID NO:184的信息
(i)序列特征
(A)长度:496个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:184:
ACCGAATTGG GACCGCTGGC TTATAAGCGA TCATGTYYNT CCRGTATKAC CTCAACGAGC 60
AGGGAGATCG AGTCTATACG CTGAAGAAAT TTGACCCGAT GGGACAACAG ACCTGCTCAG 120
CCCATCCTGC TCGGTTCTCC CCAGATGACA AATACTCTSG ACACCGAATC ACCATCAAGA 180
AACGCTTCAA GGTGCTCATG ACCCAGCAAC CGCGCCCTGT CCTCTGAGGG TCCCTTAAAC 240
TGATGTCTTT TCTGCCACCT GTTACCCCTC GGAGACTCCG TAACCAAACT CTTCGGACTG 300
TGAGCCCTGA TGCCTTTTTG CCAGCCATAC TCTTTGGCAT CCAGTCTCTC GTGGCGATTG 360
ATTATGCTTG TGTGAGGCAA TCATGGTGGC ATCACCCATA AAGGGAACAC ATTTGACTTT 420
TTTTTCTCAT ATTTTAAATT ACTACMAGAW TATTWMAGAW WAAATGAWTT GAAAAACTST 480
TAAAAAAAAA AAAAAA 496
(2)关于SEQ ID NO:185的信息
(i)序列特征
(A)长度:384个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:185:
GCTGGTAGCC TATGGCGKGG CCCACGGAGG GGCTCCTGAG GCCACGGRAC AGTGACTTCC 60
CAAGTATCYT GCGCSGCGTC TTCTACCGTC CCTACCTGCA GATCTTCGGG CAGATTCCCC 120
AGGAGGACAT GGACGTGGCC CTCATGGAGC ACAGCAACTG YTCGTCGGAG CCCGGCTTCT 180
GGGCACACCC TCCTGGGGCC CAGGCGGGCA CCTGCGTCTC CCAGTATGCC AACTGGCTGG 240
TGGTGCTGCT CCTCGTCATC TTCCTGCTCG TGGCCAACAT CCTGCTGGTC AACTTGCTCA 300
TTGCCATGTT CAGTTACACA TTCGGCAAAG TACAGGGCAA CAGCGATCTC TACTGGGAAG 360
GCGCAGCGTT ACCGCCTCAT CCGG 384
(2)关于SEQ ID NO:186的信息
(i)序列特征
(A)长度:577个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:186:
GAGTTAGCTC CTCCACAACC TTGATGAGGT CGTCTGCAGT GGCCTCTCGC TTCATACCGC 60
TNCCATCGTC ATACTGTAGG TTTGCCACCA CYTCCTGGCA TCTTGGGGCG GCNTAATATT 120
CCAGGAAACT CTCAATCAAG TCACCGTCGA TGAAACCTGT GGGCTGGTTC TGTCTTCCGC 180
TCGGTGTGAA AGGATCTCCC AGAAGGAGTG CTCGATCTTC CCCACACTTT TGATGACTTT 240
ATTGAGTCGA TTCTGCATGT CCAGCAGGAG GTTGTACCAG CTCTCTGACA GTGAGGTCAC 300
CAGCCCTATC ATGCCGTTGA MCGTGCCGAA GARCACCGAG CCTTGTGTGG GGGKKGAAGT 360
CTCACCCAGA TTCTGCATTA CCAGAGAGCC GTGGCAAAAG ACATTGACAA ACTCGCCCAG 420
GTGGAAAAAG AMCAMCTCCT GGARGTGCTN GCCGCTCCTC GTCMGTTGGT GGCAGCGCTW 480
TCCTTTTGAC ACACAAACAA GTTAAAGGCA TTTTCAGCCC CCAGAAANTT GTCATCATCC 540
AAGATNTCGC ACAGCACTNA TCCAGTTGGG ATTAAAT 577
(2)关于SEQ ID NO:187的信息
(i)序列特征
(A)长度:534个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:187:
AACATCTTCC TGTATAATGC TGTGTAATAT CGATCCGATN TTGTCTGSTG AGAATYCATW 60
ACTKGGAAAA GMAACATTAA AGCCTGGACA CTGGTATTAA AATTCACAAT ATGCAACACT 120
TTAAACAGTG TGTCAATCTG CTCCCYYNAC TTTGTCATCA CCAGTCTGGG AAKAAGGGTA 180
TGCCCTATTC ACACCTGTTA AAAGGGCGCT AAGCATTTTT GATTCAACAT CTTTTTTTTT 240
GACACAAGTC CGAAAAAAGC AAAAGTAAAC AGTTATYAAT TTGTTAGCCA ATTCACTTTC 300
TTCATGGGAC AGAGCCATYT GATTTAAAAA GCAAATTGCA TAATATTGAG CTTYGGGAGC 360
TGATATTTGA GCGGAAGAGT AGCCTTTCTA CTTCACCAGA CACAACTCCC TTTCATATTG 420
GGATGTTNAC NAAAGTWATG TCTCTWACAG ATGGGATGCT TTTGTGGCAA TTCTGTTCTG 480
AGGATCTCCC AGTTTATTTA CCACTTGCAC AAGAAGGCGT TTTCTTCCTC AGGC 534
(2)关于SEQ ID NO:188的信息
(i)序列特征
(A)长度:761个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:188:
AGAAACCAGT ATCTCTNAAA ACAACCTCTC ATACCTTGTG GACCTAATTT TGTGTGCGTG 60
TGTGTGTGCG CGCATATTAT ATAGACAGGC ACATCTTTTT TACTTTTGTA AAAGCTTATG 120
CCTCTTTGGT ATCTATATCT GTGAAAGTTT TAATGATCTG CCATAATGTC TTGGGGACCT 180
TTGTCTTCTG TGTAAATGGT ACTAGAGAAA ACACCTATNT TATGAGTCAA TCTAGTTNGT 240
TTTATTCGAC ATGAAGGAAA TTTCCAGATN ACAACACTNA CAAACTCTCC CTKGACKARG 300
GGGGACAAAG AAAAGCAAAA CTGAMCATAA RAAACAATWA CCTGGTGAGA ARTTGCATAA 360
ACAGAAATWR GGTAGTATAT TGAARNACAG CATCATTAAA RMGTTWTKTT WTTCTCCCTT 420
GCAAAAAACA TGTACNGACT TCCCGTTGAG TAATGCCAAG TTGTTTTTTT TATNATAAAA 480
CTTGCCCTTC ATTACATGTT TNAAAGTGGT GTGGTGGGCC AAAATATTGA AATGATGGAA 540
CTGACTGATA AAGCTGTACA AATAAGCAGT GTGCCTAACA AGCAACACAG TAATGTTGAC 600
ATGCTTAATT CACAAATGCT AATTTCATTA TAAATGTTTG CTAAAATACA CTTTGAACTA 660
TTTTTCTGTN TTCCCAGAGC TGAGATNTTA GATTTTATGT AGTATNAAGT GAAAAANTAC 720
GAAAATAATA ACATTGAAGA AAAANANAAA AAANAAAAAA A 761
(2)关于SEQ ID NO:189的信息
(i)序列特征
(A)长度:482个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:189:
TTTTTTTTTT TTTGCCGATN CTACTATTTT ATTGCAGGAN GTGGGGGTGT ATGCACCGCA 60
CACCGGGGCT ATNAGAAGCA AGAAGGAAGG AGGGAGGGCA CAGCCCCTTG CTGAGCAACA 120
AAGCCGCCTG CTGCCTTCTC TGTCTGTCTC CTGGTGCAGG CACATGGGGA GACCTTCCCC 180
AAGGCAGGGG CCACCAGTCC AGGGGTGGGA ATACAGGGGG TGGGANGTGT GCATAAGAAG 240
TGATAGGCAC AGGCCACCCG GTACAGACCC CTCGGCTCCT GACAGGTNGA TTTCGACCAG 300
GTCATTGTGC CCTGCCCAGG CACAGCGTAN ATCTGGAAAA GACAGAATGC TTTCCTTTTC 360
AAATTTGGCT NGTCATNGAA NGGGCANTTT TCCAANTTNG GCTNGGTCTT GGTACNCTTG 420
GTTCGGCCCA GCTCCNCGTC CAAAAANTAT TCACCCNNCT CCNAATTGCT TGCNGGNCCC 480
CC 482
(2)关于SEQ ID NO:190的信息
(i)序列特征
(A)长度:471个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:190:
TTTTTTTTTT TTTTAAAACA GTTTTTCACA ACAAAATTTA TTAGAAGAAT AGTGGTTTTG 60
AAAACTCTCG CATCCAGTGA GAACTACCAT ACACCACATT ACAGCTNGGA ATGTNCTCCA 120
AATGTCTGGT CAAATGATAC AATGGAACCA TTCAATCTTA CACATGCACG AAAGAACAAG 180
CGCTTTTGAC ATACAATGCA CAAAAAAAAA AGGGGGGGGG GACCACATGG ATTAAAATTT 240
TAAGTACTCA TCACATACAT TAAGACACAG TTCTAGTCCA GTCNAAAATC AGAACTGCNT 300
TGAAAAATTT CATGTATGCA ATCCAACCAA AGAACTTNAT TGGTGATCAT GANTNCTCTA 360
CTACATCNAC CTTGATCATT GCCAGGAACN AAAAGTTNAA ANCACNCNGT ACAAAAANAA 420
TCTGTAATTN ANTTCAACCT CCGTACNGAA AAATNTTNNT TATACACTCC C 471
(2)关于SEQ ID NO:191的信息
(i)序列特征
(A)长度:402个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:191:
GAGGGATTGA AGGTCTGTTC TASTGTCGGM CTGTTCAGCC ACCAACTCTA ACAAGTTGCT 60
GTCTTCCACT CACTGTCTGT AAGCTTTTTA ACCCAGACWG TATCTTCATA AATAGAACAA 120
ATTCTTCACC AGTCACATGT TCTAGGACCT TTTTGGATTC AGTTAGTATA AGCTCTTCCA 180
CTTCCTTTGT TAAGACTTCA TCTGGTAAAG TCTTAAGTTT TGTAGAAAGG AATTYAATTG 240
CTCGTTCTCT AACAATGTCC TCTCCTTGAA GTATTTGGCT GAACAACCCA CCTAAAGTCC 300
CTTTGTGCAT CCATTTTAAA TATACTTAAT AGGGCATTGK TNCACTAGGT TAAATTCTGC 360
AAGAGTCATC TGTCTGCAAA AGTTGCGTTA GTATATCTGC CA 402
(2)关于SEQ ID NO:192的信息
(i)序列特征
(A)长度:601个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:192:
GAGCTCGGAT CCAATAATCT TTGTCTGAGG GCAGCACACA TATNCAGTGC CATGGNAACT 60
GGTCTACCCC ACATGGGAGC AGCATGCCGT AGNTATATAA GGTCATTCCC TGAGTCAGAC 120
ATGCYTYTTT GAYTACCGTG TGCCAAGTGC TGGTGATTCT YAACACACYT CCATCCCGYT 180
CTTTTGTGGA AAAACTGGCA CTTKTCTGGA ACTAGCARGA CATCACTTAC AAATTCACCC 240
ACGAGACACT TGAAAGGTGT AACAAAGCGA YTCTTGCATT GCTTTTTGTC CCTCCGGCAC 300
CAGTTGTCAA TACTAACCCG CTGGTTTGCC TCCATCACAT TTGTGATCTG TAGCTCTGGA 360
TACATCTCCT GACAGTACTG AAGAACTTCT TCTTTTGTTT CAAAAGCARC TCTTGGTGCC 420
TGTTGGATCA GGTTCCCATT TCCCAGTCYG AATGTTCACA TGGCATATTT WACTTCCCAC 480
AAAACATTGC GATTTGAGGC TCAGCAACAG CAAATCCTGT TCCGGCATTG GCTGCAAGAG 540
CCTCGATGTA GCCGGCCAGC GCCAAGGCAG GCGCCGTGAG CCCCACCAGC AGCAGAAGCA 600
G 601
(2)关于SEQ ID NO:193的信息
(i)序列特征
(A)长度:608个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:193:
ATACAGCCCA NATCCCACCA CGAAGATGCG CTTGTTGACT GAGAACCTGA TGCGGTCACT 60
GGTCCCGCTG TAGCCCCAGC GACTCTCCAC CTGCTGGAAG CGGTTGATGC TGCACTCYTT 120
CCCAACGCAG GCAGMAGCGG GSCCGGTCAA TGAACTCCAY TCGTGGCTTG GGGTKGACGG 180
TKAAGTGCAG GAAGAGGCTG ACCACCTCGC GGTCCACCAG GATGCCCGAC TGTGCGGGAC 240
CTGCAGCGAA ACTCCTCGAT GGTCATGAGC GGGAAGCGAA TGAGGCCCAG GGCCTTGCCC 300
AGAACCTTCC GCCTGTTCTC TGGCGTCACC TGCAGCTGCT GCCGCTGACA CTCGGCCTCG 360
GACCAGCGGA CAAACGGCRT TGAACAGCCG CACCTCACGG ATGCCCAGTG TGTCGCGCTC 420
CAGGAMMGSC ACCAGCGTGT CCAGGTCAAT GTCGGTGAAG CCCTCCGCGG GTRATGGCGT 480
CTGCAGTGTT TTTGTCGATG TTCTCCAGGC ACAGGCTGGC CAGCTGCGGT TCATCGAAGA 540
GTCGCGCCTG CGTGAGCAGC ATGAAGGCGT TGTCGGCTCG CAGTTCTTCT TCAGGAACTC 600
CACGCAAT 608
(2)关于SEQ ID NO:194的信息
(i)序列特征
(A)长度:392个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:194:
GAACGGCTGG ACCTTGCCTC GCATTGTGCT TGCTGGCAGG GAATACCTTG GCAAGCAGYT 60
CCAGTCCGAG CAGCCCCAGA CCGCTGCCGC CCGAAGCTAA GCCTGCCTCT GGCCTTCCCC 120
TCCGCCTCAA TGCAGAACCA GTAGTGGGAG CACTGTGTTT AGAGTTAAGA GTGAACACTG 180
TTTGATTTTA CTTGGGAATT TCCTCTGTTA TATAGCTTTT CCCAATGCTA ATTTCCAAAC 240
AACAACAACA AAATAACATG TTTGCCTGTT AAGTTGTATA AAAGTAGGTG ATTCTGTATT 300
TAAAGAAAAT ATTACTGTTA CATATACTGC TTGCAATTTC TGTATTTATT GKTNCTSTGG 360
AAATAAATAT AGTTATTAAA GGTTGTCANT CC 392
(2)关于SEQ ID NO:195的信息
(i)序列特征
(A)长度:502个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:195:
CCSTTKGAGG GGTKAGGKYC CAGTTYCCGA GTGGAAGAAA CAGGCCAGGA GAAGTGCGTG 60
CCGAGCTGAG GCAGATGTTC CCACAGTGAC CCCCAGAGCC STGGGSTATA GTYTCTGACC 120
CCTCNCAAGG AAAGACCACS TTCTGGGGAC ATGGGCTGGA GGGCAGGACC TAGAGGCACC 180
AAGGGAAGGC CCCATTCCGG GGSTGTTCCC CGAGGAGGAA GGGAAGGGGC TCTGTGTGCC 240
CCCCASGAGG AAGAGGCCCT GAGTCCTGGG ATCAGACACC CCTTCACGTG TATCCCCACA 300
CAAATGCAAG CTCACCAAGG TCCCCTCTCA GTCCCCTTCC STACACCCTG AMCGGCCACT 360
GSCSCACACC CACCCAGAGC ACGCCACCCG CCATGGGGAR TGTGCTCAAG GARTCGCNGG 420
GCARCGTGGA CATCTNGTCC CAGAAGGGGG CAGAATCTCC AATAGANGGA CTGARCMSTT 480
GCTNANAAAA AAAAANAAAA AA 502
(2)关于SEQ ID NO:196的信息
(i)序列特征
(A)长度:665个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:196:
GGTTACTTGG TTTCATTGCC ACCACTTAGT GGATGTCATT TAGAACCATT TTGTCTGCTC 60
CCTCTGGAAG CCTTGCGCAG AGCGGACTTT GTAATTGTTG GAGAATAACT GCTGAATTTT 120
WAGCTGTTTK GAGTTGATTS GCACCACTGC ACCCACAACT TCAATATGAA AACYAWTTGA 180
ACTWATTTAT TATCTTGTGA AAAGTATAAC AATGAAAATT TTGTTCATAC TGTATTKATC 240
AAGTATGATG AAAAGCAAWA GATATATATT CTTTTATTAT GTTAAATTAT GATTGCCATT 300
ATTAATCGGC AAAATGTGGA GTGTATGTTC TTTTCACAGT AATATATGCC TTTTGTAACT 360
TCACTTGGTT ATTTTATTGT AAATGARTTA CAAAATTCTT AATTTAAGAR AATGGTATGT 420
WATATTTATT TCATTAATTT CTTTCCTKGT TTACGTWAAT TTTGAAAAGA WTGCATGATT 480
TCTTGACAGA AATCGATCTT GATGCTGTGG AAGTAGTTTG ACCCACATCC CTATGAGTTT 540
TTCTTAGAAT GTATAAAGGT TGTAGCCCAT CNAACTTCAA AGAAAAAAAT GACCACATAC 600
TTTGCAATCA GGCTGAAATG TGGCATGCTN TTCTAATTCC AACTTTATAA ACTAGCAAAN 660
AAGTG 665
(2)关于SEQ ID NO:197的信息
(i)序列特征
(A)长度:492个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:197:
TTTTNTTTTT TTTTTTTTGC AGGAAGGATT CCATTTATTG TGGATGCATT TTCACAATAT 60
ATGTTTATTG GAGCGATCCA TTATCAGTGA AAAGTATCAA GTGTTTATAA NATTTTTAGG 120
AAGGCAGATT CACAGAACAT GCTNGTCNGC TTGCAGTTTT ACCTCGTANA GATNACAGAG 180
AATTATAGTC NAACCAGTAA ACNAGGAATT TACTTTTCAA AAGATTAAAT CCAAACTGAA 240
CAAAATTCTA CCCTGAAACT TACTCCATCC AAATATTGGA ATAANAGTCA GCAGTGATAC 300
ATTCTCTTCT GAACTTTAGA TTTTCTAGAA AAATATGTAA TAGTGATCAG GAAGAGCTCT 360
TGTTCAAAAG TACAACNAAG CAATGTTCCC TTACCATAGG CCTTAATTCA AACTTTGATC 420
CATTTCACTC CCATCACGGG AGTCAATGCT ACCTGGGACA CTTGTATTTT GTTCATNCTG 480
ANCNTGGCTT AA 492
(2)关于SEQ ID NO:198的信息
(i)序列特征
(A)长度:478个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:198:
TTTNTTTTGN ATTTCANTCT GTANNAANTA TTTTCATTAT GTTTATTANA AAAATATNAA 60
TGTNTCCACN ACAAATCATN TTACNTNAGT AAGAGGCCAN CTACATTGTA CAACATACAC 120
TGAGTATATT TTGAAAAGGA CAAGTTTAAA GTANACNCAT ATTGCCGANC ATANCACATT 180
TATACATGGC TTGATTGATA TTTAGCACAG CANAAACTGA GTGAGTTACC AGAAANAAAT 240
NATATATGTC AATCNGATTT AAGATACAAA ACAGATCCTA TGGTACATAN CATCNTGTAG 300
GAGTTGTGGC TTTATGTTTA CTGAAAGTCA ATGCAGTTCC TGTACAAAGA GATGGCCGTA 360
AGCATTCTAG TACCTCTACT CCATGGTTAA GAATCGTACA CTTATGTTTA CATATGTNCA 420
GGGTAAGAAT TGTGTTAAGT NAANTTATGG AGAGGTCCAN GAGAAAAATT TGATNCAA 478
(2)关于SEQ ID NO:199的信息
(i)序列特征
(A)长度:482个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:199:
AGTGACTTGT CCTCCAACAA AACCCCTTGA TCAAGTTTGT GGCACTGACA ATCAGACCTA 60
TGCTAGTTCC TGTCATCTAT TCGCTACTAA ATGCAGACTG GAGGGGACCA AAAAGGGGCA 120
TCAACTCCAG CTGGATTATT TTGGAGCCTG CAAATCTATT CCTACTTGTA CGGACTTTGA 180
AGTGATTCAG TTTCCTCTAC GGATGAGAGA CTGGCTCAAG AATATCCTCA TGCAGCTTTA 240
TGAAGCCNAC TCTGAACACG CTGGTTATCT NAGATGAGAA NCAGAGAAAT AAAGTCNAGA 300
AAATTTACCT GGANGAAAAG AGGCTTTNGG CTGGGGACCA TCCCATTGAA CCTTCTCTTA 360
ANGGACTTTA AGAANAAACT ACCACATGTN TGTNGTATCC TGGTGCCNGG CCGTTTANTG 420
AACNTNGACN NCACCCTTNT GGAATANANT CTTGACNGCN TCCTGAACTT GCTCCTCTGC 480
GA 482
(2)关于SEQ ID NO:200的信息
(i)序列特征
(A)长度:270个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:200:
CGGCCGCAAG TGCAACTCCA GCTGGGGCCG TGCGGACGAA GATTCTGCCA GCAGTTGGTC 60
CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC 120
AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA 180
CAGCCGGAAC AGAGCCCGGT GAANGCGGGA GGCCTCGGGG AGCCCCTCGG GAAGGGCGGC 240
CCGAGAGATA CGCAGGTGCA GGTGGCCGCC 270
(2)关于SEQ ID NO:201的信息
(i)序列特征
(A)长度:419个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:201:
TTTTTTTTTT TTTTGGAATC TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA 60
GCTAGCAAGG TAACAGGGTA GGGCATGGTT ACATGTTCAG GTCAACTTCC TTTGTCGTGG 120
TTGATTGGTT TGTCTTTATG GGGGCGGGGT GGGGTAGGGG AAANCGAAGC ANAANTAACA 180
TGGAGTGGGT GCACCCTCCC TGTAGAACCT GGTTACNAAA GCTTGGGGCA GTTCACCTGG 240
TCTGTGACCG TCATTTTCTT GACATCAATG TTATTAGAAG TCAGGATATC TTTTAGAGAG 300
TCCACTGTNT CTGGAGGGAG ATTAGGGTTT CTTGCCAANA TCCAANCAAA ATCCACNTGA 360
AAAAGTTGGA TGATNCANGT ACNGAATACC GANGGCATAN TTCTCATANT CGGTGGCCA 419
(2)关于SEQ ID NO:202的信息
(i)序列特征
(A)长度:509个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:202:
TTTNTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 60
TGGCACTTAA TCCATTTTTA TTTCAAAATG TCTACAAANT TTNAATNCNC CATTATACNG 120
GTNATTTTNC AAAATCTAAA NNTTATTCAA ATNTNAGCCA AANTCCTTAC NCAAATNNAA 180
TACNCNCAAA AATCAAAAAT ATACNTNTCT TTCAGCAAAC TTNGTTACAT AAATTAAAAA 240
AATATATACG GCTGGTGTTT TCAAAGTACA ATTATCTTAA CACTGCAA C ATNTTTNNAA 300
GGAACTAAAA TAAAAAAAAA CACTNCCGCA AAGGTTAAAG GGAACAACAA ATTCNTTTTA 360
CAACANCNNC NATTATAAAA ATCATATCTC AAATCTTAGG GGAATATATA CTTCACACNG 420
GGATCTTAAC TTTTACTNCA CTTTGTTTAT TTTTTTANAA CCATTGTNTT GGGCCCAACA 480
CAATGGNAAT NCCNCCNCNC TGGACTAGT 509
(2)关于SEQ ID NO:203的信息
(i)序列特征
(A)长度:583个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:203:
TTTTTTTTTT TTTTTTTTGA CCCCCCTCTT ATAAAAAACA AGTTACCATT TTATTTTACT 60
TACACATATT TATTTTATAA TTGGTATTAG ATATTCAAAA GGCAGCTTTT AAAATCAAAC 120
TAAATGGAAA CTGCCTTAGA TACATAATTC TTAGGAATTA GCTTAAAATC TGCCTAAAGT 180
GAAAATCTTC TCTAGCTCTT TTGACTGTAA ATTTTTGACT CTTGTAAAAC ATCCAAATTC 240
ATTTTTCTTG TCTTTAAAAT TATCTAATCT TTCCATTTTT TCCCTATTCC AAGTCAATTT 300
GCTTCTCTAG CCTCATTTCC TAGCTCTTAT CTACTATTAG TAAGTGGCTT TTTTCCTAAA 360
AGGGAAAACA GGAAGAGANA ATGGCACACA AAACAAACAT TTTATATTCA TATTTCTACC 420
TACGTTAATA AAATAGCATT TTGTGAAGCC AGCTCAAAAG AAGGCTTAGA TCCTTTTATG 480
TCCATTTTAG TCACTAAACG ATATCNAAAG TGCCAGAATG CAAAAGGTTT GTGAACATTT 540
ATTCAAAAGC TAATATAAGA TATTTCACAT ACTCATCTTT CTG 583
(2)关于SEQ ID NO:204的信息
(i)序列特征
(A)长度:589个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:204:
TTTTTTTTNT TTTTTTTTTT TTTTTTNCTC TTCTTTTTTT TTGANAATGA GGATCGAGTT 60
TTTCACTCTC TAGATAGGGC ATGAAGAAAA CTCATCTTTC CAGCTTTAAA ATAACAATCA 120
AATCTCTTAT GCTATATCAT ATTTTAAGTT AAACTAATGA GTCACTGGCT TATCTTCTCC 180
TGAAGGAAAT CTGTTCATTC TTCTCATTCA TATAGTTATA TCAAGTACTA CCTTGCATAT 240
TGAGAGGTTT TTCTTCTCTA TTTACACATA TATTTCCATG TGAATTTGTA TCAAACCTTT 300
ATTTTCATGC AAACTAGAAA ATAATGTNTT CTTTTGCATA AGAGAAGAGA ACAATATNAG 360
CATTACAAAA CTGCTCAAAT TGTTTGTTAA GNTTATCCAT TATAATTAGT TNGGCAGGAG 420
CTAATACAAA TCACATTTAC NGACNAGCAA TAATAAAACT GAAGTACCAG TTAAATATCC 480
AAAATAATTA AAGGAACATT TTTAGCCTGG GTATAATTAG CTAATTCACT TTACAAGCAT 540
TTATTNAGAA TGAATTCACA TGTTATTATT CCNTAGCCCA ACACAATGG 589
(2)关于SEQ ID NO:205的信息
(i)序列特征
(A)长度:545个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:205:
TTTTTNTTTT TTTTTTCAGT AATAATCAGA ACAATATTTA TTTTTATATT TAAAATTCAT 60
AGAAAAGTGC CTTACATTTA ATAAAAGTTT GTTTCTCAAA GTGATCAGAG GAATTAGATA 120
TNGTCTTGAA CACCAATATT AATTTGAGGA AAATACACCA AAATACATTA AGTAAATTAT 180
TTAAGATCAT AGAGCTTGTA AGTGAAAAGA TAAAATTTGA CCTCAGAAAC TCTGAGCATT 240
AAAAATCCAC TATTAGCAAA TAAATTACTA TGGACTTCTT GCTTTAATTT TGTGATGAAT 300
ATGGGGTGTC ACTGGTAAAC CAACACATTC TGAAGGATAC ATTACTTAGT GATAGATTCT 360
TATGTACTTT GCTANATNAC GTGGATATGA GTTGACAAGT TTCTCTTTCT TCAATCTTTT 420
AAGGGGCNGA NGAAATGAGG AAGAAAAGAA AAGGATTACG CATACTGTTC TTTCTATNGG 480
AAGGATTAGA TATGTTTCCT TTGCCAATAT TAAAAAAATA ATAATGTTTA CTACTAGTGA 540
AACCC 545
(2)关于SEQ ID NO:206的信息
(i)序列特征
(A)长度:487个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:206:
TTTTTTTTTT TTTTTTAGTC AAGTTTCTNA TTTTTATTAT AATTAAAGTC TTGGTCATTT 60
CATTTATTAG CTCTGCAACT TACATATTTA AATTAAAGAA ACGTTNTTAG ACAACTGTNA 120
CAATTTATAA ATGTAAGGTG CCATTATTGA GTANATATAT TCCTCCAAGA GTGGATGTGT 180
CCCTTCTCCC ACCAACTAAT GAANCAGCAA CATTAGTTTA ATTTTATTAG TAGATNATAC 240
ACTGCTGCAA ACGCTAATTC TCTTCTCCAT CCCCATGTNG ATATTGTGTA TATGTGTGAG 300
TTGGTNAGAA TGCATCANCA ATCTNACAAT CAACAGCAAG ATGAAGCTAG GCNTGGGCTT 360
TCGGTGAAAA TAGACTGTGT CTGTCTGAAT CAAATGATCT GACCTATCCT CGGTGGCAAG 420
AACTCTTCGA ACCGCTTCCT CAAAGGCNGC TGCCACATTT GTGGCNTCTN TTGCACTTGT 480
TTCAAAA 487
(2)关于SEQ ID NO:207的信息
(i)序列特征
(A)长度:332个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:207:
TGAATTGGCT AAAAGACTGC ATTTTTANAA CTAGCAACTC TTATTTCTTT CCTTTAAAAA 60
TACATAGCAT TAAATCCCAA ATCCTATTTA AAGACCTGAC AGCTTGAGAA GGTCACTACT 120
GCATTTATAG GACCTTCTGG TGGTTCTGCT GTTACNTTTG AANTCTGACA ATCCTTGANA 180
ATCTTTGCAT GCAGAGGAGG TAAAAGGTAT TGGATTTTCA CAGAGGAANA ACACAGCGCA 240
GAAATGAAGG GGCCAGGCTT ACTGAGCTTG TCCACTGGAG GGCTCATGGG TGGGACATGG 300
AAAAGAAGGC AGCCTAGGCC CTGGGGAGCC CA 332
(2)关于SEQ ID NO:208的信息
(i)序列特征
(A)长度:524个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:208:
AGGGCGTGGT GCGGAGGGCG TTACTGTTTT GTCTCAGTAA CAATAAATAC AAAAAGACTG 60
GTTGTGTTCC GGCCCCATCC AACCACGAAG TTGATTTCTC TTGTGTGCAG AGTGACTGAT 120
TTTAAAGGAC ATGGAGCTTG TCACAATGTC ACAATGTCAC AGTGTGAAGG GCACACTCAC 180
TCCCGCGTGA TTCACATTTA GCAACCAACA ATAGCTCATG AGTCCATACT TGTAAATACT 240
TTTGGCAGAA TACTTNTTGA AACTTGCAGA TGATAACTAA GATCCAAGAT ATTTCCCAAA 300
GTAAATAGAA GTGGGTCATA ATATTAATTA CCTGTTCACA TCAGCTTCCA TTTACAAGTC 360
ATGAGCCCAG ACACTGACAT CAAACTAAGC CCACTTAGAC TCCTCACCAC CAGTCTGTCC 420
TGTCATCAGA CAGGAGGCTG TCACCTTGAC CAAATTCTCA CCAGTCAATC ATCTATCCAA 480
AAACCATTAC CTGATCCACT TCCGGTAATG CACCACCTTG GTGA 524
(2)关于SEQ ID NO:209的信息
(i)序列特征
(A)长度:159个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:209:
GGGTGAGGAA ATCCAGAGTT GCCATGGAGA AAATTCCAGT GTCAGCATTC TTGCTCCTTG 60
TGGCCCTCTC CTACACTCTG GCCAGAGATA CCACAGTCAA ACCTGGAGCC AAAAAGGACA 120
CAAAGGACTC TCGACCCAAA CTGCCCCAGA CCCTCTCCA 159
(2)关于SEQ ID NO:210的信息
(i)序列特征
(A)长度:256个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:210:
ACTCCCTGGC AGACAAAGGC AGAGGAGAGA GCTCTGTTAG TTCTGTGTTG TTGAACTGCC 60
ACTGAATTTC TTTCCACTTG GACTATTACA TGCCANTTGA GGGACTAATG GAAAAACGTA 120
TGGGGAGATT TTANCCAATT TANGTNTGTA AATGGGGAGA CTGGGGCAGG CGGGAGAGAT 180
TTGCAGGGTG NAAATGGGAN GGCTGGTTTG TTANATGAAC AGGGACATAG GAGGTAGGCA 240
CCAGGATGCT AAATCA 256
(2)关于SEQ ID NO:211的信息
(i)序列特征
(A)长度:264个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:211:
ACATTGTTTT TTTGAGATAA AGCATTGAGA GAGCTCTCCT TAACGTGACA CAATGGAAGG 60
ACTGGAACAC ATACCCACAT CTTTGTTCTG AGGGATAATT TTCTGATAAA GTCTTGCTGT 120
ATATTCAAGC ACATATGTTA TATATTATTC AGTTCCATGT TTATAGCCTA GTTAAGGAGA 180
GGGGAGATAC ATTCNGAAAG AGGACTGAAA GAAATACTCA AGTNGGAAAA CAGAAAAAGA 240
AAAAAAGGAG CAAATGAGAA GCCT 264
(2)关于SEQ ID NO:212的信息
(i)序列特征
(A)长度:328个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:212:
ACCCAAAAAT CCAATGCTGA ATATTTGGCT TCATTATTCC CANATTCTTT GATTGTCAAA 60
GGATTTAATG TTGTCTCAGC TTGGGCACTT CAGTTAGGAC CTAAGGATGC CAGCCGGCAG 120
GTTTATATAT GCAGCAACAA TATTCAAGCG CGACAACAGG TTATTGAACT TGCCCGCCAG 180
TTNAATTTCA TTCCCATTGA CTTGGGATCC TTATCATCAG CCAGAGAGAT TGAAAATTTA 240
CCCCTACNAC TCTTTACTCT CTGGANAGGG CCAGTGGTGG TAGCTATAAG CTTGGCCACA 300
TTTTTTTTTC CTTTATTCCT TTGTCAGA 328
(2)关于SEQ ID NO:213的信息
(i)序列特征
(A)长度:250个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:213:
ACTTATGAGC AGAGCGACAT ATCCNAGTGT AGACTGAATA AAACTGAATT CTCTCCAGTT 60
TAAAGCATTG CTCACTGAAG GGATAGAAGT GACTGCCAGG AGGGAAAGTA AGCCAAGGCT 120
CATTATGCCA AAGGANATAT ACATTTCAAT TCTCCAAACT TCTTCCTCAT TCCAAGAGTT 180
TTCAATATTT GCATGAACCT GCTGATAANC CATGTTAANA AACAAATATC TCTCTNACCT 240
TCTCATCGGT 250
(2)关于SEQ ID NO:214的信息
(i)序列特征
(A)长度:444个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:214:
ACCCAGAATC CAATGCTGAA TATTTGGCTT CATTATTCCC AGATTCTTTG ATTGTCAAAG 60
GATTTAATGT TGTCTCAGCT TGGGCACTTC AGTTAGGACC TAAGGATGCC AGCCGGCAGG 120
TTTATATATG CAGCAACAAT ATTCAAGCGC GACAACAGGT TATTGAACTT GCCCGCCAGT 180
TGAATTTCAT TCCCATTGAC TTGGGATCCT TATCATCAGC CANAGAGATT GAAAATTTAC 240
CCCTACGACT CTTTACTCTC TGGAGAGGGC CAGTGGTGGT AGCTATAAGC TTGGCCACAT 300
TTTTTTTTCC TTTATTCCTT TGTCAGAGAT GCGATTCATC CATATGCTAN AAACCAACAG 360
AGTGACTTTT ACAAAATTCC TATAGANATT GTGAATAAAA CCTTACCTAT AGTTGCCATT 420
ACTTTGCTCT CCCTAATATA CCTC 444
(2)关于SEQ ID NO:215的信息
(i)序列特征
(A)长度:366个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:215:
ACTTATGAGC AGAGCGACAT ATCCAAGTGT ANACTGAATA AAACTGAATT CTCTCCAGTT 60
TAAAGCATTG CTCACTGAAG GGATAGAAGT GACTGCCAGG AGGGAAAGTA AGCCAAGGCT 120
CATTATGCCA AAGGANATAT ACATTTCAAT TCTCCAAACT TCTTCCTCAT TCCAAGAGTT 180
TTCAATATTT GCATGAACCT GCTGATAAGC CATGTTGAGA AACAAATATC TCTCTGACCT 240
TCTCATCGGT AAGCAGAGGC TGTAGGCAAC ATGGACCATA GCGAANAAAA AACTTAGTAA 300
TCCAAGCTGT TTTCTACACT GTAACCAGGT TTCCAACCAA GGTGGAAATC TCCTATACTT 360
GGTGCC 366
(2)关于SEQ ID NO:216的信息
(i)序列特征
(A)长度:260个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:216:
CTGTATAAAC AGAACTCCAC TGCANGAGGG AGGGCCGGGC CAGGAGAATC TCCGCTTGTC 60
CAAGACAGGG GCCTAAGGAG GGTCTCCACA CTGCTNNTAA GGGCTNTTNC ATTTTTTTAT 120
TAATAAAAAG TNNAAAAGGC CTCTTCTCAA CTTTTTTCCC TTNGGCTGGA AAATTTAAAA 180
ATCAAAAATT TCCTNAAGTT NTCAAGCTAT CATATATACT NTATCCTGAA AAAGCAACAT 240
AATTCTTCCT TCCCTCCTTT 260
(2)关于SEQ ID NO:217的信息
(i)序列特征
(A)长度:262个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:217:
ACCTACGTGG GTAAGTTTAN AAATGTTATA ATTTCAGGAA NAGGAACGCA TATAATTGTA 60
TCTTGCCTAT AATTTTCTAT TTTAATAAGG AAATAGCAAA TTGGGGTGGG GGGAATGTAG 120
GGCATTCTAC AGTTTGAGCA AAATGCAATT AAATGTGGAA GGACAGCACT GAAAAATTTT 180
ATGAATAATC TGTATGATTA TATGTCTCTA GAGTAGATTT ATAATTAGCC ACTTACCCTA 240
ATATCCTTCA TGCTTGTAAA GT 262
(2)关于SEQ ID NO:218的信息
(i)序列特征
(A)长度:205个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:218:
ACCAAGGTGG TGCATTACCG GAANTGGATC AANGACACCA TCGTGGCCAA CCCCTGAGCA 60
CCCCTATCAA CTCCCTTTTG TAGTAAACTT GGAACCTTGG AAATGACCAG GCCAAGACTC 120
AGGCCTCCCC AGTTCTACTG ACCTTTGTCC TTANGTNTNA NGTCCAGGGT TGCTAGGAAA 180
ANAAATCAGC AGACACAGGT GTAAA 205
(2)关于SEQ ID NO:219的信息
(i)序列特征
(A)长度:114个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:219:
TACTGTTTTG TCTCAGTAAC AATAAATACA AAAAGACTGG TTGTGTTCCG GCCCCATCCA 60
ACCACGAAGT TGATTTCTCT TGTGTGCAGA GTGACTGATT TTAAAGGACA TGGA 114
(2)关于SEQ ID NO:220的信息
(i)序列特征
(A)长度:93个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:220:
ACTAGCCAGC ACAAAAGGCA GGGTAGCCTG AATTGCTTTC TGCTCTTTAC ATTTCTTTTA 60
AAATAAGCAT TTAGTGCTCA GTCCCTACTG AGT 93
(2)关于SEQ ID NO:221的信息
(i)序列特征
(A)长度:167个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:221:
ACTANGTGCA GGTGCGCACA AATATTTGTC GATATTCCCT TCATCTTGGA TTCCATGAGG 60
TCTTTTGCCC AGCCTGTGGC TCTACTGTAG TAAGTTTCTG CTGATGAGGA GCCAGNATGC 120
CCCCCACTAC CTTCCCTGAC GCTCCCCANA AATCACCCAA CCTCTGT 167
(2)关于SEQ ID NO:222的信息
(i)序列特征
(A)长度:351个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:222:
AGGGCGTGGT GCGGAGGGCG GTACTGACCT CATTAGTAGG AGGATGCATT CTGGCACCCC 60
GTTCTTCACC TGTCCCCCAA TCCTTAAAAG GCCATACTGC ATAAAGTCAA CAACAGATAA 120
ATGTTTGCTG AATTAAAGGA TGGATGAAAA AAATTAATAA TGAATTTTTG CATAATCCAA 180
TTTTCTCTTT TATATTTCTA GAAGAAGTTT CTTTGAGCCT ATTAGATCCC GGGAATCTTT 240
TAGGTGAGCA TGATTAGAGA GCTTGTAGGT TGCTTTTACA TATATCTGGC ATATTTGAGT 300
CTCGTATCAA AACAATAGAT TGGTAAAGGT GGTATTATTG TATTGATAAG T 351
(2)关于SEQ ID NO:223的信息
(i)序列特征
(A)长度:383个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:223:
AAAACAAACA AACAAAAAAA ACAATTCTTC ATTCAGAAAA ATTATCTTAG GGACTGATAT 60
TGGTAATTAT GGTCAATTTA ATWRTRTTKT GGGGCATTTC CTTACATTGT CTTGACAAGA 120
TTAAAATGTC TGTGCCAAAA TTTTGTATTT TATTTGGAGA CTTCTTATCA AAAGTAATGC 180
TGCCAAAGGA AGTCTAAGGA ATTAGTAGTG TTCCCMTCAC TTGTTTGGAG TGTGCTATTC 240
TAAAAGATTT TGATTTCCTG GAATGACAAT TATATTTTAA CTTTGGTGGG GGAAANAGTT 300
ATAGGACCAC AGTCTTCACT TCTGATACTT GTAAATTAAT CTTTTATTGC ACTTGTTTTG 360
ACCATTAAGC TATATGTTTA AAA 383
(2)关于SEQ ID NO:224的信息
(i)序列特征
(A)长度:320个碱基对
(B)类型:核酸
(C)链型:单链
(D)拓扑结构:线性
(ii)分子类型:cDNA
(xi)序列描述:SEQ ID NO:224:
CCCCTGAAGG CTTCTTGTTA GAAAATAGTA CAGTTACAAC CAATAGGAAC AACAAAAAGA 60
AAAAGTTTGT GACATTGTAG TAGGGAGTGT GTACCCCTTA CTCCCCATCA AAAAAAAAAT 120
GGATACATGG TTAAAGGATA RAAGGGCAAT ATTTTATCAT ATGTTCTAAA AGAGAAGGAA 180
GAGAAAATAC TACTTTCTCR AAATGGAAGC CCTTAAAGGT GCTTTGATAC TGAAGGACAC 240
AAATGTGGCC GTCCATCCTC CTTTARAGTT GCATGACTTG GACACGGTAA CTGTTGCAGT 300
TTTARACTCM GCATTGTGAC 320
Claims (17)
1.含有前列腺蛋白的多肽,其中所述前列腺蛋白含有由具SEQ IDNO:110所示核苷酸序列的DNA分子编码的氨基酸序列。
2.权利要求1的多肽,其中所述前列腺蛋白质包含SEQ ID NO:113所示的氨基酸序列。
3.含有编码权利要求1所述多肽的核苷酸序列的DNA分子。
4.含有示于SEQ ID NO:110中的序列的DNA分子。
5.含有权利要求3或4的DNA分子的表达载体。
6.转化有权利要求5的表达载体的宿主细胞。
7.权利要求6的宿主细胞,其中该宿主细胞选自由大肠杆菌、酵母和哺乳动物细胞系组成的组。
8.含有权利要求1的多肽和生理学上可接受的载体的药物组合物。
9.含有权利要求1的多肽和非特异性免疫反应增强剂的疫苗。
10.权利要求9的疫苗,其中所述非特异性免疫反应增强剂是佐剂。
11.含有权利要求3或4的DNA分子和非特异性免疫反应增强剂的疫苗。
12.权利要求11的疫苗,其中非特异免疫反应增强剂是佐剂。
13.含有两种或多种权利要求1所述多肽的融合蛋白。
14.含有权利要求1的多肽和已知前列腺抗原的融合蛋白。
15.含有权利要求13或14的融合蛋白以及生理学上可接受的载体的药物组合物。
16.含有权利要求13或14的融合蛋白以及非特异性免疫反应增强剂的疫苗。
17.权利要求16的疫苗,其中的非特异性免疫反应增强剂是佐剂。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80609997A | 1997-02-25 | 1997-02-25 | |
US08/806,099 | 1997-02-25 | ||
US90480497A | 1997-08-01 | 1997-08-01 | |
US08/904,804 | 1997-08-01 | ||
US09/020,956 US6261562B1 (en) | 1997-02-25 | 1998-02-09 | Compounds for immunotherapy of prostate cancer and methods for their use |
US09/020,956 | 1998-02-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510009116 Division CN1690077A (zh) | 1997-02-25 | 1998-02-25 | 用于前列腺癌免疫疗法的化合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1252837A CN1252837A (zh) | 2000-05-10 |
CN1195851C true CN1195851C (zh) | 2005-04-06 |
Family
ID=27361556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988041391A Expired - Fee Related CN1195851C (zh) | 1997-02-25 | 1998-02-25 | 用于前列腺癌免疫疗法的化合物及其用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6262245B1 (zh) |
EP (1) | EP1005546A2 (zh) |
CN (1) | CN1195851C (zh) |
AU (1) | AU731840B2 (zh) |
BR (1) | BR9808881A (zh) |
CA (1) | CA2281952C (zh) |
CZ (1) | CZ298465B6 (zh) |
HU (1) | HUP0002095A3 (zh) |
IL (1) | IL131560A0 (zh) |
NO (1) | NO994069L (zh) |
NZ (1) | NZ337446A (zh) |
PL (1) | PL196260B1 (zh) |
TR (1) | TR199902053T2 (zh) |
WO (1) | WO1998037093A2 (zh) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620922B1 (en) | 1997-02-25 | 2003-09-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6759515B1 (en) | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6465611B1 (en) * | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
PL196260B1 (pl) | 1997-02-25 | 2007-12-31 | Corixa Corp | Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty |
US6818751B1 (en) | 1997-08-01 | 2004-11-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7270980B2 (en) * | 1997-02-25 | 2007-09-18 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
US6800746B2 (en) | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6329505B1 (en) | 1997-02-25 | 2001-12-11 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
US6894146B1 (en) | 1997-02-25 | 2005-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6630305B1 (en) | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
US6657056B2 (en) * | 1997-02-25 | 2003-12-02 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
US7202342B1 (en) * | 1999-11-12 | 2007-04-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20060024301A1 (en) * | 1997-02-25 | 2006-02-02 | Corixa Corporation | Prostate-specific polypeptides and fusion polypeptides thereof |
US20030185830A1 (en) * | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6261562B1 (en) | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
US6613872B1 (en) | 1997-02-25 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6395278B1 (en) | 1997-02-25 | 2002-05-28 | Corixa Corporation | Prostate specific fusion protein compositions |
ES2402947T3 (es) | 1997-04-10 | 2013-05-10 | Stichting Katholieke Universiteit University Medical Centre Nijmegen | PCA3, genes PCA3 y métodos de uso |
US6365369B1 (en) | 1998-04-01 | 2002-04-02 | Human Genome Sciences, Inc. | Prostate specific secreted protein |
US6048970A (en) * | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
DK1086223T3 (da) | 1998-06-01 | 2009-11-30 | Agensys Inc | Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf |
US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
DE69943020D1 (de) * | 1998-06-01 | 2011-01-20 | Agensys Inc | Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs |
US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
EP1870466A3 (en) * | 1998-07-14 | 2008-03-19 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
EP1117794A2 (en) * | 1998-10-02 | 2001-07-25 | Urogenesys, Inc. | Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 |
US6902892B1 (en) | 1998-10-19 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
ATE407949T1 (de) * | 1998-12-30 | 2008-09-15 | Beth Israel Hospital | Charakterisierung der proteinfamilie von soc/crac kalziumkanälen |
US7063959B1 (en) | 1998-12-30 | 2006-06-20 | Beth Israel Deaconess Medical Center, Inc. | Compositions of the SOC/CRAC calcium channel protein family |
WO2000050592A1 (en) * | 1999-02-24 | 2000-08-31 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
EP1724351A3 (en) * | 1999-03-11 | 2007-11-14 | Mount Sinai Hospital | Human Kallikrein-like genes |
US7022497B1 (en) * | 1999-03-11 | 2006-04-04 | Mt. Sinai Hospital | Human kallikrein-like genes |
CO5450246A1 (es) * | 1999-07-13 | 2004-10-29 | Smithkline Beecham Corp | Vacuna |
WO2001004143A2 (en) * | 1999-07-13 | 2001-01-18 | Smithkline Beecham Biologicals S.A. | Prostase vaccine |
ATE321857T1 (de) * | 1999-09-29 | 2006-04-15 | Diagnocure Inc | Pca3 mrna in gutartigen und bösartigen prostatageweben |
AU7994200A (en) * | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
AU7753700A (en) * | 1999-10-07 | 2001-05-10 | Schering Aktiengesellschaft | Dna encoding prost 07 polypeptide |
WO2001034802A2 (en) * | 1999-11-12 | 2001-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
BR0107643A (pt) * | 2000-01-14 | 2003-06-10 | Corixa Corp | Composições e processos para a terapia e diagnóstico de c ncer de próstata |
US7510855B2 (en) * | 2000-01-26 | 2009-03-31 | Agensys, Inc. | 84P2A9: a prostate and testis specific protein highly expressed in prostate cancer |
AU2001238596A1 (en) * | 2000-02-22 | 2001-09-03 | Millennium Pharmaceuticals, Inc. | 18607, a novel human calcium channel |
US20020009455A1 (en) * | 2000-04-27 | 2002-01-24 | Ted Lau | DNA encoding a novel PROST 03 polypeptide |
EP1292675A2 (en) * | 2000-05-26 | 2003-03-19 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
AU2001271284A1 (en) * | 2000-06-07 | 2001-12-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
CA2412084A1 (en) * | 2000-06-26 | 2002-01-03 | Glaxosmithkline Biologicals S.A. | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
CA2417671A1 (en) | 2000-07-28 | 2002-02-07 | Ulrich Wissenbach | Trp8, trp9 and trp10, novel markers for cancer |
US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
BR0115715A (pt) | 2000-11-28 | 2004-02-03 | Wyeth Corp | Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata |
EP2295606A1 (en) | 2000-11-28 | 2011-03-16 | Wyeth LLC | Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
US6897024B2 (en) * | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
US20030113762A1 (en) * | 2001-08-17 | 2003-06-19 | Warrington Janet A. | Gleason grade 4/5 prostate cancer genes |
US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
JP2005505271A (ja) | 2001-09-06 | 2005-02-24 | アジェンシス, インコーポレイテッド | 癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質 |
US20040029151A1 (en) * | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
US20050272052A1 (en) * | 2002-04-09 | 2005-12-08 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
AU2003259913A1 (en) * | 2002-08-19 | 2004-03-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2004209578A1 (en) | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
BRPI0418766B8 (pt) | 2004-04-22 | 2021-05-25 | Agensys Inc | anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico |
US7292452B2 (en) * | 2004-06-10 | 2007-11-06 | Intel Corporation | Reference layer openings |
CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
US9957569B2 (en) * | 2005-09-12 | 2018-05-01 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
AU2006291054B2 (en) | 2005-09-12 | 2011-10-13 | The Brigham And Women's Hospital, Inc. | Recurrent gene fusions in prostate cancer |
ES2636089T3 (es) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Anticuerpos e inmunoconjugados y usos para los mismos |
US20100129804A1 (en) * | 2006-11-08 | 2010-05-27 | Chinnaiyan Arul M | Spink1 as a prostate cancer marker and uses thereof |
CA2692441C (en) | 2007-07-06 | 2020-01-21 | The Regents Of The University Of Michigan | Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer |
ES2376509T3 (es) | 2007-07-06 | 2012-03-14 | The Regents Of The University Of Michigan | Reordenamientos de genes mipol 1-etv1. |
US20090047269A1 (en) | 2007-08-16 | 2009-02-19 | The Regents Of The University Of Michigan | Metabolomic cancer targets |
EP2291553A4 (en) | 2008-05-28 | 2011-12-14 | Genomedx Biosciences Inc | SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER |
JP2012514475A (ja) | 2009-01-09 | 2012-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌における再現性の遺伝子融合物 |
US20100311815A1 (en) * | 2009-02-23 | 2010-12-09 | The Regents Of The University Of Michigan | Mir-101 cancer markers |
US9938582B2 (en) * | 2009-09-17 | 2018-04-10 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
CN106434870A (zh) | 2010-11-19 | 2017-02-22 | 密执安大学评议会 | ncRNA及其用途 |
US8945556B2 (en) | 2010-11-19 | 2015-02-03 | The Regents Of The University Of Michigan | RAF gene fusions |
CA2881627A1 (en) | 2012-08-16 | 2014-02-20 | Genomedx Biosciences Inc. | Cancer diagnostics using biomarkers |
EP3243077B1 (en) | 2015-01-05 | 2019-09-04 | University Of Oslo | Prostate cancer markers and uses thereof |
EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
US11208697B2 (en) | 2017-01-20 | 2021-12-28 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
WO2018165600A1 (en) | 2017-03-09 | 2018-09-13 | Genomedx Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
CA3055132A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
AU2018266733A1 (en) | 2017-05-12 | 2020-01-16 | Veracyte, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
CN111000858B (zh) * | 2019-05-10 | 2021-04-09 | 常州市第二人民医院 | Nupr1抑制剂在制备膀胱癌治疗药物中的用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4673562A (en) | 1983-08-19 | 1987-06-16 | The Children's Medical Center Corporation | Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5041289A (en) | 1987-11-13 | 1991-08-20 | Becton Dickinson And Company | Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells |
US5851764A (en) | 1990-10-25 | 1998-12-22 | The Trustees Of Columbia University In The City Of New York | Human prostate tumor inducing gene-1 and uses thereof |
AU3467493A (en) | 1992-01-27 | 1993-09-01 | Board Of Trustees Of The Leland Stanford Junior University | Histamine derivatives and methods for their use |
US5428011A (en) | 1992-06-16 | 1995-06-27 | Procyon Biopharma, Inc. | Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
ATE342356T1 (de) | 1992-11-05 | 2006-11-15 | Sloan Kettering Inst Cancer | Prostata-spezifisches membranantigen |
CA2168952A1 (en) * | 1993-08-11 | 1995-02-16 | Lynn E. Spitler | Prostatic cancer vaccine |
EP0652014A1 (en) | 1993-11-10 | 1995-05-10 | National Institute Of Immunology | Treatment of prostatic hypertrophy |
AU8116494A (en) | 1993-11-12 | 1995-06-13 | Kenichi Matsubara | Gene signature |
AU699748B2 (en) | 1994-05-10 | 1998-12-10 | Hybritech Incorporated | Recombinant HK2 polypeptide |
KR19990087802A (ko) | 1996-03-15 | 1999-12-27 | 길리스 스티브 | 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법 |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
CA2269755A1 (en) | 1996-10-25 | 1998-04-30 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
EP0972022A2 (en) | 1997-01-21 | 2000-01-19 | Human Genome Sciences, Inc. | Polynucleotides and polypeptides encoding receptors |
US6887660B2 (en) | 1997-02-25 | 2005-05-03 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
PL196260B1 (pl) | 1997-02-25 | 2007-12-31 | Corixa Corp | Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty |
US6020478A (en) | 1997-02-28 | 2000-02-01 | Incyte Pharmaceuticals, Inc. | Human tumor-associated antigen |
EP0972029A1 (en) | 1997-03-07 | 2000-01-19 | Human Genome Sciences, Inc. | Human secreted proteins |
JP2001519666A (ja) | 1997-04-10 | 2001-10-23 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌発現配列タグ(sESTs) |
US6130043A (en) | 1997-05-02 | 2000-10-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6222029B1 (en) | 1997-08-01 | 2001-04-24 | Genset | 5′ ESTs for secreted proteins expressed in brain |
ES2267192T3 (es) | 1997-08-01 | 2007-03-01 | Serono Genetics Institute S.A. | Ests 5' para proteinas secretadas no especificas de tejido. |
JP2001512013A (ja) | 1997-08-01 | 2001-08-21 | ジェンセット | 前立腺に発現される分泌タンパク質の5’est |
EP1029045A2 (en) | 1997-11-13 | 2000-08-23 | Genset | EXTENDED cDNAs FOR SECRETED PROTEINS |
ATE440951T1 (de) | 1997-12-17 | 2009-09-15 | Serono Genetics Inst Sa | Verlängerte cdns, die für sekretierte proteine kodieren |
DE19805633A1 (de) | 1998-02-12 | 1999-08-19 | Basf Ag | Neue Serinprotease aus der Prostata |
-
1998
- 1998-02-25 PL PL335348A patent/PL196260B1/pl not_active IP Right Cessation
- 1998-02-25 IL IL13156098A patent/IL131560A0/xx unknown
- 1998-02-25 CZ CZ0301699A patent/CZ298465B6/cs not_active IP Right Cessation
- 1998-02-25 BR BR9808881-5A patent/BR9808881A/pt not_active Application Discontinuation
- 1998-02-25 HU HU0002095A patent/HUP0002095A3/hu unknown
- 1998-02-25 US US09/030,607 patent/US6262245B1/en not_active Expired - Fee Related
- 1998-02-25 WO PCT/US1998/003492 patent/WO1998037093A2/en active IP Right Grant
- 1998-02-25 EP EP98906649A patent/EP1005546A2/en not_active Withdrawn
- 1998-02-25 AU AU61818/98A patent/AU731840B2/en not_active Expired
- 1998-02-25 CA CA2281952A patent/CA2281952C/en not_active Expired - Fee Related
- 1998-02-25 TR TR1999/02053T patent/TR199902053T2/xx unknown
- 1998-02-25 CN CNB988041391A patent/CN1195851C/zh not_active Expired - Fee Related
- 1998-02-25 NZ NZ337446A patent/NZ337446A/en active IP Right Revival
-
1999
- 1999-08-24 NO NO19994069A patent/NO994069L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2281952A1 (en) | 1998-08-27 |
CN1252837A (zh) | 2000-05-10 |
HUP0002095A2 (hu) | 2000-10-28 |
CA2281952C (en) | 2011-07-19 |
AU731840B2 (en) | 2001-04-05 |
WO1998037093A2 (en) | 1998-08-27 |
CZ298465B6 (cs) | 2007-10-10 |
PL196260B1 (pl) | 2007-12-31 |
EP1005546A2 (en) | 2000-06-07 |
NO994069D0 (no) | 1999-08-24 |
HUP0002095A3 (en) | 2002-02-28 |
CZ9903016A3 (cs) | 2002-03-13 |
US6262245B1 (en) | 2001-07-17 |
NZ337446A (en) | 2001-02-23 |
NO994069L (no) | 1999-10-22 |
IL131560A0 (en) | 2001-01-28 |
WO1998037093A3 (en) | 1998-12-17 |
AU6181898A (en) | 1998-09-09 |
TR199902053T2 (xx) | 2000-04-21 |
BR9808881A (pt) | 2001-09-11 |
PL335348A1 (en) | 2000-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1195851C (zh) | 用于前列腺癌免疫疗法的化合物及其用途 | |
KR100572817B1 (ko) | 전립선 암 면역치료용 화합물 | |
US20020081580A1 (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
US6465611B1 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
AU762812B2 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
US6329505B1 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
CN1436234A (zh) | 用于前列腺癌治疗和诊断的组合物及方法 | |
US6395278B1 (en) | Prostate specific fusion protein compositions | |
KR20150129847A (ko) | 융합 단백질 및 이들의 방법 | |
JP2001504333A (ja) | 前立腺特異カリクレイン | |
JP2001515349A (ja) | Tm4sfヒト腫瘍関連抗原 | |
US6657056B2 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
CN1690077A (zh) | 用于前列腺癌免疫疗法的化合物及其用途 | |
US6613872B1 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
TWI228593B (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
MXPA99007858A (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
MXPA99007831A (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
US20020086384A1 (en) | Splice variants of oncogenes | |
US20020182596A1 (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
TWI250208B (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
MXPA01000432A (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
TW200815476A (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
JP7237064B2 (ja) | 単一免疫グロブリンインターロイキン-1受容体関連(sigirr)変異型及びその使用 | |
JP2000226400A (ja) | アポトーシス制御能を有する蛋白質、その遺伝子及びそれらの用途 | |
JP2000316580A (ja) | ヒト雄優位発現抗原−2、それをコードする遺伝子、およびそれらの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050406 Termination date: 20100225 |